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1. Summary
Glycosphingolipids (GSLs) are essential structural components of each eukaryotic 
cell and comprise a heterogeneous group of membrane lipids covalently linked to a 
glycan moiety. GSLs play fundamental role in proliferation, differentiation, adhesion, 
protein and lipid trafficking, signaling events and binding ligands of bacterial toxin 
and viruses. Aberrant glycosylation on GSLs has been associated with malignant 
transformation. The presence of tumor associated GSLs has also been observed in 
epithelial ovarian cancer, which is the eight most common cause of cancer in the 
women worldwide bearing the highest mortality rate among all gynecological cancers. 
Several studies from our group suggest a potential role of GSLs  (Gb3 and P1) in 
ovarian cancer. Both are the members of neutral GSLs belonging to globo series 
(Gb3) and (neo-) lacto series (P1). The α1-4 galactosyltransferase (A4GALT) 
terminates both Gb3 and P1 in the GSLs biosynthesis pathway. Gb3 is expressed on 
different human cell types (erythrocytes, monocytes, granulocytes, fibroblasts, 
smooth muscle cells of digestive tract and urogenital system, and various cancer cell 
lines) as well as in cancer tissues (primary lesions of metastatic colon cancer and the 
colon cancer metastases to liver) while the presence of P1 is only known to be on 
erythrocytes. The functional role of these neutral GSLs has not been well understood 
in general and particular in context of ovarian cancer. To address this question, here 
we utilized two strategies: 1) enzymatic inhibition of key glycosyltransferase 
glucosylceramide synthase (GCS) and 2) CRISPR-Cas9 mediated genome editing to 
generate homozygous, stable, and heritable knockout cell lines to consequently 
establish an experimental tool depleted for specific glycans. The effects of inhibition 
and abolishment of these GSLs on cellular process is investigated with the appropriate 
assays.  Our results displayed that ablation of  (neo-) lacto series GSLs by CRISPR-
Cas9 mediated genome editing (ΔB3GNT5) leads an unexpected loss of α 2-6 
sialylation on N-glycoproteins. Profiling of α 2-6 sialyltransferase encoding genes 
revealed that loss of α 2-6 sialylation is due to the silencing of ST6GAL1 expression. 
Another study reported that globoside glycosyltransferases are elevated in epithelial 
signature and depletion of globosides by CRISPR-Cas9 mediated A4GALT deletion 
induce epithelial to mesenchymal transition (EMT) and consequently enhance chemo 
resistances. Cells undergoing EMT lost E-cadherin expression through epigenetic 
silencing at the promoter of CDH1 via DNA methylation, however, in A4GALT 
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deleted cells demethylation was only able to rescue E-cadherin expression while wild 
type A4GALT was provided. Our data demonstrated another class of biomolecules 
vital for epithelial homeostasis to maintaining cell integrity and function. Taken 
together, our studies demonstrate that GSLs, and in particular globosides, play an 
important role in the transition of ovarian cancer cells towards epithelial (MET) or 
mesenchymal (EMT) phenotypes. Thus, these data suggest that particular GSLs are 
involved in a complex network affecting molecular events such as alteration of α 2,6- 
sialylation on N-glycoproteins and influencing E-cadherin mediated cell-cell adhesion 
in intermediate EMT ovarian cancer cell lines. In summary this PhD thesis highlights 
a close relationship between the EMT process and GSLs, which allows a new 
direction for targeting new therapies.  
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2. Introduction
2.1 Ovarian cancer is one of the deadliest malignancies 
worldwide 
Ovarian cancer is the seventh most common type of cancer in women with highest 
mortality rate among all gynecological cancer, representing 4% of all cancer in 
women [1, 2]. Worldwide 239,000 new cases of ovarian cancer are diagnosed each 
year, with 152,000 cancer-specific deaths [2-6]. The incidence and survival rates vary 
by country; 55% of all new cases occurred in countries with high or very high levels 
of human development, whereas 37% of new cases and 39% of deaths occurred in 
Europe and North America [2, 7, 8]. Interestingly, the annual incidence rates are 
declining in certain countries with very high levels of human development, notably in 
Europe and North America [2]. This might have been influenced by the use of oral 
contraceptives and changing pattern of hormonal replacement therapy [9, 10]. The 
high mortality rate has several reasons, which are discussed in more details in the 
introductory sections below. 
Figure 1: Global distribution of estimated age-standardized (world) incidence 
rates (ASR) per 100,000 for ovarian cancer, 2012 (adapted from [2]).  
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2.1.1 Epithelial ovarian cancer is a heterogeneous disease 
Epithelial ovarian tumors/carcinomas are account for approximately 90% of the all-
ovarian tumors and are classified into five major subtypes: high grade serous 
carcinoma (HGSC), low grade serous carcinoma (LGSC), clear cell carcinoma, 
endometrioid adenocarcinoma and mucinous adenocarcinoma, that vary in biological 
behavior, response to treatment and overall prognosis (Table 1) [10, 11]. There is 
considerable heterogeneity within specific subtypes, particularly most frequent serous 
cancers [12, 13]. Although international federation of gynecology and obstetrics 
(FIGO) stage and grade are still used to classify ovarian cancer, two separate and 
quite distinct groups (Type1 and Type 2) have been recently re-organized according 
to their molecular profiles [14, 15]. Type 1 tumors include LGSC, endometrioid, clear 
cell and mucinous carcinoma, which are characterized by indolent course and early 
stage detection, when the tumor is microinvasive and confined to the ovary. They 
commonly have mutations in in KRAS, BRAF, ARID1A, PIK3CA, and PTEN [15]. By 
contrast, Type 2 tumors include HGSC, malignant mixed mesodermal tumors and 
undifferentiated carcinomas [14, 15], which are more aggressive and detected in 
advanced stages (stages III-IV) in more than 75% of cases. A very high frequency of 
TP53 mutation (>95%) and BRCA1/2 alteration (15%) are associated with Type 2 
tumors [16]. 
Table: 1 Types of ovarian cancer by histology, clinical findings and genomic 
characteristics (adapted from [10]) 
Histological 
subtype 
Clinical findings Genetic characteristics 
High grade 
serous 
carcinoma 
Present with peritoneum, 
ascites and/or pelvic mass. 
Typically advanced stage 
Associated with BRCA (15%)and 
TP53 (>95%) mutations & 
>50% tumors with HR 
deficiencies 
Low grade 
serous 
carcinoma 
Presents in young patients 
(43-55 years). 
Early or late stages 
KRAS (20-40%)and BRAF (5%) 
mutations. 
Tumors with genomic instability 
Clear-cell 
carcinoma 
Parenchymal metastasis (in 
the liver and lungs) 
ARID1A (46-57%)and PIK3CA 
(33%) mutations 
Endometrioid 
adenocarcinoma 
Potentially associated with 
endometriosis 
PTEN (35-50%), ARID1A (30%) 
and PIK3CA (30%) mutations. 
Microsatellite instability (20-
40%) 
Mucinous 
adenocarcinoma 
Presents in younger patients 
and typically early stage 
KRAS mutations (43-57%) 
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2.1.2 The uncertain origin of ovarian cancer 
Ovarian cancer strikes silently, usually revealing no obvious symptoms until disease 
advances to a metastatic stage [17]. Approximately 70% of ovarian cancer patients are 
often diagnosed when disease metastasized to a distant site because of nonexistence 
screen methods and only 20% of women with such cancers can expect to survive 5 
years [18-20]. Therefore a better insight into the biology of the disease is needed in 
order to detect at an early and potentially curable stage and to develop more targeted 
and effective treatment strategies. As implicit in the name, ovarian cancer is supposed 
to be a cancer originating in the ovary [21]. Yet the exact cell of origin has been 
unclear whether the cancer actually arises from the ovary, especially for HGSC, the 
most common and deadliest ovarian cancer [22, 23]. HGSC is rarely detected in stage 
I (<1.5% cases) [24-26], when tumors are confined to ovary, most cases are in 
advanced FIGO stage with wide spread metastases in the peritoneal cavity [27]. 
However, mostly non-epithelial tumors – such as granulosa-cell and germ-cell tumors 
or epithelial ovarian cancers like endometrioid, clear-cell, mucinous, and borderline 
tumors are limited to ovary without metastasis [28, 29].  
Several sites have been proposed to give rise to the cell of origin for EOC, including 
ovarian surface epithelium (OSE), fallopian tubes and other derivatives of secondary 
Mullerian system [30-33]. Epithelial ovarian tumors have long been considered to 
originate from the OSE or the cortical inclusion cysts [34, 35], but a convincing 
precursor for HGSC has not been identified yet. A recent study has been proposed 
that the transitional zone (named as hilum) between OSE, mesothelium and tubal 
epithelium may also be a candidate for the EOC cell of origin because of their plastic 
and presumably, less differentiated states [36-38]. The study demonstrated that the 
hilum OSE cells are cycling slowly and display long-term stem cell properties ex vivo 
and in vivo, shown by serial sphere formation and long-term lineage tracing assay. 
The increased transformation potential was also identified after inactivation of Trp53 
and Rb1, whose pathways are altered frequently in the most aggressive and common 
type of human EOC (HGSC) [39]. 
Another hypothesis is based pathologist observations in the late 1990s and early 
2000s where meticulously sections of the fallopian tubes and ovaries from women at 
high risk of developing ovarian cancer were investigated. Women with high risk to 
develop ovarian cancer usually display a family history of breast or ovarian cancer 
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and carry germline mutations in BRCA1 and BRCA2 [40]. Surprisingly, they found no 
ovarian lesions but instead discovered occult noninvasive and invasive carcinomas in 
the fallopian tubes, typically in the fimbria, named as serous tubal intraepithelial 
carcinomas (STIC), [41-46]. The STIC lesions carry TP53 mutation positive cells and 
show increased proliferative capacity in at least 60% of women with HGSC [47, 48] 
and similar lesions are not observed in OSE [49]. These early lesions exhibits shorten 
telomerase, which is a notable hallmark of early molecular carcinogenesis [50, 51]. 
Subsequently, Piek et al. proposed that these occult tubal carcinomas might shed 
malignant cells to ovary [52]. According to this concept, STIC cells detach from the 
distal fimbriated end of fallopian tube and implant on the ovarian surface, stimulating 
primary ovarian cancer [53-55]. Therefore, it has been suggested that additional sites 
of origin exist and a substantial proportion of cases may arise from precursor lesions 
located in the fallopian tubal epithelium. The hypothesis also supported by clinical 
observations in which STICs can originate from secretory epithelial cells of the 
fallopian tube and progress to HGSC by rapidly disseminating to involve ovarian and 
peritoneal surfaces. The shared morphologic and immunophenotypic features of 
STICs and HGSCs is further supported by this hypothesis. Moreover, injection of 
transformed primary human fallopian tube secretory epithelial cells (FTSECs) into the 
peritoneum of nude mice induces tumors that grossly, histologically, 
immunophenotypically, and genomically resemble human HGSCs [56-58]. In the 
most recent study, demonstrated that HGSOC can originate in fallopian tube secretory 
epithelial cells (FTSEC) and also established STIC as a precursor lesion to HGSC and 
peritoneal carcinoma in mouse model targeting the Brca, Tp53 and Pten [59].  
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2.2 Glycosylation of cellular components in eukaryotes  
Glycans are the most abundant biological molecules on our planet and represent one 
of the four fundamental building blocks (protein, lipid, nucleic acid and glycan) of life 
[60]. They are assemblies of carbohydrates (oligosaccharides and polysaccharides), 
which exist in either free form or in covalent complexes with proteins or lipids, 
named as glycoconjugates [61]. These glycoconjugates are primarily defined 
according to the nature and their non-glycosyl part, whether glycoproteins or 
glycolipids [62]. 
Several main families of glycoconjugates have been identified in the past. Secreted 
and transmembrane proteins can be modified with oligosaccharides at the amino acid 
asparagine (Asn) referring to N-glycoproteins, at the amino acids serine (Ser)- or 
threonine (Thr)- forming O-glycoproteins. In contrast, intracellular proteins such as 
glycosylphosphatidylinositol (GPI)-linked proteins bear a glycan chain linked to 
phosphatidylinositol. Nuclear and cytoplasmic proteins are modified with the 
monosaccharide as O-linked N-acetylglucosamine (O-GlcNAc) linked to serine, often 
at sites that are normally phosphorylated [63] (Figure 2). Beside proteins, 
glycosaminoglycans present as free polysaccharides (such as hyaluronan) or as part of 
proteoglycans (such as heparan sulphate and chondroitin sulphate). The remaining 
glycosphingolipids (GSLs) usually linked to ceramides being part of the cell surface 
membrane [63] (Figure 2).  
Most of these glycans exist in the glycocalyx as membrane-bound glycoconjugates or 
secreted molecules, which can become integral parts of the extra cellular matrix 
(ECM) [61]. These locations place glycans in a position to mediate cell adhesion and 
motility, as well as intracellular signaling events [64]. The enzymatic process that 
produces glycosidic linkages of saccharides to other saccharides, proteins or lipids 
usually catalyzed through glycosyltransferases is defined as glycosylation [65, 66] 
and act as a key regulatory mechanism controlling several pathophysiological 
processes. Glycosylation defects in humans and their links to disease have shown that 
the mammalian glycome contains a remarkable amount of biological information [67]. 
It has also been shown that characterizing the biological functions of each glycan 
[68], as well as glycan-binding proteins and lipids made important contributions to the 
cancer field [61, 69-71].  
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Figure 2: Common classes of glycans in mammalian cells (adapted from [62]) 
Glycans has been found in various types of macromolecules. Ceramide linked glycans 
are composed of a variable series of structures, which can be further modified with 
terminal sialic acids [64, 72]. Proteins are glycosylated by the covalent attachment of 
a monosaccharide to a polypeptide backbone, via N-linkage to Asn or O-linkage to 
Ser/Thr. O-glycans can be extended, producing various ‘cores’ and different terminal 
structures that are usually fucosylated and sialylated [73]. Other types of O-glycans 
include the O-mannose (O-Man), O-fucose (O-Fuc), O-galactose (O-Gal) and 
nucleocytoplasmic O-linked β-N-acetylglucosamine (O-GlcNAc) [74, 75]. N-glycans 
share a common pentasaccharide core region (highlighted in the figure as a dotted line 
box) that can be further diversified into oligomannose, hybrid or complex types and 
further modified by the terminal structures GlcNAc, Gal and sialic acid [64]. Some 
glycoproteins can also be found in the outer leaflet of the plasma membrane linked to 
a phosphatidylinositol; known as GPI-anchored proteins [64]. Glycosaminoglycans 
are linear co-polymers of acidic disaccharide repeating units mostly found attached to 
the so-called proteoglycans [64]. An exception is hyaluronic acid, which is a 
glycosaminoglycan found free in the extracellular matrix. 
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2.2.1 Aberrant glycosylation in cancer development and 
progression 
More than six decades ago, it was first described that changes in glycosylation are 
associated with oncogenic transformation [76, 77]. Tumor cells display a wide range 
of aberrant glycosylation, which may affect cell glycoconjugates such as N-glycans 
and O-glycans on glycoproteins, glycolipids or glycosaminoglycans compared with 
their non-transformed counter cells [78, 79]. This might be due to the expression 
levels of glycosyltransferases, sugar nucleotide donors, as well as disorganization of 
the Golgi, which may contribute to significant changes between normal and diseased 
states [79]. Malignant transformation is often accompanied by the expression of 
oncofetal antigens-epitopes and those observations were further investigated with 
advent monoclonal antibody technology, which showed that tumor specific antibodies 
were directed against glycan epitopes [80, 81]. Thus, cancer associated carbohydrates 
are potential targets for new diagnostic biomarkers or as therapeutic targets. 
Interestingly, the majority of the cancer-associated biomarkers that are clinically 
applied nowadays are either glycoproteins or glycolipids (Table 3). This might be 
because of human serum proteomes, most of which are made up of glycoproteins 
[82]. Glyconjugates are entering to the circulatory system from tissues or blood cells 
through active secretion or leakage, including necrotic and apoptotic processes, which 
displayed great complexity fluctuate in carbohydrate structures and reflecting the 
physiological and pathological state of the organism. Thus, serum with its ease of 
accessibility from peripheral blood and reduced risk to the patient due to minimally 
invasive nature of harvesting is an attractive option from a clinical and diagnostic 
perspective [83].   
Current strategy to detect the ovarian cancer involves ultrasonography and monitoring 
levels of the serum glycoprotein CA125 also referring to MUC16 [84, 85]. However, 
CA125 is inadequate as it is non-specific for ovarian cancer and thus unreliable for 
diagnosing early stage for this disease [86]. For the last two decades, numerous 
studies (including large clinical trails) have been conducted to develop potential 
biomarker for ovarian cancer. Several markers are currently being investigated 
including OVX1, M-CSF, inhibin, kallikreins, TPS, and lysophosphatidic acid [86, 
87]. 
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Table 3: List of FDA approved biomarkers (adapted from [64]) 
Biomarker Type Source Cancer 
Type 
Clinical Use 
α-Fetoprotein Glycoprotein Serum Liver Monitoring 
α-Fetoprotein-L3 Glycoprotein Serum Liver Risk 
DCP Protein Serum Liver Risk 
Human chorionic 
gonadotropin-3 
Glycoprotein Serum Testicular Staging 
CA19-9 Carbohydrate Serum Pancreatic Monitoring 
CA125 Glycoprotein Serum Ovarian Monitoring 
Pap smear Cervical smear Cervix Cervical Screening 
CEA Glycoprotein Serum Colon Monitoring 
EGF receptor Glycoprotein Colon Colon Selection of 
therapy 
KIT Protein (IHC) GI tumor GI stromal 
tumors 
Diagnosis & 
selection of 
therapy 
Thyroglobulin Glycoprotein Serum Thyroid Monitoring 
PSA Glycoprotein Serum Prostate Monitoring 
CA15-3 Glycoprotein Serum Breast Monitoring 
CA27-29 Glycoprotein Serum Breast Monitoring 
Cytokeratins Protein (IHC) Breast tumor Breast Prognosis 
Estrogen & proge-
sterone receptors 
Protein (IHC) Breast tumor Breast Selection of 
therapy 
HER2/NEU Glycoprotein Breast tumor Breast Prognosis & 
selection of 
therapy 
HER2/NEU Glycoprotein Serum Breast Monitoring 
HER2/NEU DNA (FISH) Breast tumor Breast Prognosis & 
selection of 
therapy 
Chromosome 3,7, 9, 
and 17 
DNA (FISH) Urine Bladder Screening & 
Monitoring 
NMP22 Protein Urine Bladder Screening & 
Monitoring 
Fibrin/FDP Protein Urine Bladder Monitoring 
BTA protein Urine Bladder Monitoring 
CEA and mucin Glycoprotein Urine Bladder Monitoring 
 
In regards to glycoconjugates as biomarkers, recent work identify glycan-based 
markers, efforts have been made with array technologies searching for glycan-binding 
proteins [88-91]. In a recent study we used the first custom made high throughput 
printed glycan array, consist of a library of over 200 glycans including well-known 
tumor associated carbohydrate antigens, and identified plasma-derived anti-glycan 
antibody signatures in blood of ovarian cancer patients compared to healthy controls 
10
[92]. In comparison to the clinically applied tumor markers CA125, anti-glycan 
antibodies to individual glycan structures on the array showed a comparable 
sensitivity and specificity in this cohort, which was increased by a combination of up 
to 6 glycans with a sensitivity (79.2%) and specificity (84.8%). A combination of 
both, the top candidate P1 and CA125 only marginally improved the sensitivity (76%) 
and specificity (73.9%) [92]. The subsequent studies validate the predictive value of 
printed glycan array using two independent glycan based immunoassay, suspension 
array and ELISA [93]. Within the top five candidates two of them were 
glycosphingolipids (Gb3 and P1). These data demonstrated that specific GSLs might 
play a role in ovarian cancer patients, however, their cellular function in this context 
remains to be elucidated.  
 
2.2.2 Glycosphingolipids in eukaryotic cells 
Glycosphingolipids (GSLs) were first discovered and named by Ernst Klenk after 
their isolation from brain tissue in 1942 [94]. GSLs represent the major components 
of outer leaflet of each eukaryotic cell plasma membrane, which are a heterogeneous 
class of amphipathic compounds that constituted by complex glycan moieties linked 
to a ceramide lipophilic backbone by a β-glycosidic bond [95]. GSLs comprising 
ceramide is synthesized in endoplasmic reticulum (ER) [96, 97] and then transported 
to Golgi apparatus and converted to glucosylceramide (GlcCer) by the activity of 
glycosyltransferase, then it flips to the Golgi lumen [98, 99]. Glycosyltransferases are 
enzymes that establish natural glycosidic linkages via catalyzing the transfer of 
saccharide moieties from an activated nucleotide sugar to a nucleophilic glycosyl 
acceptor target, which can be oxygen- carbon-, nitrogen-, or sulfur-based. It is 
estimated that glycosyltransferases in mammals utilize at least nine sugar nucleotide 
donors: CMP-sialic acid, UDP-glucose, -galactose, -GlcNAc, -GalNAc, -xylose, -
glucoronic acid, -mannose, and -fucose. Specific carbohydrates from the appropriate 
activated sugar nucleotide (e.g. UDP-Galactose, CMP-sialic acids, UDP-Fucose, etc.) 
are then added to the non-reducing end of the growing carbohydrate chain linked to 
GlcCer [100]. The GSLs ceramide seems to part of the membrane and sugars are 
facing the extracellular space of the cells [101]. 
The structural and functional classifications of GSLs have traditionally been based on 
their glycan part [64]. The first monosaccharides β1-1-linked to ceramide in higher 
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animals are typically galactose or glucose forming galactosylceramide (GalCer) and 
glucosylceramide (GlcCer), respectively. The latter is further elongated by the 
addition of β1-4-linked galactose resulting in lactosylceramide (galactosyl-1,4-β-
glucosylceramide). The further extension of the GSL generates a series of neutral 
“core” structures, which are divided into three major series: ganglio-series (Galβ1-
3GalNAcβ1-4Galβ1-4Glcβ1-1Cer), (neo-) lacto-series (GlcNAcβ1-3Galβ1-4Glcβ1-
1Cer), and globo-series (Galα1-4Galβ1-4Glcβ1-1Cer) (Figure 3) [64].  
 
 
Figure 3: GSLs biosynthesis pathway Depiction of the three major 
glycosphingolipid series - globo, (neo-) lacto, and ganglio series shown in light blue, 
green and grey box, respectively. LacCer is the precursor of all three 
glucosylceramide-related GSL series. Extensions of globo and (neo-) lacto series 
GSLs are occurred by the action of A4GALT and B3GNT5, respectively, whereas the 
ganglio series biosynthesis occurred by ST3GAL5 & B4GALNT1. Glycosidic linkages 
are displayed next to CFG annotated monosaccharides. The red scissor indicated the 
deletion of the particular glycosyltransferase. The phenotypic consequences of 
different genetic manipulations of GSL synthesis pathway in mice are indicated in 
blue text.   
 
The GSL expression varies among different tissue-specific patterns. For example, in 
mammals gangliosides are broadly distributed predominately in the brain and the 
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(neo-) lacto-series GSLs are in secretory organs and certain hematopoietic cells 
including leukocytes. In contrast, globo-series are the most abundant in erythrocytes 
[64]. This diversity showed the important differences in GSLs functions [64].. GSLs 
can also sub-divided as neutral (no charged sugars or ionic groups), sialylated (having 
one or more sialic acid residues), or sulfated groups [64], where all sialylated GSLs 
are known as “gangliosides,” regardless of whether they are based on the ganglio-
series neutral core structure mentioned above [64].  
 
2.2.3 Cellular Function of Glucosylceramide-related GSLs 
2.2.3.1 Physiological role of GSLs in mice 
GSLs have been extensively studied using genetic, biochemical, biophysical and cell 
biology approaches to identify their physiological roles. A general framework for the 
understanding of functions of GSLs in mammals has been provided by mouse 
genetics. Studies have shown that ablation of the key glycosyltransferase of 
glucosylceramide-related GSLs, Ugcg leads to embryonic lethality during gastrulation 
as a result of massive apoptosis in mice [102]. Similarly, depletion of the B4galt5, 
responsible for LacCer synthesis expression [103], gives rise to embryonic lethality 
by embryonic day 10.5, possibly as a result of growth inhibition [104]. These results 
suggest that glucosylceramide-related GSLs are cumulatively required for correct 
embryo development. On the other hand, the GM3 synthase (St3gal5) knockout does 
not impair to any major abnormalities, although this is associated with enhanced 
insulin sensitivity [105], impaired neuropsychological behaviour [106] and hearing 
loss [107]. Downstream GA2/GM2/GD2 synthase (B4galnt1) [108] ablation leads to 
male infertility [109], axonal degeneration, myelination defects [110], motor deficit 
[111] and Parkinsonism [112]. Depletion of St8sia1 (GD3 synthase) promotes thermal 
hyperalgesia, mechanical allodynia [113] and reduced neuroregeneration [114]. All of 
these gangliosides strongly involve in neuronal function. Along the same lines, 
combined deletion of the GM3 and GA2/GM2/GD2 synthases showed severe 
neurodegeneration [115], whereas, combined ablation of GD3 and GA2/GM2/GD2 
synthases induces lethal audiogenic seizures [116] and peripheral nerve degeneration, 
leading to reduced sensory function and skin lesions as a result of over-scratching 
[117] in mice. (Neo)-lacto series depletion by B3gnt5 knockout, which is responsible 
for Lc3 synthesis, leads to either preimplantation lethality [118] or multiple postnatal 
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defects, such as: early death, growth inhibition, loss of fur, obesity, reproductive 
problems and B-cell functional defects [119]. By contrast, A4galt knockout mice 
showed loss of globoside synthesis with no overt phenotypes [120] (Figure 3). Results 
from all of these studies made GSLs as an important player, which might have an 
influence with several human diseases including cancer. 
2.2.3.2 Glycosphingolipids in cancer 
GSLs have been actively modulate various features of the cell, including apoptosis, 
cell proliferation, endocytosis, intracellular transport, cell migration and senescence, 
and inflammation [121], which are the crucial aspects related to tumorigenesis and 
cancer progression, as well as the responses to anti-cancer therapies [122]. In 
addition, a large number of GSLs have also been identified as tumor-associated 
carbohydrate antigens [123]. In different cancer cells, it has been shown that 
alterations of cell surface GSL-expression patterns are associated with tumor-relevant 
phenotypes [122]. For example, the exogenous addition of gangliosides Gt1b, GD1A, 
GM3 and GM1 inhibit human neuroblastoma (NBL-W) cell proliferation and 
epidermal growth factor (EGF) receptor tyrosine phosphorylation [124]. By contrast, 
the globosides Gb4 and Gb5 strongly enhance colon cancer cell proliferation and 
motility [125]. The disialyl GSL has been demonstrated to enhance tumor phenotypes 
[126] such as GD3 for cell growth and invasiveness in malignant melanoma [127-
130], by activating Src family kinases [130] and Focal adhesion kinase activation 
[128], whereas GD2 promotes proliferation in small cell lung cancers [131] and 
GD3/GD2 enhance malignant properties in osteosarcoma cells [132]. On the same 
line, in highly metastatic osteosarcoma cells the ganglioside GD1a inhibits cell 
migration [133] by suppressing matrix metalloproteinase-9 (MMP-9) [134], tumor 
necrosis factor α [135], nitric oxide synthase 2 [136] and hepatocyte growth factor 
(HGF) expression [137], thus impacting on HGF induced c-Met phosphorylation 
[138]. In addition, Gt1b has been shown to inhibit integrin dependent keratinocyte 
adhesion to fibronectin [139]. In cancer cells, the same effect has been shown for 
GM3 and GM2, inhibition of integrin-dependent cancer cell motility via promoting 
the formation of a ganglioside/tetraspanine/integrin complex and inactivating Src or 
Met [140, 141]. Collectively, all these data demonstrated the specific roles in 
mammalian physiology and pathology to different classes of GSLs, and the molecular 
mechanisms through which they exert these functions involve interactions of GSLs 
with proteins and glycans [123].  
14
Over the last three decades, GSLs have been identified to interact with a number of 
plasma membrane located signaling receptors to modulate their activation [124, 142-
159] (Table 2) and the best-characterized example is the interaction between EGF 
receptor and GM3. The exogenously added GM3 inhibits cell growth [160, 161] 
through the modulation of EGF receptor phosphorylation, which is dependent on the 
presence of the Neu5Ac residue in GM3 and of lysine 642 in the EGFR [142]. The 
GM3 binding to EGFR inhibits homo-dimerization and are not allowing the ligand 
(EGF) to activate EGFR phosphorylation [142]. A similar interaction was also 
reported between the insulin receptor and GM3, which again involves a key lysine 
(IR944) positioned in the proximity of the transmembrane portion of the insulin 
receptor [157].  
Table 2: Known interaction between GSLs and proteins  
Protein GSLs References 
EGFR GM1, GM3, GD1, GT1, Gb4 [124, 142-147] 
FGFR GM3 [148, 149] 
PDGFR GM1, GM3, GD1, GT1 [150, 151] 
NGFR/TrK GM1 [152, 153] 
NgR1 GT1 [154] 
VEGFR GM3 [155] 
TGFβ1R Gb4, GM3 [144, 156] 
IR GM3 [157, 158] 
Lyn/Cbp GD3, GD1 [159] 
Tetraspanins GM3, GM2 [162-164] 
CD11b/CD18 LacCer [165] 
α5β1 integrin GT1 [166] 
Caveolin-1 GM3 [166, 167] 
PMCA GM3, GM2, GM1, GD1 [168] 
Galectin-1 GM1 [169] 
Galectin-3 GM1 [170] 
 
GSLs have also been shown to interact with a number of non-receptor plasma 
membrane proteins, including tetraspanins, integrins, caveolin-1 [139, 162-168], and 
galectins [169, 170]. Some of these interactions involve the binding of glycans to 
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protein modules or specific amino acids [142, 157, 169, 170] known as carbohydrate- 
protein interactions, whereas a GSLs interacting with glycan moieties on proteins or 
lipids are termed carbohydrate–carbohydrate interactions [171]. The carbohydrate–
carbohydrate interactions can be established both in cis (i.e. glycans on the cell 
membrane of one cell) and in trans (i.e. glycans on the cell membrane of adjacent 
cells) [171]. The cis carbohydrate–carbohydrate interactions include the interactions 
between GM3 and the terminal GlcNAc moieties of the EGFR and HGF receptor 
glycans modulating properties of receptor activation [171]. Similarly, GSLs 
Gt1b/GD3 bind to mannose residues in integrin α5 and modulating integrin α5-β1 
function that is cell-ECM (fibronectin) adhesion [139]. The trans carbohydrate–
carbohydrate interactions were described for the interaction of GM3– Gg3 and GM3–
LacCer contributing to the adhesion of tumor cells to endothelial cells [172, 173].  
In addition to that GSLs also have the unique feature of forming molecular clusters by 
acting as both hydrogen bond donors and acceptors [95, 123, 174, 175] and promoting 
self-aggregation [174], which are defined as lipid rafts, GSL-enriched membranes or 
glycosynapses [123]. These lipid rafts on the plasma membrane serve for signaling, 
cargo sorting at the different traffic stations along the secretory and endocytic 
pathways [174] and adhesion molecules, to regulate their functions (e.g. integrin) 
[176]. Recent reports also suggest that ceramide heterogeneity impacts the molecular 
function of GSLs [177, 178]. Taken together, the current literature indicates that 
GSLs are involved in membrane-organization [123, 179], as well as they can interact 
with specific proteins and/or lipids [123]. These properties concur with the role that 
GSLs have in ‘environment sensing’, both in terms of modulation of cell 
responsiveness to extracellular stimuli and of cell–cell adhesion/recognition. These 
concepts position GSLs as important modulators of multicellularity, and more 
generally relate to ‘cell sociology’ [123]. Thus, GSLs have emerged to be key 
controllers in processes that imply cell differentiation and tissue patterning, whereas 
their deregulation plays a driving role in diseases such as cancers [180]. It should also 
be noted that, although these concepts are supported by a number of studies, only a 
few GSLs have been studied in more detail, thus, leaving the understanding of the 
specific roles of most GSLs to future research.  
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3. Aim of the thesis 
Previous results by the Heinzelmann group have been demonstrated that blood 
plasma-derived anti-glycan antibodies vary in levels discriminating ovarian cancer 
patients from healthy controls [181]. Interestingly, most of the glycan structures 
identified are suppose to be naturally attached to lipids presented on the cell surface 
membrane, also referring to glycosphingolipids (GSLs). GSLs have been found to 
participate in numerous biological processes involved in cancer, such as 
inflammation, immune surveillance, cell–cell adhesion, cell–matrix interaction, inter- 
and intracellular signaling, and cellular metabolism. Despite these observations, there 
remains a considerable lack of knowledge about the functional implications of GSLs 
in relation to ovarian cancer. In order to gain insight into the function of GSLs in 
ovarian cancer, the overall goal of this project is to understand the role of 
glucosylceramide-related glycosphingolipids, and in particular the function of globo 
(Gb3, SSEA3, etc.) and (neo-) lacto series GSLs (nLc4 and P1).  
Specific aims of the project are: 
1. To establish a workflow for characterizing cancer samples from patients and 
cell lines for the GSLs expression using flow cytometry and mass 
spectrometry. 
2. To elucidate whether circulating anti-glycan antibodies from patient samples 
specifically bind GSLs on ovarian cancer cells. 
3. To establish an experimental strategy for studying GSLs by developing an 
experimental workflow through testing GSLs-synthesizing glycosyltransferase 
inhibitors and the use of genome editing in ovarian cancer cell lines. The latter 
comprised the design and establishment of a strategy to site-specifically and 
heritably knock out specific glycosyltransferase-encoding genes using zinc 
finger nucleases or the CRISPR-Cas9 system (‘glyco-engineered cell lines’) 
together with re-expression of the enzyme for establishment of a functional 
rescue system. 
4. To study the role of GSLs using fully characterized glyco-engineered ovarian 
cancer cell lines in vitro and in vivo in regards to Epithelial-to-Mesenchymal 
transition, a process in embryonic development and cancer progression, in 
particularly well reported in ovarian carcinogenesis. Moreover, the impact of 
glyco-engineering on the entire glycome was also of interest. 
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4.1 The glycosphingolipid P1 is an ovarian cancer-associated 
carbohydrate antigen involved in migration 
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My contributions to this paper: 
I contributed to this work by profiling GSLs on different ovarian cancer cell lines 
using flow cytometry. I have also characterized naturally occurring anti-P1 antibodies 
present in ovarian cancer ascites capable in binding or cancer cell lines. I was 
involved in analyzing the data and designing the corresponding figures as well as in 
writing parts of the manuscript.
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The glycosphingolipid P1 is an ovarian
cancer-associated carbohydrate antigen
involved in migration
F Jacob*,1,2, M Anugraham3, T Pochechueva1, B W C Tse2,4, S Alam1, R Guertler1,2, N V Bovin5, A Fedier1,
N F Hacker6, M E Huflejt7, N Packer3 and V A Heinzelmann-Schwarz1,2,6
1Gynecological Research Group, Department of Biomedicine, University Hospital Basel, University of Basel, Hebelstrasse 20, Basel
4031, Switzerland; 2Ovarian Cancer Group, Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales,
Prince of Wales Clinical School, Building C25 Kensington Campus, Sydney, NSW 2052, Australia; 3Department of Chemistry and
Biomolecular Sciences, Biomolecular Frontiers Research Centre, Faculty of Science, Macquarie University, Balaclava Road,
North Ryde, Sydney, NSW 2109, Australia; 4Australian Prostate Cancer Research Centre Queensland, Institute of Health and
Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, QLD 4102, Australia;
5Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Ul. Miklukho-Maklaya, 16/10, Moscow
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Health, Barker Street, Randwick, NSW 2031, Australia and 7Division of Thoracic Surgery and Thoracic Oncology, Department of
Cardiothoracic Surgery, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
Background: The level of plasma-derived naturally circulating anti-glycan antibodies (AGA) to P1 trisaccharide has previously been
shown to significantly discriminate between ovarian cancer patients and healthy women. Here we aim to identify the Ig class that
causes this discrimination, to identify on cancer cells the corresponding P1 antigen recognised by circulating anti-P1 antibodies
and to shed light into the possible function of this glycosphingolipid.
Methods: An independent Australian cohort was assessed for the presence of anti-P1 IgG and IgM class antibodies using suspension
array. Monoclonal and human derived anti-glycan antibodies were verified using three independent glycan-based immunoassays and
flow cytometry-based inhibition assay. The P1 antigen was detected by LC-MS/MS and flow cytometry. FACS-sorted cell lines were
studied on the cellular migration by colorimetric assay and real-time measurement using xCELLigence system.
Results: Here we show in a second independent cohort (n¼ 155) that the discrimination of cancer patients is mediated by the IgM
class of anti-P1 antibodies (P¼ 0.0002). The presence of corresponding antigen P1 and structurally related epitopes in fresh tissue
specimens and cultured cancer cells is demonstrated. We further link the antibody and antigen (P1) by showing that human
naturally circulating and affinity-purified anti-P1 IgM isolated from patients ascites can bind to naturally expressed P1 on the cell
surface of ovarian cancer cells. Cell-sorted IGROV1 was used to obtain two study subpopulations (P1-high, 66.1%; and P1-low,
33.3%) and observed that cells expressing high P1-levels migrate significantly faster than those with low P1-levels.
Conclusions: This is the first report showing that P1 antigen, known to be expressed on erythrocytes only, is also present on
ovarian cancer cells. This suggests that P1 is a novel tumour-associated carbohydrate antigen recognised by the immune system in
patients and may have a role in cell migration. The clinical value of our data may be both diagnostic and prognostic; patients with
low anti-P1 IgM antibodies present with a more aggressive phenotype and earlier relapse.
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Glycosphingolipids (GSLs) have critical roles in embryonic
development, signal transduction, cell signalling, apoptosis,
receptor modulation, cell adhesion, growth and cell differentiation
and carcinogenesis (Jarvis et al, 1996; Hakomori, 1998; Kasahara
and Sanai, 1999). The presence of tumour-associated GSLs
antigens have been observed in epithelial ovarian cancer
(Pochechueva et al, 2012), which is the fifth most common cause
of death from all cancers in women and the leading cause of death
from gynaecological malignancies (Ozols, 2006).
Printed glycan array technology (a glycan-based discovery
approach) previously demonstrated that naturally occurring anti-
glycan antibodies (AGA) in plasma of ovarian cancer patients
exhibited specificities towards synthetic P1 trisaccharide. In our
previous study, we have demonstrated using a printed glycan array
that anti-P1 antibodies can discriminate healthy controls from
ovarian cancer patients (Jacob et al, 2012). This study (on a Swiss
Discovery Cohort) showed that anti-P1 antibodies of IgM, IgG and
IgA together were significantly lower in ovarian cancer patients,
thereby discriminating them from healthy controls. The predictive
value of the printed glycan array was validated by two independent
glycan-based immunoassays, ELISA and suspension array
(Pochechueva et al, 2011b).
The Pk, P and P1 carbohydrate antigens, commonly expressed
on GSL, are members of the P blood group system that differ in
their specificity based on their oligosaccharide sequences. In
cancer, the globo (Pk and P) and neolacto (P1) series are precursor
GSL that give rise to well-known tumour-associated carbohydrate
antigens, such as Forssman antigen (Hakomori et al, 1977;
Taniguchi et al, 1981) and Globo H (Gilewski et al, 2001; Chang
et al, 2008; Wang et al, 2008). High levels of Pk (Gala1-4Galb1-
4Glcb1-1Ceramide; Gb3, CD77), P (GalNAcb1-3Gala1-4Galb1-
4Glcb1-1Ceramide; Gb4) and Globo H were described in the past
(Wenk et al, 1994).
As shown previously, naturally occurring AGA to P1 have the
potential to be used diagnostically in plasma of ovarian cancer
patients. However, it remains unknown whether P1-bearing GSL
are present on ovarian cancer cells and whether naturally occurring
anti-P1 antibodies to chemically synthesised carbohydrates in
glycan-based immunoassays bind to these GSL antigens. To our
knowledge, no published reports regarding the role of P1 in
malignant transformation, particularly in ovarian cancer, are
available, and the molecular mechanisms underlying GSL expres-
sion on the cell surface, as well as its function, have yet to be
elucidated. Therefore, this study aims (A) to determine the
responsible naturally occurring AGA immunoglobulin class
discriminating cancer from normal; (B) to determine whether
the level of these antibodies are predictive of patient outcome; (C)
to investigate whether the related P1 glycan epitopes are present on
cells isolated from ovarian cancer tissues as well as on ovarian
cancer cell lines; (D) to compare the AGA profiles in ascites and
matched plasma; (E) to compare monoclonal anti-P1 antibodies
produced in humans and affinity purified anti-P1 antibodies
isolated from ascites; and finally (F) to investigate the functional
role of the P1 antigen in ovarian cancer.
MATERIALS AND METHODS
Biospecimens. Two independent patient cohorts from two
different continents were used for the experiments: (A) matched
plasma and ascites from 11 serous FIGO stage III/IV cancer
patients from the previously described Swiss Discovery Cohort
(Jacob et al, 2012); (B) plasma from 155 Australian samples
(Australian Validation Cohort) comprising healthy controls,
borderline tumour and ovarian cancer patients. The Australian
Validation Cohort was split into: (1) borderline tumours and
adenocarcinomas of the ovary, tube and peritoneum (‘tumour
group’), and (2) healthy control women (‘control group’). Patients
were either admitted with an adnexal mass to the Gynaecological
Cancer Centre of the Royal Hospital for Women, Randwick,
Australia or were seen as outpatients to the Hereditary Cancer
Centre of The Prince of Wales Hospital, Randwick, Australia. All
patients were prospectively included after giving informed consent
in accordance with ethical regulations (Hunter Area Research
Ethics 04/04/07/3.04; South Eastern Sydney Illawarra HREC/
AURED Ref:08/09/17/3.02). The processing of blood plasma
samples was performed constantly on ice within 3 h after collection
as previously described (Jacob et al, 2011a, 2012). All clinico-
pathological data (Supplementary Table S1) such as FIGO stage
and grade were incorporated in a specifically designed in-house
database (‘PEROV’), which was developed using Microsoft Access
(Microsoft Corporation, Redmond, WA, USA). Diagnosis and
histopathological features were independently re-evaluated by a
pathologist specialised in gynaecological oncology (JS). Blood
samples were stored in aliquots at " 80 1C.
Glycan-based immunoassays (printed glycan array, suspension
array and ELISA). The printed glycan array was performed as
previously described (Huflejt et al, 2009; Bovin et al, 2012; Jacob
et al, 2012). AGA were detected by ImmunoPure goat anti-human
IgAþ IgGþ IgM conjugated to long chain biotin (1 : 100, ‘Combo’,
Pierce, Rockford, IL, USA). To detect the immunoglobulin class,
developed printed glycan array slides were individually incubated
with 1 : 50-diluted biotin-conjugated goat anti-human IgA, IgG or
IgM (ZYMED Laboratories, Invitrogen, Carlsbad, CA, USA). The
coupling procedures for end-biotinylated glycopolymers and
antibody binding were described before (Pochechueva et al,
2011a, b). Experimental protocol was performed as described
previously (Pochechueva et al, 2011b). Exceptions were made with
respect to the use of goat anti-human IgG-R-PE or IgM-R-PE
secondary antibodies (Southern Biotech Ass. Inc., Birmingham,
AL, USA). ELISA was performed as described previously
(Pochechueva et al, 2011b).
Extraction and identification of GSLs from cancer tissue
samples and IGROV1 cell line. Fresh primary tissue samples
(B100mg) from a serous ovarian cancer and an endometrioid
peritoneal cancer patient were collected to analyse glycolipids by
negative ion electrospray ionisation mass spectrometry (LC-ESI-
MS/MS). Detailed analysis of the procedure is described in
Supplementary Information.
Affinity purification of anti-P1 antibodies. Ascites fluid was
collected from a late-stage serous ovarian cancer patient during
primary surgery. The ascites was processed by centrifugation at
4 1C, 3000 g for 15min. Supernatant was aliquoted and kept frozen
at " 80 1C. Thawed ascites (50ml) was filtered through a 0.22-mm
filter (Millipore, Billerica, MA, USA) and diluted three times in
PBS (pH 7.4). Glycan-polyacrylamide-Sepharose stored in 20%
(v/v) ethanol was washed with 10 volumes 20% ethanol,
20 volumes milliQ water and equilibrated with 10 volumes of PBS.
Preprocessed ascites affinity purified against Gala1-4Galb1-
4GlcNAcb-polyacrylamide-Sepharose (P1-PAA-Seph; 10ml). A
constant flow rate of 1mlmin" 1 was controlled by the use of an
auxiliary pump (Model EP-1 Econo Pump, Bio-Rad, Hercules, CA,
USA). Protein content and buffer composition was recorded by UV
at 280 nm and conductivity, respectively (BioLogic DuoFlow
Workstation, Bio-Rad). The column was washed with PBS
containing 0.05% (v/v) Tween 20, unplugged and stored overnight
at 4 1C. The next day, the column was inserted back into the
chromatography system and washed until no protein was detected
anymore. Bound anti-P1 antibodies were eluted using 0.2 M TrisOH
(pH 10.2) and neutralised by 2.0 M Glycine HCl (pH 2.5). Eluted
anti-P1 antibodies were concentrated using the Amicon Ultra-0.5
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centrifugal filter (Millipore), and their concentration was deter-
mined using spectrophotometrically at 280 nm.
Flow cytometry. GSL expression on the cell surface membranes
was analysed by flow cytometry (CyAn ADP Analyzer, Beckman
Coulter, Nyon, CH, USA) prior to antibody labelling. Unconju-
gated antibodies included anti-P1 human IgM (clone P3NIL100;
Immucor Gamma, Ro¨dermark, Germany), anti-P1 murine mono-
clonal IgM (clone OSK17; Immucor Gamma) and anti-Gb3
monoclonal IgG2b (CD77, Pk) (clone BGR23; Seikagaku Biobusi-
ness Corporation, Tokyo, Japan). Biotin-conjugated antibodies
included anti-human mouse IgM (BD Bioscience, Basel, Switzer-
land), rat anti-mouse IgM and rat anti-mouse IgG2b (BD
Bioscience). Streptavidin conjugated to FITC (BD Bioscience)
was used for fluorescence detection. Dead and apoptotic cells were
separated from live cells using propidium iodide (BD Bioscience).
Matching isotype monoclonal antibodies conjugated to FITC were
used as controls (BD Bioscience). All investigated cell lines were
gated individually to exclude debris, followed by single cell gating
to remove dead cells and doublets. Data acquisition was performed
using Summit v4.3 (CyAn ADP Analyzer, Beckman Coulter). Data
analysis was performed using FlowJo v9 (Tree Star Inc., Ashland,
OR, USA).
FACS sorting. IGROV1 cells were grown to 80% confluence,
washed twice in PBS and harvested using non-enzymatic cell
dissociation buffer (Sigma Aldrich, Buchs, Switzerland). Cells were
then washed in PBS containing 1% FCS and resuspended to 106
cellsml" 1. Cell suspension (100ml) was stained with human anti-
P1 IgM (BD Bioscience) as mentioned above and run on a BD
FACS Vantage SE DiVa Cell Sorter (BD Bioscience). IGROV1 cell
line was sorted using 490% and o10% fluorescence signal
intensity for P1-positive cells to receive P1-high and P1-low
fractions, respectively.
Flow cytometry-based inhibition assay. Monoclonal human IgM
antibody directed to P1 (Immucor Gamma, Ro¨dermark) was
preincubated either with Sepharose-P1-PAA or Sepharose-P
k-PAA
(Lectinity Holdings, Moscow, Russia) in different amounts ranging
from 0.015 mmol to 0.06 mmol for 60min at RT. The supernatant
was further processed as described in the flow cytometry section.
Colorimetric cell migration assay. Sub-confluent tumour cells
were ‘starved’ from serum by incubation in serum-free media for
24 h, before harvesting using a non-enzymatic cell dissociation
buffer (Sigma Aldrich, Buchs, Switzerland), washed twice and
resuspended in serum-free media containing 5% (w/v) BSA.
Tumour cells (7.5$ 105 in 300 ml) were loaded into cell culture
inserts containing a polyethylene terephthalate membrane with
8-micron pores (Millipore). The inserts were assembled into
24-well plates with each well containing 700ml of media with 10%
supplemented with fetal calf serum, which was used as chemoat-
tractant. After incubation for 18 h at 37 1C, the media in the
interior of the insert was removed, and the entire insert was
immersed in 400 ml of 0.2% crystal violet/10% ethanol for 20min.
The insert was washed several times in water, and the non-
migrated cells in the interior of the insert were removed using a
cotton-tip swab. After air-drying, five random areas of the inserts
showing the migrated cells were photographed, and cell counts
were performed. Colorimetric cell migration assay was performed
three times.
In addition, parental IGROV1 cells were preincubated with 1%
(w/v) BSA in PBS, the corresponding isotype control (ChromPure
human IgM, Jackson ImmunoResearch Laboratories, Inc., MILAN
Analytica AG, Rheinfelden, Switzerland) and human anti-P1 IgM
(clone P3NIL100), both antibodies in a final concentration of
500 mgml" 1). After 1 h incubation, cells were processed according
to previously described cell migration protocol.
MTT assay. Cultures were incubated with 500 mgml" 1 (final
concentration) MTT dye (Sigma-Aldrich, Buchs, Switzerland) in
PBS for 3 h, followed by removal of the medium and dissolution of
the violet crystals in 200 ml of DMSO. The optical density
(absorbance at 540 nm) was measured with a SynergyH1 Hybrid
Reader (Biotek, Luzern, Switzerland). The data are given as
absorbance at 540 nm, representing cell viability as a function of
araC concentration. Each experiment was performed indepen-
dently twice from multiple cultures.
Real-time cell migration analysis (xCELLigence). Real-time cell
analysis (RTCA; xCELLigence System, Roche Diagnostics GmbH,
Mannheim, Germany) was used to investigate cell migration in
P1-low and -high serous ovarian cancer IGROV1 cells in a label-
free environment (Solly et al, 2004; Ke et al, 2011). Migration
was examined on 16-transwell plates (Roche Diagnostics GmbH)
with microelectrodes attached to the underside bottom of the
membrane for impedance-based detection of the migrated cells.
Prior to each experiment, cells were deprived of FCS over a period
of 24 h. Initially, 160 ml ‘chemoattractant’ media (RPMI 1640
containing 10% FCS) and 50 ml RPMI 1640 containing 1% FCS
was added to the lower and upper chambers, respectively. Sterile
PBS was loaded into the evaporation trophs. CIM-16 plates were
further prepared according to the manufacture’s protocol. Back-
ground signals generated by the cell-free media were recorded.
Cells were harvested using trypsin, counted and re-suspended in an
appropriate volume of RPMI 1640 containing 1% FCS. Cells
(100 000 cells per 100 ml medium) were seeded onto the upper
chamber of the CIM-16 plate and allowed to settle onto the
membrane. Cell-free media was used as negative control. Each
experiment was performed two times in duplicates. The pro-
grammed signal detection for quantification of the cell index was
measured every 15min over a period of 30 h. In an independent
migration assay, 5mM of 1-beta-D-arabinofuranosylcytosine (araC;
Sigma-Aldrich), a DNA polymerase inhibitor, was added to avoid
possible effects on migration caused by cell proliferation.
Statistical analysis. Detailed statistical procedure applied is
described in Supplementary Information.
RESULTS
IgM antibodies in plasma against P1 trisaccharide are reduced in
patients with tubal, peritoneal and ovarian cancer. In our
previous study, the use of three glycan-based immunoassays
(printed glycan array, ELISA and suspension array), detecting IgM,
IgG and IgA together, revealed significant AGA interactions with
the members of the P blood group system (Pochechueva et al,
2011a, b; Jacob et al, 2012). Overall, less AGA to P1 trisaccharide
(printed glycan array, ELISA and suspension array) and Pk
(printed glycan array) were observed in the plasma of the cancer
patient group compared with the control group (Pochechueva et al,
2011b; Jacob et al, 2012).
In this study, we investigated the levels of IgM and IgG AGA in
the plasma of an independent Australian Validation Cohort
(n¼ 155). The cohort consisted of a ‘benign’ control group
(healthy controls and benign gynaecological conditions; n¼ 81)
and a ‘tumour’ group (ovarian borderline tumours, ovarian, tubal
and peritoneal cancers; n¼ 74) (Supplementary Table S1). Based
on suspension array data, AGA to the P1 trisaccharide belonged
mainly to the IgM class (median, IQR; 9.948log(MFI), 9.351–
10.090log(MFI)) in all the tested samples. Significantly lower IgM
anti-P1 antibody levels were observed in the blood plasma samples
of the tumour as compared with the control group (P¼ 0.0002)
(Figure 1A). The tumour group revealed 15/74 (20.3%) samples
having lower AGA levels compared with the lowest control group
sample. Logistic regression did not reveal any relationship between
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clinicopathological parameters and anti-P1 IgM antibody signatures
in the tumour group. In contrast to IgM, generally lower IgG
antibody levels (median, IQR; 7.35log(MFI), 6.726–7.858log(MFI))
were observed. Both the control and tumour groups were similar in
IgG AGA levels, with no significant difference in between both the
groups (P¼ 0.7248, Figure 1A). We have compared various clinical
parameters recorded along with collection of plasma samples for
each patient. Statistical evaluation revealed a significant discrimina-
tion in FIGO stage of the non-mucinous cancer of ovary, tube and
peritoneum group (FIGO Stage, non-mucinous cancer of the ovary,
tube and peritoneum I/II vs III/IV, P¼ 0.01773, t-test). The
remaining investigated clinical parameters were not significantly
different in their anti-P1 IgM antibody levels mentioning Grade (G1
vs G2/3, P¼ 0.2883; t-test) or tumour origin (ovary vs tube vs
peritoneum, P¼ 0.322; ANOVA). An increasing age has previously
been demonstrated to be associated with reduction of AGA in a
cohort of 48 control plasma samples using glycopeptide arrays
(Oyelaran et al, 2009). To investigate the influence of age on anti-P1
antibodies (IgG and IgM), we have applied Pearson’s correlation to
suspension array data and found a moderate negative correlation
(rho¼ " 0.33, Po0.01) in the entire cohort (mean age 56.4 (28–87)
years). However, in contrast to the control group that showed a
moderate negative correlation (rho¼ " 0.37, Po0.01), there was no
correlation between age and anti-P1 IgM levels in the tumour group
(rho¼ " 0.18, P¼ 0.123). This demonstrates that the reduction of
anti-P1 IgM is independent of age in the tumour group and further
indicates an association of these lowered IgM levels with the disease.
In contrast, we observed no correlation between age and anti-P1 IgG
levels in the control and tumour groups (Supplementary Figure S1).
With regards to the risk of cancer recurrence (relapse-free survival),
we observed that women with low IgM AGA levels to P1 (lower than
median fluorescence intensity, n¼ 33) were associated with a
slightly higher risk (P¼ 0.055) of having an earlier recurrence than
patients (n¼ 25) with higher levels of IgM anti-P1 antibodies
(hazard rate ratio 2.328, 95% CI 0.96–5.64) (Figure 1B). The disease-
free survival analysis did not reveal any significant effect (P¼ 0.605).
Identification of P blood group-related GSL in cancer tissues.
GSLs were extracted from fresh collected cancer tissues, and the
glycans released from the glycolipids in the form of alditols
(see ‘Materials and methods’) were analysed in the negative ion
mode using LC-ESI-MS/MS to identify P blood group-related
GSLs (Figure 2). The MS2 spectra contained adequate information
to facilitate the structural assignment of the glycans based
on the fragment ions arising from various glycosidic and cross-
ring cleavages, which were described previously (Domon and
Costello, 1988).
The base peak chromatograms of the glycan alditols released
from the GSLs extracted from serous ovarian (Figure 2A (a)) and
peritoneal (Figure 2B (a)) cancer tissue showed several compo-
nents. Globotriaosylceramide (Gb3, Pk) was detected as [M-H] 1"
m/z 505.31" at low intensities, and the extracted ion chromato-
gram (EIC) showed it eluting at 15.4min (Figures 2A b(i) and B
b(i)). The MS2 spectra of the precursor ion at m/z 505.31"
(Figure 2C (i)) showed prominent B- and C-type fragment ions (B1
at m/z 161.11" , C1 at m/z 179.2
1" and C2 at m/z 341.1
1" )
corresponding to a (Hex)3 or Gal-Gal-Glc sequence of Pk.
Characteristic cross ring fragment ions corresponding to 2,4A2 at
m/z 221.21" and 0,2A2 at m/z 281.0
1" were also present in the
spectrum, thereby confirming the presence of the 4-linked terminal
Gal to the (Gal-Glc) disaccharide (Karlsson et al, 2010). A similar
study indicated the absence of 0,2A2 fragment ion in the MS
2
spectrum of isoglobotriosylceramide (Gala1-3Galb1-4Glcb1)
(Karlsson et al, 2010) while previous reports have also noted that
this characteristic cross ring cleavage was useful in distinguishing
between Type 1 (Galb1-3GlcNAc) and Type 2 (Galb1-4GlcNAc)
chains commonly found in mucins (Chai et al, 2001; Robbe et al,
2004; Everest-Dass et al, 2012).
Globotetraosylceramide (P antigen, Gb4) was detected at [M-H] 1" -
m/z 708.31" and the EIC showed it to elute at 17.0min (Figures
2A c(ii) and B c(ii)). Despite appearing at low intensities, the MS2
spectra of the precursor ion at m/z 708.31" (Figure 2C (ii)) was
indicated by the B- and C-type fragment ions (B1 at m/z 202.0
1" ,
B3 at m/z 526.0
1" , C1 at m/z 220.0
1" and C2 at m/z 382.1
1" ),
which corresponded to the tetrasaccharide sequence, HexNA-
c1Hex3 or GalNAc-Gal-Gal-Glc of the P antigen. Several Y-ion
fragments seen from the reducing-end were also identified at m/z
343.21" (Y2) and m/z 505.2
1" (Y3) while the diagnostic cross ring
cleavages corresponding to 2,4A3 at m/z 424.1
1" and 0,2A3–H2O at
m/z 467.11" further confirmed the presence of 4-linked Gal to the
internal Galb1-4Glcb1 of the Gb4 tetrasaccharide.
The pentasaccharide P1, HexNAc1Hex4 or Gal-Gal-GlcNAc-
Gal-Glc, was detected at [M-H] 1" m/z 870.31" at 18.0min in
both tissue samples (Figures 2A d(iii) and B d(iii)). The glycosidic
fragment ions occurring at m/z 305.11" (B2–H2O ion) and m/z
341.01" (C2 ion) indicated the presence of the terminal Gal-Gal
epitope while the Y-type fragment ions at m/z 546.21" (Y3 ion)
and a prominent m/z 708.21" (Y4 ion) corresponded to the loss of
the Gal-Gal epitope and terminal Gal, respectively, from the
precursor ion, [M-H] 1" m/z 870.31" (Figure 2C (iii)). Besides
that, the prominent 2,4x4 fragment ion observed at m/z 648.3
1" in
the MS2 spectra was also characteristic of the terminal Gal residue
linked via a 4-linkage to the Gal-GlcNAc-Gal-Glc tetrasaccharide.
The cross ring cleavage at 0,2A3–H2O at m/z 425.1
1" and the
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Figure 1. Significantly lower levels of anti-P1 IgM in cancer patients in the Australian validation cohort (n¼ 155). (A) Box-and-whisker plots
showing distribution of AGA levels of IgM and IgG to covalently attached P1 trisaccharide using suspension array. Decreased AGA levels in cancer
patients were observed for IgM. (B) Kaplan–Meier curve on relapse-free survival showing that patients with low antibody levels (n¼33; lower than
median fluorescence signal) have slightly earlier relapse (P¼ 0.055) than those with high antibody levels (n¼25, higher than median fluorescence
signal).
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absence of the 0,2A4 at m/z 646.1
1" further demonstrates the
4-substitution of the GlcNAc residue and the 3-substitution of the
internal Gal and thus tentatively identified this compound as
Gala1–4Galb1-4GlcNAcb1–3Galb1-4Glc, the P1 antigen. The
three P blood group antigens were thus shown to be expressed
on the GSL of serous ovarian and peritoneal cancer tissues. There
was insufficient tubal cancer tissue sample to identify the presence
of these antigens.
P1 is expressed on IGROV1 cell surface. As IgMs were raised
against the P1 antigen in plasma from all types of ovarian cancer
patients, and the P1 (P
k and P) antigens were found to be expressed
on the GSL extracted from the cancer tissue of these patients, we
established an experimental cell culture model for the investigation
into the functional role of P1. Our panel of immortal cell lines,
including human ovarian surface epithelial cells (HOSE6-3 and
HOSE17-1) and various ovarian cancer cell lines (n¼ 6), were
profiled for P1 and P
k expression using flow cytometry (Figure 2D).
Serous ovarian cancer cell line IGROV1 was heterogenic for P1
expression (mean 34.1% ranging from 22.8% to 52.8%) based on
human anti-P1 IgM (clone P3NIL100) antibody. The second
antibody used in this study, monoclonal murine anti-P1 IgM (clone
OSK17), confirmed P1 expression on IGROV1 (mean 22.3%
ranging from 22.0% to 33.6%). IGROV1 cells were also positive for
Pk (mean 33.6% ranging from 12.0% to 54.0%). The normal
control cell line HOSE6-3 was negative for both P1 and P
k as were
the remaining ovarian cancer cell lines (n¼ 5).
To verify the presence of P1 on IGROV1 cell line, we isolated
GSLs from this cell line and analysed the released glycan alditols
using negative ion mode LC-ESI-MS/MS. The P1 pentasaccharide
at m/z 870.31" was shown to elute at 20.3min, and the MS2
spectra consisted of B2 (m/z 323.1
1" ), Y3 (m/z 546.3
1" -) and Y4
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Figure 2. P1 is expressed on cancer tissue cells. (A, B) Base peak chromatograms shown for serous ovarian cancer (A (a)) and endometrioid
peritoneal cancer tissue (B (a)). Selected mass peaks (red arrow) corresponding to the composition of the Pk trisaccharide (Hex3) (A and B b(i); m/z
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represented as an extracted ion chromatogram (EIC). (C) MS2 spectrum of Pk trisaccharide (Gala1-4Galb1-4Glcb1) (i), P tetrasaccharide (GalNAcb1-
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(m/z 708.31" ) fragment ions, which corresponded to the Gal-Gal-
GlcNAc-Gal-Glc sequence. The terminal Gala1–4Gal linkage was
also determined by the cross ring fragment ion at 2,4x4 fragment
ion observed at m/z 648.31" (Supplementary Figure S2).
Monoclonal anti-P1 IgM bind IGROV1 cells. Both P1 and P
k
share terminal disaccharide structure of composition Gala1–
4Galb1–4Glc(NAc). The monoclonal antibody to P1 (clone
P3NIL100) was used in a flow cytometry-based inhibition assay.
Sepharose conjugated PAA-lactose, -N-acetyllactoseamine (Lac-
NAc), -P1 trisaccharide, -P
k was incubated with the monoclonal
antibody to P1 before immunostaining of IGROV1 cells to observe
the degree of inhibition of IgM antibody binding to the expressed
P1 on IGROV1 cell surface. In this experiment, repeated three
times, flow cytometry of 52.8% P1-positive IGROV1 cells revealed
complete inhibition of monoclonal anti-P1 antibody by preincu-
bating with 0.015 mmol P1 glycoabsorbents (0.04%). In contrast,
less reduction (28.3% by 0.06 mmol Pk) of bound anti-P1 antibodies
to IGROV1 cells was observed in case of Pk glycoabsorbent
(Figure 3). Anti-P1 antibodies were only slightly inhibited by
preincubation with glycoadsorbents Lactose (0.06 mmol; 46.8%)
and LacNAc (0.06 mmol, 44.8%). This clearly demonstrates that
IGROV1 cells express P1 on their cell surface, and monoclonal
antibody to P1 shows clearly higher affinity to P1 compared with
Pk. It also demonstrates specifically that galactose a1–4 link is
required for antibody binding and that lactose and LacNAc are not
primarily epitopes of P1.
Anti-glycan antibodies levels are similar in ascites and blood
plasma. To determine whether anti-tumour antibodies were
expressed in ascites as well as plasma of patients, we investigated
the presence and distribution of AGA in matched ascites and blood
plasma samples (n¼ 11 patients) for IgA, IgG and IgM together
and separately using the printed glycan array. This was also done
for epitope mapping of ascites-derived human anti-P1 antibodies.
We detected a broad spectrum of AGA in both plasma and
ascites (Figure 4). The fluorescence scan of the binding to the
immobilised glycans on the array showed high amplitude of AGA
in ascites of IgG, IgM and IgA in both 50 mM and 10 mM glycan-
printed arrays (Supplementary Figure S3). We observed the highest
median relative fluorescence signals in ascites (median, 32.75$ 104
RFU) and in plasma (43.33$ 104 RFU) for anti-glycan IgM
antibodies. Anti-glycan IgG antibodies showed lower interaction
with the glycans (ascites (8.11$ 104 RFU), plasma (9.80$ 104
RFU) as well as anti-glycan IgA (ascites (8.8$ 104 RFU),
plasma (10.4$ 104 RFU)). Different levels of AGA to P1
trisaccharide were detected in all the tested ascites and plasma
samples (Figure 4). Highest binding to P1 was observed for IgM
(ascites (18.1$ 104 RFU), plasma (14.3$ 104 RFU)) compared
with IgG and IgA.
Matched ascites and plasma AGA signals were not dependent
on the volume of patient’s ascites. Based on raw data sets of 50mM
printed glycan arrays, strong correlation between matched ascites
and blood plasma samples was observed (Figure 4): IgAþ IgGþ
IgM (CCC¼ 0.889), IgA (CCC¼ 0.888), IgG (CCC¼ 0.961), and
IgM (CCC¼ 0.950). Correlations were similar for 10 mM printed
glycans. This demonstrates that detected AGA levels were
independent of the volume of ascites.
Naturally occurring anti-P1 antibodies in ascites bind to cancer
cells expressing P1 on their cell surface. The results achieved
from the above experiments demonstrated that (A) anti-P1
antibodies detected by glycan-based immunoassays are reduced
in plasma of cancer patients, (B) P blood group-related glycans are
detectable in tissue samples of cancer patients, (C) IGROV1
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ovarian cancer cell line was found to express P1 on its cell surface
among all the tested cell lines and (D) profiled ascites contained
AGA to P1 trisaccharide. Therefore the following series of
experiments were aimed to investigate whether IgM antibodies
derived from ascites bind to IGROV1 and in particular to P1
presented on its cell surface in the same way as the plasma-derived
autoantibodies.
We investigated AGA to P1 trisaccharide from an ascites sample
of a late-stage serous ovarian cancer patient. The ascites fluid was
first applied to the IGROV1 cell line in a 1 : 3 dilution, in which
24.3% of cells were stained positive with ascites-derived IgM
antibodies (Figure 5A). Based on this result, we proceeded to
affinity purify antibodies bound specifically to P1 trisaccharide
conjugated to sepharose beads. Affinity-purified proteins yielded a
maximum amount of IgM of 24 mg after concentration. Detection
of purified anti-P1 antibodies of class IgM revealed binding to
P1-expressing IGROV1 (15.1%) (Figure 5A). In contrast, the
ovarian cancer cell line SKOV3, negative for P1 and P
k expression,
had a positive staining of only 0.29% using the purified IgM-P1
antibodies. This demonstrates for the first time that ascites-derived
AGA directed to P1 trisaccharide also bind to naturally expressed
P1 on cell surface of ovarian cancer cells. In the following ELISA
experiment on purified IgM-P1 antibodies (Figure 5B), higher
values for IgM (OD450 nm¼mean 3.23±s.d. 0.08) compared with
IgG (OD450 nm¼ 1.08±0.02) were observed.
Next, we investigated whether purified IgM-P1 antibodies bind
to glycan structures other than P1 (potential cross-reactivity).
ELISA to a limited number of glycoconjugates revealed in the case
of IgM specific binding to P1 trisaccharide, with cross-reactivity to
Gala1-3GalNAc and Gala1-4GlcNAc (Figure 5B). Suspension and
printed glycan array were additionally utilised to study the cross-
reactivity to broader range of glycan structures, other than P1. In
suspension array, the binding of ascites-derived anti-P1 antibodies
to P1, P
k, Ley and a-rhamnose was tested. No preferential binding
was observed comparing P1 and P
k (P1 4.11log(MFI); P
k
4.24log(MFI), IgM class). In contrast, Ley and a-rhamnose coupled
beads revealed only minor binding. In the printed glycan array
(Figure 5C), we applied a threshold of 5% to the highest median
fluorescence signal (19 443 RFU; Gala1–4Galb1–4Glc-sp3) to
eliminate potentially unspecific binding as described previously
(Huflejt et al, 2009). We identified that affinity-purified IgM-P1
antibodies bound to P blood group-related structures as the top 10
glycans (Supplementary Table S2). Most of the identified low-
affinity binding to glycan structures had substructures of the P1
antigen such as Galb1-4Glc(NAc) with 63.0% and Gala1-4Galb
with 22.2% binding reactivity (Supplementary Table S2). This
demonstrates that affinity-purified IgM-P1 antibodies preferen-
tially bound to both Pk and P1 trisaccharide.
P1 expression leads to elevated migration rate in ovarian cancer
cells. GSLs on the cell surface are described to have several
functions in cellular processes, such as pathogen recognition,
angiogenesis, cell motility and cell migration (Panjwani et al, 1995;
Todeschini et al, 2008; Hakomori, 2010). Migration is a common
feature in cancer cells, and therefore we investigated whether or
not the presence of P1 affects cell migration by using a flow
cytometry-based cell sorting of IGROV1 cells to separate P1-high-
from P1-low-expressing subpopulations. After further sub-cultiva-
tion, P1 expression in P1-low IGROV1 cells was determined by
murine monoclonal anti-P1 IgM (OSK17; 18%) or human anti-P1
IgM (P3NIL100; 33.3%). In contrast, P1-high-expressing IGROV1
cells were 50.0% and 66.1% positive for P1, respectively, for these
antibodies (Figure 6A).
Utilising these P1-sorted cell lines, we hypothesised that the
presence of P1 affects cell migration. Significantly higher migration
was detected in P1-high-expessing when compared with P1-low-
expressing IGROV1 cells after an 18 h incubation period
(P¼ 0.0006) (Figure 6B), as shown by colorimetric cell migration
assay. In addition to end-point migration assay, real-time and
label-free measurement of P1-sorted IGROV1 cells was performed
using the xCELLigence system. A number of 100 000 cells was
seeded into each well of the upper chamber, and migration through
the microporous membrane were recorded as cell index. IGROV1
cells with higher P1 were significantly faster after 20 h (P¼ 0.035)
than low P1 cells. Longer incubation periods resulted in no
difference between both subpopulations (30 h; P¼ 0.1337, 40 h;
P¼ 1; Figure 6C). To avoid the influence of potentially elevated
proliferation effects, 5mM cytosine arabinoside (araC) was added to
the cell culture (Supplementary Figure S4). In concordance with
results on the colorimetric cell migration assay and observations on
initial xCELLigence experiment, cells with elevated P1 displayed
high basal migratory activity as indicated by the increases in cell
index values, reflecting the number of migrating cells. In contrast,
P1-low-expressing cells failed to migrate under experimental
conditions. With regard to migratory kinetics, P1-high-expressing
cells migrated rapidly and demonstrated elevated (4.7-fold) cell
index of 0.3434±0.054 (mean±s.d.) as compared with P1-low-
expressing cells (0.0726±0.029; P¼ 0.004, CI 0.1–0.45). This
difference remained constant throughout the 40 h time course
experiment (20 h–3.6-fold (Po0.001, CI 0.32–0.66); 30 h–3.6-fold
(Po0.001, CI 0.40–0.75); 40 h–4.6-fold (Po0.001, CI 0.49–0.84);
Figure 6C). These findings demonstrate that ovarian cancer cells
expressing P1 on their cell surface migrate faster compared with
low-P1-expressing cells originated from the same parental cell line.
In order to confirm that P1 is involved in cell migration, we
performed the colorimetric cell migration assay with anti-P1 IgM-
pretreated IGROV1 cells. The results (Figure 6D) showed that the
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percentage of migrated cells was significantly lower (reduction by
64%; Po0.001) in cultures preincubated with the anti-P1 IgM
antibody. Pretreatment with the respective IgM isotype control did
not affect the migration of IGROV1 cells.
DISCUSSION
Unlike Pk, which has been extensively studied in the areas of
verotoxin-mediated cytotoxicity, human immunodeficiency virus
infection, immunology and epithelial carcinogenesis, there is,
to our knowledge, no published study of P1 and its potential
presence, immunogenicity and its functional role in oncogenesis.
Using glycan-based immunoassays, we have previously demon-
strated that naturally occurring AGA significantly distinguish
healthy controls from ovarian cancer patients (Pochechueva et al,
2011b; Jacob et al, 2012). The present study demonstrates that: (A)
an unknown subpopulation of cancer patients show reduced levels
of anti-P1 IgM antibodies in an extended and independent cohort
from another continent (Australian Validation Cohort), (B) Pk, P
and P1 carbohydrate antigens are detectable in cancer tissue as well
as on the cell surface of cultured ovarian cancer cells, (C) ascites
contains similar anti-glycan IgM-P1 antibody levels compared with
blood plasma independent of its volume at the primary diagnosis,
(D) naturally occurring AGA of IgM class derived from ascites of a
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ovarian cancer patient bind to naturally expressed and chemically
synthesised P1 on glycan arrays, and (E) the presence of P1 on
ovarian cancer cultured IGROV1 cells leads to enhanced migration.
Our results demonstrate that the significantly lower anti-P1
antibody levels observed in cancer patients were primarily due to
the reduction of IgM but not IgG antibodies. This is in full
concordance with the literature on the IgM type anti-Thomsen
Friedenreich antibodies (Desai et al, 1995) and anti-Lewis C
antibodies in breast cancer (Bovin, 2013). A very recently
published work demonstrated significantly reduced human IgM
antibodies to another GSL (N-glycolylneuraminyl)-lactosylcera-
mide (NeuGcGM3) in non-small cell lung cancer patients
(Rodriguez-Zhurbenko et al, 2013). Therefore we can assume that
IgM class of naturally occurring AGA was able to discriminate
between cancer and healthy controls. Natural IgM antibodies
belong to the innate immune system and are primarily produced
by B1 or CD5þ cells (Boes, 2000; Martin and Kearney, 2001; Viau
and Zouali, 2005). As part of the natural immunity, the binding of
IgM to conserved carbohydrate structures acts as a first barrier to
all invasive particles (‘external’) and alterations on proteins and
lipids within an organism (‘internal’) (Vollmers and Brandlein,
2007). To date, several human monoclonal antibodies directed to
tumour-associated carbohydrate antigens have been isolated. For
instance, the monoclonal IgM antibody, SAM-6, specific for
cancerous tissue was first derived from a gastric cancer patient
(Pohle et al, 2004). Later, it was found that the receptor for SAM-6
is a tumour-specific O-linked carbohydrate epitope on GRP78, a
central regulator of endoplasmatic reticulum in protein folding
(Li and Lee, 2006). PAM-1, another monoclonal IgM antibody,
binds to a tumour-specific N-linked carbohydrate epitope, a
posttranslational modification on cysteine-rich fibroblast growth
factor receptor, CFR-1. This antibody also inhibited tumour
growth in vitro and in animal model systems by inducing apoptosis
(Brandlein et al, 2003, 2004a, b). Consistent with the findings of
Vollmers and colleagues regarding SAM-6 and PAM-1, our
observation based on hierarchical clustering indicates that AGA
preferentially bind to substructures of the glycan epitope (Jacob
et al, 2012). Besides that the decrease of AGA mainly of the IgM
class in gynaecological cancer patients (Jacob et al, 2012) also
points to an involvement of naturally occurring IgM autoantibo-
dies, which recognise GSL structures. We further propose that
Gala1-4Galb1-4Glc(NAc) (present in P, Pk and P1 antigens) are a
result of malignant transformation and could serve as an ‘internal’
epitope on GSLs that is recognised by naturally circulating anti-
glycan IgM antibodies.
The observation of lower levels of anti-P1 IgM compared with
anti-P1 IgG in cancer patients is very intriguing, and although
exploring the underlying mechanisms was beyond the scope of the
study, we speculate on a number of possibilities. The elevated
presence of corresponding antigens on cancer cells, in our case P1
GSL, may be bound by circulating anti-P1 IgM and therefore no
longer be freely floating in the plasma and ascites. Another
potential mechanism may be tumour-induced immune suppres-
sion. It is known that ovarian cancers employ a range of strategies,
such as secretion of immunosuppressive cytokines, to facilitate
their escape from immune destruction (Lavoue et al, 2013). It is
possible that this may lead to reduced antibody production against
cancer-associated antigens, for example, P1, conferring a survival
advantage to cancer cells. The antibody repertoire in cancer
patients would therefore be different. Another possible mechanism
is the occupation of anti-P1 IgMs by cancer cells (including
circulating tumour cells) by virtue of their surface expression of
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Figure 6. Elevated P1 expression results in increased migration rate. (A) FACS-sorted subpopulations of P1-low- and -high-expressing IGROV1
cells. Representative histograms showing P1 expression (abscissa) on cell-sorted IGROV1 cells to normalised cell count (ordinate). P1 distribution
for unstained controls (red), P1-positivity P3NIL100 antibody (green) and OSK17 antibody (blue). (B) Colorimetric cell migration assay showing
enhanced migratory ability of IGROV1 cells expressing high compared with low levels of P1. Stained cells counted in five fields and averaged.
Representative image of cell sorted subpopulations of migrated cells (stained violet) after 18 h. (C) RTCA assay for P1-sorted IGROV1 cells showing
the migrated cells (cell index) in bar graphs at the time points 0 h, 10 h, 20 h and 30h. Left bar graph shows RTCA experiment without araC, right
bar graph with araC as proliferation inhibitor. Representative figure out of two independent experiments. (D) Bar chart showing the inhibition of
cell migration of human IGROV1 cells incubated with anti-P1 IgM compared with corresponding incubation with IgM isotype control. Number of
migrated cells was normalised to control. Not significant (NS); *Po0.05, **Po0.01, ***Po0.001.
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P1, leading to a reduction in the amount of unbound antibody in
plasma and/or ascites. The formation of immune complexes
consisting of P1 antigen shed from cancer cells, and anti-P1 IgMs,
may further contribute to this reduction. A prominent example in
the literature for the formation of circulating immune complexes
consisting of Lewis x and antibodies has been shown in
Helicobacter pylori-infected human (Chmiela et al, 1998). With
regards to no change being observed in the anti-P1 IgG levels, we
expected differences preferentially in the case of IgM rather than of
IgG as glycan-based antigens are T-cell-independent antigens and
are recognised by the innate immune system.
Our mass spectrometry results demonstrated that these P1, P
k
and P antigens are expressed on ovarian and peritoneal cancer
tissues. The functional role of the GSL that carry these structures in
carcinogenesis is poorly understood, especially in the case of P1
and P. It was recently described that a monoclonal anti-Pk
antibody (E3E2) inhibited angiogenesis and tumour development
(Desselle et al, 2012). Enhanced expression of Pk has also been
shown to cause doxorubicin resistance in breast cancer cells (Gupta
et al, 2012). Cisplatin-resistant pleural mesothelioma cells were
shown to be sensitised to cisplatin by the addition of sub-toxic
concentrations of Verotoxin 1 (Johansson et al, 2010). In addition,
we also demonstrate that P1 and P
k antigens are also present on the
surface of the IGROV1 serous ovarian cancer cells. IGROV1 is,
therefore, to the best of our knowledge, the only immortal cell line
from several investigated that expresses P1. Using monoclonal
antibodies against P1, only minor cross-reactivity to other glycan
structures was observed in glycan-based immunoassays (not
shown). Furthermore, based on the flow cytometry inhibition
assay using IGROV1 cells as an investigative model, the specificity
of monoclonal antibodies to P1 as shown by the full saturation of
anti-P1 antibodies by inhibition with 0.06 mmol glycan on
sepharose beads indicates that IGROV1 expresses P1 on the cell
surface.
Serous pelvic masses commonly present with malignant ascites,
a plasma–protein-rich intraperitoneal exudate of up to several
litres. Several pathophysiological mechanisms are necessary for
malignant ascites occur: (a) decreased lymphatic ascites absorption,
(b) increased capillary permeability, (c) increased overall capillary
membrane-surface area available for filtration, and consequently
(d) an increased intraperitoneal oncotic pressure due to intraper-
itoneal protein concentration (Tamsma et al, 2001). Using the
printed glycan array, we observed an unexpectedly rich spectrum
of AGA with similar amounts in plasma and ascites. These findings
suggested that there is an equilibrium between both body fluids.
Early lymphatic obstruction is one of the first manifestations of an
inflammatory reaction (Feldman, 1975). As IgM has an important
role in inflammation with multivalent antigen binding due to its
pentameric structure and as the first immunoglobulin class
produced in a primary response to an antigen, lymphatic
obstruction may result in a rapid increase in IgM secreting plasma
cells. Natural circulating AGA have also been described in various
inflammatory conditions, including diabetes mellitus type 1
(Gillard et al, 1989), chronic inflammatory bowel and Crohn’s
disease (Malickova et al, 2006) and in patients with cancer (Young
et al, 1979; Springer, 1984; Springer et al, 1988; Desai et al, 1995).
We also investigated the expression of A4GALT P1- and P
k-
profiled cell lines. As seen in our study, A4GALT is overexpressed
in the P1- and P
k-positive ovarian cancer cell line IGROV1 (Jacob
et al, 2011b), suggesting that A4GALT is not only involved in Pk
but also in P1 synthesis in ovarian cancer cells. We propose that
A4GALT is involved in the progression of various ovarian and
peritoneal cancers; however, the molecular link between A4GALT
mRNA levels and P1 expression remains unknown. This is
consistent with suspension array results in which no tested clinical
parameters were shown to correlate with lower AGA levels to P1
trisaccharide. A recently identified single nucleotide polymorphism
(CT conversion) encoding an additional exon in the genomic
region of A4GALT (Thuresson et al, 2011) could probably explain
the presence of P1 in cancer cells. However, it is unclear whether
the overexpression of A4GALT is causative for the synthesis of P1
or Pk in profiled cancer cell lines. The invasive phenotype of colon
cells lacking Pk could be induced and inhibited by the transfection
of Gb3 synthase (A4GALT) or RNA interference, respectively
(Kovbasnjuk et al, 2005). Another immunohistochemistry-based
study showed that Pk expression was elevated in colorectal cancers
and their metastases; however, A4GALT mRNA levels, protein
expression or galactosyltransferase activity were not investigated
(Falguieres et al, 2008). The potential role of A4GALT in cancer
initiation or progression needs to be elucidated in future studies
with respect to all P blood group-related glycans.
For the first time, we also observed migration rate in P1-high-
expressing cells, and this was even more obvious when araC, a
proliferation inhibitor, was added to the cultures (Roy et al, 2006).
The addition of araC confirmed that the observed difference in
migration was indeed due to altered cell migration and not cell
proliferation. Our results suggest an involvement of P1 in cell
migration, but the underlying molecular mechanisms are unknown.
Finally, this study provides further evidence that P blood group-
related antigens have a role in carcinogenesis and those naturally
occurring anti-glycan IgM antibodies against them may have the
potential to discriminate ovarian cancer patients from healthy
individuals. If these surface antigens prove to be indeed tumour-
specific, they may become candidate molecular targets for potential
imaging tools for confocal fluorescence endoscopy and positron
emission tomography and as tools in targeted immunotherapy
(Janssen et al, 2006; Viel et al, 2008).
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Abstract
Glucosylceramide synthase (GCS) catalyzes the ﬁrst committed step in the biosynthesis of glucosyl-
ceramide (GlcCer)-related glycosphingolipids (GSLs). Although inhibitors of GCS, PPMP and PDMP
have beenwidely used to elucidate their biological function and relevance, our comprehensive litera-
ture review revealed that the available data are ambiguous.We therefore investigatedwhether and to
what extent GCS inhibitors affect the expression of lactosylceramide (LacCer), neolacto (nLc4 and
P1), ganglio (GM1 and GD3) and globo (Gb3 and SSEA3) series GSLs in a panel of human cancer
cell lines using ﬂow cytometry, a commonly applied method investigating cell-surface GSLs after
GCS inhibition. Their cell-surface GSL expression considerably varied among cell lines andmore im-
portantly, sublethal concentrations (IC10) of both inhibitors preferentially and signiﬁcantly reduced
the expression of Gb3 in the cancer cell lines IGROV1, BG1, HT29 and T47D, whereas SSEA3 was
only reduced in BG1. Unexpectedly, the neolacto and ganglio series was not affected. LacCer, the
precursor of all GlcCer-related GSL, was signiﬁcantly reduced only in BG1 cells treated with PPMP.
Future research questions addressing particular GSLs require careful consideration; our results indi-
cate that the extent to which there is a decrease in the expression of one or more particular GSLs is
dependent on the cell line under investigation, the type of GCS inhibitor and exposure duration.
Key words: cancer cell lines, ﬂow cytometry, PDMP, PPMP
Introduction
The altered glycan moiety on glycosphingolipids (GSLs) has been con-
nected to malignant transformation (Hakomori 2002). GSLs are made
of a hydrophobic ceramide (Cer) lipid tail to which an oligosaccharide
head group such as glucose (Glc) or galactose (Gal) is attached to form
either glucosylceramide (GlcCer) or GalCer. GSLs are constituents of
each eukaryotic cell located at the outer layer of the plasma membrane
and play fundamental roles in cell adhesion, cell proliferation and dif-
ferentiation, protein and lipid trafﬁcking, signaling events, and even
function as binding ligands of bacterial toxins and viruses (Hakomori
1992; D’Angelo et al. 2013; Ishibashi et al. 2013; Jennemann and
Grone 2013).
GlcCer is the precursor to the synthesis of lactosylceramide
(LacCer) that is, in turn, the key precursor for further branching
into the neolacto, ganglio and globo series (Figure 1A). The transfer
of Glc to Cer is catalyzed by the glucosylceramide synthase [UDP-
glucose N-asylsphingosine glucosyl transferase (EC 2.4.1.80), GCS]
and is the ﬁrst committed and rate-limiting step in GSL biosynthesis
(Kan and Kolesnick 1992). GlcCer and GCS are therefore crucial
players in many biological processes and competitive GCS inhibitors
have been used to study the biological functions of GSLs in more detail
(Park et al. 2012).
We have previously shown that blood plasma-derived anti-glycan
antibodies discriminate ovarian cancer patients from healthy controls
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using glycan-based immunoassays (Pochechueva et al. 2011; Jacob
et al. 2012). More recently, the neolacto series GSL P1 (Figure 1A)
was identiﬁed on malignant tissue and cultured cancer cells and there-
fore may be considered as a cancer-associated carbohydrate (Jacob
et al. 2014). To investigate the still poorly understood cellular andmo-
lecular functions of neolacto series P1 and globo series P
k (Gb3), an-
other tumor-associated carbohydrate described in the literature
(Kovbasnjuk et al. 2005; Johansson et al. 2009) and encouraged by
previous studies showing that GCS inhibitors such as PPMP deplete
or reduce the expression of particular GSLs, we evaluated the possibil-
ity of depleting cancer cell lines from various cell-surface GSLs using
commercially available GCS inhibitors PPMP and PDMP. In order to
carefully design our study, we performed a systematic review of the
currently available literature in this context and investigated the effect
of both inhibitors on representative GSLs of the globo, neolacto and
ganglio series in various cell lines.
Results
Literature search
A total of 137 studies have been published since 1989. We identiﬁed
73 studies reporting on human cancer cell lines of different tissue that
were treated with either with PPMP or PDMP. Since 1989 a continu-
ously growing number of reports have been observed (Figure 1B). In
general, both GCS inhibitors were shown to cause cytotoxic, antipro-
liferative, antiangiogenic and tumor-volume-reducing effects, modu-
late drug responses in cell lines both cytodestructive (as a drug
sensitizer) and -protective (Morjani et al. 2001; Gouaze et al. 2005;
Ma et al. 2011; Basu et al. 2012), modulate the level of LacCer and
GlcCer and particular reduces the expression of Gb3 in cells (Johans-
son et al. 2009), modulated the transcription of a set of glycogenes
(Ma et al. 2009; Basu et al. 2012), affect protein and lipid trafﬁcking
and membrane metabolism (Stefanic et al. 2010) and affect signaling
Fig. 1. Glucosylceramide-related biosynthesis, the use of GCS inhibitors in the literature and the differential expression of GlcCer–GSL in a pool of cancer cell lines.
(A) Depiction of biosynthetic pathway of the globo, neolacto and ganglio series GSLs (respective shaded areas) from GlcCer and LacCer. The key step in this
biosynthesis of GlcCer-related GSLs is catalyzed by GCS and is competitively inhibited by PPMP and PDMP (red). GSLs of interest are highlighted in green. Gray
arrows indicate further extensions of GSLs. (B) Summarized literature showing cumulative increase of publications per year using either both or single inhibitor (top
left). Pie chart (top right) presenting the number of studies subdivide according to the origin of the cell lines investigated; >2 organs in one study (mixed) and ≤3
publications on one organ investigated summarized by “others”. Box plot (bottom left) showing the median and interquartile range of PPMP (green) and PDMP
(blue) concentrations used in the literature. Bar graph depicting the percentage of all studies for categorized time of treatments. (C) Flow cytometry data on nine
cancer cell lines shown as histogram for negative control (white area under the curve) and GSL-speciﬁcally stained sample (dark gray). The value provided in each
histogram refers to the percentage of positively stained cells and is a representative of three independent experiments.
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pathways in cells (Park et al. 2012). Most of the studies investigated
cancer cell lines originated from blood (27.5%; Figure 1B). PDMP
was generally used in higher concentrations than PPMP (Figure 1B).
Information on the mock control [dimethyl sulfoxide (DMSO), iso-
propanol or water] was provided in only one-fourth (24.7%) of the
studies and only 15.0% provided the information (IC10–50) on how
the concentration of the inhibitor(s) was determined. The duration
of the treatment varied from 30 min up to 168 h (Figure 1B). Particu-
larly interesting to us we found that less than half of the studies
(45.2%) addressed the issue of GCS inhibitor-mediated accumulation
of Cer or reduction of mainly gangliosides and globosides.
Expression of GSLs in different cancer cell lines
Before addressing the effect of PPMP and PDMP on GSL expression,
we measured the GSL content on the cell surface of nine cancer cell
lines (Figure 1C). The investigated glycan epitopes include GSLs
such as LacCer, globo (Gb3 and SSEA3), neolacto (nLc4 and P1)
and ganglio series (GM1 and GD3) (Figure 1C). We observed a dis-
tinct expression of cell-surface GSLs in tested cell lines (Figure 1C).
The precursor for all GlcCer-related GSL, LacCer, was highly ex-
pressed on BG1 (88%) and T47D (63%), moderately on IGROV1
and A2780 (12 to 30%) and absent on SKOV3, OVCAR5,
HCT116, HT29 and MCF7. All cell lines except for HT29 were posi-
tive for a globo series GSL, SSEA3. Another member of this series,
Gb3, was absent on A2780 and OVCAR5, weakly expressed on
SKOV3, HCT116 and MCF7 (2 to 20%) and highly expressed on
IGROV1, HT29 and T47D (41 to 67%) (Figure 1C). With regards
to neolacto series GSL, more than half of the cell lines were positive
for paragloboside (nLc4) except for HT29, T47D, MCF7 and
OVCAR5. The second GSL of this series, P1, was exclusively present
on IGROV1 conﬁrming our previous ﬁndings (Jacob et al. 2011,
2014). The ganglio series member GM1 was highly expressed in all
cell lines while GD3 was completely absent. In summary, all cancer
cell lines expressed at least two GSL on their cell surface but had sig-
niﬁcant differences in GSL distribution, ranging from 6 positive out of
7 measured GSL (IGROV1) to cancer cells expressing only 2 GSL
(OVCAR5 and HT29).
Effect of GCS inhibitors on the survival of cancer cell
lines and determination of optimal concentration and
incubation period
Based on the ﬂow cytometry data, we selected IGROV1, BG1, HT29
and T47D for further analysis according to the following criteria: (i) at
least one cell line from each cancer type, (ii) glycan expression,
(iii) moderate or high GSL expression and (iv) whether P1 and/or
Gb3 were expressed in cell lines as these are GSL of our primary inter-
est. HT29 was favored due to its higher expression of Gb3 than
HCT116. T47D and MCF7 were negative for the neolacto series
but T47D had generally higher expression of GSL compared with
MCF7 (Figure 1C).
In order to avoid the effects of PPMP and PDMP on the GSL ex-
pression, which are compromised by a reduction in cell survival, we
ﬁrst determined optimal inhibitor concentrations. MTT assay was
performed in order to obtain the inhibitory concentrations, i.e. the
“sublethal” concentrations for PPMP and PDMP (reduces cell
survival by no >10%, i.e. IC10) in combinations with different incu-
bation times (24–72 h). The IC10 was chosen since concentrations
were previously shown to be sufﬁcient to inhibit the GCS activity
leading to accumulation of ceramides in the cells (Baran et al.
2007). We also determined the IC50 concentrations in order to
compare the potency of both inhibitors to inﬂuence cell viability.
PPMP substantially decreased the cell viability (80–90%) and was
more cytotoxic in all cell lines than PDMP (50–85%). This observa-
tion was independent of the incubation time (Figure 2A). Both inhi-
bitors signiﬁcantly differed in their molarity based on IC10 and IC50
among three cell lines. The only exception was T47D, in which case
the treatment time over 24 and 72 h did not result in different cell
viabilities.
PPMP and PDMP selectively reduce GSLs in a cell
line-dependent manner
Both inhibitors were used to treat selected cell lines (IGROV1, BG1,
HT29 and T47D) using IC10 (Figure 2A) for 48 h following immuno
staining and ﬂow cytometry analysis on viable cells. We expected a re-
duction in all GlcCer-related GSLs on the cell surface. However, our
ﬁndings clearly demonstrates that Gb3 is the only GSL reduced on the
cell surface of almost all investigated cell lines (n = 4) and for both in-
hibitors. The only exception was observed in case of PDMP treatment
on T47D (Figure 2B). In contrast, the expression of the other globo
series GSL SSEA3 was only affected in BG1.
While PPMP signiﬁcantly reduced LacCer expression in BG1 cells,
PDMP did not affect LacCer expression in all cell lines. Unexpectedly,
remaining GSL levels (nLc4, GM1 and P1) were not changed by either
one or both GCS inhibitors.
Discussion
Chemical compounds PDMP and PPMP are structural analogs of cer-
amide and were designed to inhibit the GCS, the only known glycosyl-
transferase in the biosynthesis of GlcCer–GSLs. Consequently, an
inhibition of this enzyme is expected to result in reduction of
GlcCer–GSLs. We have demonstrated that the extent of the inhibitor-
induced decrease of GSL expression is different for each cell line. Some
GSLs are even not affected. Gb3 seems to be the only GSL which can
be generalized, exhibiting in signiﬁcant reduction in almost all cell
lines for both inhibitors (IC10). This is also in concordance with the
literature. However, we would expect a similar reduction for SSEA3,
a pentasaccharide GSL comprising of Gb3 in its carbohydrate moiety.
This was, however, not observed in our experiments, which may be
explained by SSEA3 being mentioned to be linked toN-glycopeptides
(Shevinsky et al. 1982). Another major ﬁnding is that we could not ob-
serve a marginal extent of reduction within the ganglio (GM1) and the
neolacto series (P1 and nLc4) GSLs. Therefore, our data suggest that
both inhibitors are not suitable to reduce GSL of these series in the
investigated cell lines.
The unexpected ﬁnding on selective reduction of GSLs using GCS
inhibitors could possibly be explained by the complex cellular turn-
over of GSLs. The GSL turnover is dependent on several factors
such as metabolic pathways and ﬂuxes, the ﬂow of the endo- and exo-
cytotic routes, the rate of plasma membrane turnover dependent on
functional status of a cell, and the occurrence of external stimuli
that may inﬂuence neosynthesis or degradation. Therefore, the half-
life of a certain GSL can vary from only a few hours to several days
(Tettamanti 2004). In the case of globosides, Gb3 may has a shorter
turnover compared with SSEA3 in our investigated cell lines and is
therefore affected by GCS inhibitors. This may also account for neo-
lacto and ganglio series. In addition, the latter may be mostly affected
by GCS inhibitors due to the fact that large amounts of gangliosides
are expressed in human tumors of the neuroectodermal origin and
only minor in normal tissue (Hakomori 1985).
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Another explanation for our observations may be found in the col-
lected data of our systematic review of the currently available literature
for the GCS inhibitor PPMP and PDMP affecting the expression of
members of the GlcCer-related GSL in human cancer cells. The litera-
ture search revealed that in most cases only one or two cell lines and
only a small set of GSL (mostly conﬁned to gangliosides) were inves-
tigated within a single study. None of the studies investigated three
GSL series in parallel. Moreover, the effect on the expression of
GlcCer, the direct product of GCS and LacCer, the branching point
for three major GlcCer-related GSL series was only determined in a
few cases. In contrast, our experimental setup studied the effect of
both inhibitors on a large panel of GSLs representing three GlcCer–
GSL series in four cell lines, all measured at the same time. Further dis-
crepancies among studies such as inhibitor concentrations, the treat-
ment duration and the type of the vehicle/mock (if provided) may
also cause variable results.
Chemical modiﬁcations at various sites of these inhibitors were de-
scribed in order to enhance their inhibitory effect and to increase the
extent of ceramide accumulation or of GlcCer-related GSL reduction.
A longer acyl chain in PDMP homologs consisting of various lengths
(C6–C18) more efﬁciently inhibited GlcCer synthesis in MDCK cells.
Chemical modiﬁcations at the fatty acid chain as well as replacement
of the morpholino with a pyrrolidoni ring forming D,L-threo-P4 en-
hanced the inhibitory activity (Abe et al. 1992). Phenyl group substi-
tutions resulting in the compound EtDO-P4 inhibited GCS at an IC50
of 90 nM (Lee et al. 1999) and therefore was more potent compared
with respective IC50 values in the current literature and to our data.
However, the same inhibitor displayed an IC50 at 4 µM in murine
myeloma cells (Manning and Radin 1999). Another important aspect
is off-target effects. Enantiomers of GCS inhibitors were shown
to raise ceramide levels by inhibition of a pathway forming
1-O-acylceramide that does not involve glucosylceramide synthesis
(Shayman et al. 2004). Other GCS inhibitors, Genz-123346
(Silberstein et al. 2011) and EXEL-0346 (Richards et al. 2012), have
been recently introduced and may enhance the impact on all GlcCer
GSLs.
The initial purpose of our study was to reduce Gb3 and P1 using
PPMPor PDMP in ovarian cancer cell lines. However, a reductionwas
only seen in case of Gb3 suggesting that both inhibitors can be applied.
In case of P1, we consider the tested GCS inhibitor strategy not suitable
to deplete cells of the neolacto series. We therefore conclude that a
careful consideration of the type of the inhibitor, of its appropriate
concentration, exposure duration and the type of cell line is recom-
mended for experimental studies in which the depletion of a particular
GSL is used to address the research question of interest. This, of
course, applies to all inhibitor-based studies.
Material and methods
A systematic literature search was performed for the identiﬁcation of
scientiﬁc papers addressing human cell lines in combination with
PPMP and PDMP using PubMed (http://www.ncbi.nlm.nih.gov/
pubmed). The following key words were used: “PPMP” and/or
“PDMP”, “PPMP and cancer” or “PDMP and cancer”. The retrieval
Fig. 2. Effect of PPMP and PDMP on cell survival and on expression of GSLs in IGROV1, BG1, HT29 and T47D cells. (A) MTT assay showing cell survival (ordinate) a
function of the indicated concentrations and treatment duration [24 h (red), 48 h (green) and 72 h (blue)] for PPMP (left panel) and PDMP (right panel). Results are
presented as percentage of the respective mock-treated control. Mean ± SD of three independent experiments performed in quadruplet cultures. The IC10 used for
further ﬂow cytometry experiments is shown for each cell line and inhibitor. (B) Box andWhisker plots representing inhibitor-induced (IC10) changes in expression of
individual GSLs (percentage of FITC-positive cells, ordinate) for each cell line (abscissa) after a 48 h treatment with DMSO (red), PPMP (green) or PDMP (blue). Data
are representative of four independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 were obtained by two-way ANOVA.
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was limited from 1989 to August 2014 and included research papers
and scientiﬁc reports written in English.
Ovarian (IGROV1, A2780, SKOV3, BG1 and OVCAR5), colon
(HCT116 and HT29) and breast (T47D and MCF7) cancer cell
lines were grown in RPMI-1640 media (Sigma-Aldrich) supplemented
with 10% fetal bovine serum (FBS), penicillin (100 U/mL) and strep-
tomycin (100 µg/mL) (Sigma-Aldrich) at 37°C in a 95% humidiﬁed
atmosphere containing 5% CO2.
Primary antibodies to detect the cell-surface-associated GSL were
applied as follows: mouse IgM anti-LacCer (CD17) conjugated to bio-
tin (Ancell, USA, 1 : 200), rat IgM anti-Pk (Gb3) antibody (ABDsero-
tec, Germany, 1 : 200), rat IgM anti-SSEA3 antibody (eBioscience,
Austria, 1 : 200), mouse IgM anti-nLc4 (paragloboside) antibody
[clone 1B2 kindly provided by Prof. Mandel and Prof. Clausen
(Young et al. 1981), 1 : 10], human IgM anti-P1 antibody (Millipore,
Germany, 1 : 10), mouse IgG anti-GD3 (BD Pharmingen, Switzerland,
1 : 200) and Cholera toxin B subunit (1 mg/mL, Sigma, 1 : 200) to de-
tect GM1. Secondary antibodies (obtained from BD Pharmingen)
were used in 1 : 100 dilutions and include: mouse anti-rat IgM anti-
body conjugated to biotin, rat anti-mouse IgM conjugated to biotin,
mouse anti-human IgM conjugated to biotin and anti-mouse IgG/
IgM antibody conjugated to ﬂuorescein isothiocyanate. Cell-surface ex-
pressed GSL was detected with FITC streptavidin (1 : 200). Non-viable
cells were positively stained with 7-amino-actinomycin (BD Pharmin-
gen, 1 : 50). Isotype controls for each primary antibody were used
including puriﬁed rat IgM (BD Pharmingen), puriﬁed mouse IgM and
chrompure human IgM (JacksonImmunoResearch, USA).
D,L-Threo-1-Phenyl-2-palmitoylamino-3-morpholino-1-propanol
(PPMP; Sigma-Aldrich) and D,L-erythro-1-Phenyl-2-decanoylamino-
3-morpholino-1-propanol•HCl (PDMP; Matreya, USA) were ali-
quoted in DMSO to 20 and 50 mM stocks, respectively, and stored
at −20°C.
The MTT assay was performed to deﬁne the inhibitor concentra-
tion (IC50) and working concentration (IC10) for ﬂow cytometry ex-
periments. Cells seeded in 96-well plates (BD Falcon, Switzerland)
were incubated with various concentrations of PPMP, PDMP or re-
spective DMSO concentrations (mock control) for 24, 48 and 72 h.
Cell cultures were incubated withMTT-dye (Sigma) at ﬁnal concentra-
tion 500 µg/mL for 3 h. After removal of the supernatant 200 µL
DMSO was added to dissolve the crystals. The optical density (OD,
absorbance at 540 nm) was measured with a SynergyH1 Hybrid
Reader (Biotek, Switzerland). The data (mean ± SD of three independ-
ent experiments performed in quadruplets) were presented as the sur-
vival (percentage of control) calculated from the OD after subtraction
of the contribution of DMSOmock as a function of PPMP and PDMP
concentration and incubation time. IC10 and IC50 concentrations of
PPMP and PDMP were calculated by linear extrapolation.
To evaluate the distribution of GSL LacCer, Gb3, SSEA3, nLc4,
P1, GD3 and GM1, cells grown in T25 cm
2
ﬂask to 80% conﬂuence
were washed with PBS and harvested with 1× Cell Dissociation Solu-
tion non-enzymatic (Sigma-Aldrich) at 37°C. Cells were transferred to
a 96-well V-bottom micro test plate (105 cells/well), and pelletized at
400 × g for 5 min.
Primary antibodies were added to the cells, resuspended and incu-
bated on ice for 1 h. Cells were then washed twice with FACSWASH
(1%, w/v, BSA in PBS) and incubated with the respective secondary
antibodies. After additional washing, cells were incubated with strep-
tavidin conjugated to FITC on ice for 30 min. Removal of unbound
streptavidin was accomplished by additional washing. Following
ﬁnal washing, cells were re-suspended in 200 µL of FACSWASH and
immediately analyzed with the ﬂow cytometer (BD Accuri C6, BD
Pharmingen). Each cell line was gated individually to exclude debris
(FSC-A vs. SSC-A) and subjected to single cell gating FSC-A vs.
FSC-H. Doublets and non-viable cells were excluded from analysis
by gating width vs. 7-AAD. Data acquisition were performed using
(BD Accuri C6 software, BD Pharmingen), while data analysis were
performed using FlowJo v10.0.4 (Tree Star Inc., Ashland, USA).
All comparisons for the MTT assay were statistically evaluated
with two-tailed Student’s t-test. P-values of < 0.05 were considered
statistically signiﬁcant. Flow cytometry data were evaluated with
two-way ANOVA comparing mock control with GCS-inhibitor
treatments.
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Naturally occurring anti-glycan antibodies
binding to Globo H-expressing cells identify
ovarian cancer patients
Tatiana Pochechueva1†, Shahidul Alam1,2†, Andreas Schötzau1, Alexander Chinarev3, Nicolai V. Bovin3,
Neville F. Hacker4, Francis Jacob1,2* and Viola Heinzelmann-Schwarz1,5*
Abstract
Background: Glycosphingolipids are important compounds of the plasma membrane of mammalian cells and
a number of them have been associated with malignant transformation and progression, reinforcing tumour
aggressiveness and metastasis. Here we investigated the levels of naturally occurring anti-glycan antibodies to
Globo H in blood plasma obtained from high-grade serous ovarian cancer patients (SOC) and women without
gynaecological malignancies (control) using suspension glycan array technology employing chemically synthesized
glycans as antibody targets.
Results: We found that anti-human Globo H IgG antibodies were able to significantly discriminate SOC from
controls (P < 0.05). A combination with the clinically used tumour marker CA125 increased the diagnostic
performance (AUC 0.8711). We next compared suspension array with standard flow cytometry in plasma samples
and found that the level of anti-Globo H antibodies highly correlated (r = 0.992). The incubation of plasma-derived
anti-glycan antibodies with chemically synthesized (presented on fluorescence microspheres) and native Globo H
(expressed on Globo H-positive cell lines) revealed strong reactivity of naturally occurring human anti-Globo H
antibodies towards its antigen expressed on ovarian cancer cells.
Conclusions: Our data demonstrate that human plasma-derived antibodies to Globo H as well as the presence of
the antigen might be considered as therapeutic option in ovarian cancer.
Keywords: Ovarian cancer, Glycosphingolipids, Suspension array, Glycan
Background
Globo H is a glycosphingolipid of the globo series with a
sugar terminus resembling the blood group antigen H
determinant. First identified in human teratocarcinoma
and breast cancer cells [1, 2], Globo H was found to be
overexpressed on the cell surface of several epithelial
cancers such as breast, colon, endometrial, gastric,
pancreatic, lung, and prostate cancers [3–5]. It is also
moderately expressed in normal epithelial tissues (lung,
breast, prostate, stomach, pancreas, and ovary), but its
distribution is restricted to apical epithelial cells at
lumen borders [5]. Functionally, Globo H has been
associated with tumour stem cells [6], to be a potent
inducer of angiogenesis [7], and an immunosuppressor
through Notch signalling [8]. The high Globo H
expression by only cancer and cancer stem cells made it
an attractive target for generation of therapeutic cancer
vaccines. These vaccines underwent the long history of
development and improvement and are currently being
tested in clinical trials for treatment [9–11]. Globo H
has therefore been considered as one promising tumor-
associated glycan biomarker, in particular for breast
cancer.
Plasma-derived naturally occurring anti-glycan anti-
bodies (AGA) have been associated to various human
diseases including cystic fibrosis [12], Crohn’s disease
[13], and various malignancies [14–18]. Also healthy
humans harbour sets of AGA to blood group-, xeno-
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(heterophil), and infection-related glycan motifs [19].
Globo H was also shown to be an antigen for natur-
ally occurring plasma-derived AGA in breast and
some other epithelial cancers with high specificity
[20]. These antibodies were assessed by the glycan
microarray technology and their levels were signifi-
cantly different in serum of breast cancer patients
and healthy individuals [21]. Despite these few re-
ports, there is limited knowledge on Globo H antigen
expression on cell lines and the presence of naturally
circulating AGA in plasma from ovarian cancer
patients.
We assessed the levels of anti-Globo H antibodies of
IgG and IgM isotypes in healthy and serous ovarian
cancer (SOC) patients. We used our “in house” devel-
oped suspension glycan array (SGA), a robust tool for
AGA profiling [15, 22], to detect anti-Globo H anti-
bodies in human plasma samples for discrimination of
ovarian cancer patients and normal controls. We also
compared SGA and standard flow cytometry in order to
address the following questions; a) whether AGA levels
are comparable in both methods, and b) whether those
antibodies can recognize native Globo H epitope on the
cell surface of cancer cell lines.
Methods
Human subjects
Two groups of female donors were involved in the current
study. All patients were over the age of 18 and were
prospectively included after giving informed consent in
accordance with ethical regulations (Hunter Area Re-
search Ethics 04/04/07/3.04; South Eastern Sydney
Illawarra HREC/AURED Ref:08/09/17/3.02). The serous
ovarian cancer (SOC) group consisted from patients with
serous ovarian cancer with Grade 2 and 3 of all FIGO
stages (SOC n = 19). The control group (n = 29) consisted
of women without macroscopically confirmed gynaeco-
logical malignancy including comprising of benign donors,
patients with benign gynaecological tumours (leiomyoma,
cystadenoma, or fibroadenoma) and patients undergoing
medical control due to previous family history of breast
cancer or bearing known BRCA mutations. Women in the
control group had no other type of malignancy at the date
of collection. Patients were either admitted with an
adnexal mass to the Gynaecological Cancer Centre of the
Royal Hospital for Women, Randwick, Australia or were
seen as outpatients to the Hereditary Cancer Centre of
The Prince of Wales Hospital, Randwick, Australia. The
processing of blood plasma samples was performed as
previously described [15, 23].
Suspension glycan array
Glyco-polymers with end-biotin group- Sialylated and
sulfated glycans were chemically synthesised (Lectinity
Holdings, Moscow, Russia. The glycopolymers, Glyc(20)–
PAA–biot1, used for coupling to fluorescent beads were
produced in-house as previously described [24]. The
glycopolymers are composed of a polyacrylamide carrier
(PAA, number of the average polymerisation degree, n =
220) provided with end biotin groups and side-pendant Glyc
residues, that are statistically distributed along the polymer
backbone. The content of monomer units with glycan
substitution is 20 mol %. Non-glycosylated monomer units
are substituted with an ethanolamine residue for the regular
Glyc(20)–PAA–biot1. GD3 and GM2 glycans were pur-
chased from Elicityl (Crolles, France) and then used for
synthesis of Glyc(20)–PAA–biot1, as described above.
Modification of fluorescent microbeads- Biotinylated
glycopolymers were coupled to fluorescent Bio-Plex
Pro™ Magnetic COOH beads of 6.5 μm diameter with
distinct spectral “addresses” (Bio-Rad Laboratories Inc.,
Cressier, Switzerland). Each bead’s region was embedded
with a precise ratio of red and infrared fluorescent dyes
allowing its identification using Bio-Plex 200 Suspension
Array System (Bio-Rad Laboratories Inc., Hercules, CA,
USA). Coupling of biotinylated glycopolymers using biot–
PEG23–NH2 (Hetero-bifunctional PEG, MW= 1300, Iris
Biotech GmbH, Marktredwitz, Germany) modification of
microbeads was accomplished as described previously
[25]. All remaining steps were performed as described
previously [25]. Data are presented as median MFI and
interquartile range (IQR).
ELISA
CA125 levels in blood samples obtained from patients
were measured using the human CA125 ELISA kit
(MUC16) SimpleStep (Abcam, LucernaChem AG,
Switzerland, #ab195213). ELISA was performed according
to manufacture’s protocol.
Cell culture
Ovarian (IGROV1, A2780, SKOV3, BG1, OVCAR3,
OVCAR4, OVCAR5, OVCAR8, OAW42, TYK-nu, KUR-
AMUCHI, OVSAHO, CAOV3, and TOV21G), and breast
(T47D and MCF7) cancer cell lines, ovarian surface
epithelial cells (HOSE17.1 and HOSE6.3) and normal
mammary epithelial cell line MCF10A were grown in
RPMI-1640 media (Sigma-Aldrich, Buchs, Switzerland)
supplemented with 10% fetal bovine serum (FBS), penicil-
lin (100U/ml) and streptomycin (100 μg/ml) (obtained
from Sigma-Aldrich). Fallopian tube secretory epithelial
cells (FT237 and FT240) were grown in DMEM-Ham’s
F12 medium without HEPES buffer (Sigma) supple-
mented with UltroserTm (PALL corporation, Life Science,
Switzerland), penicillin (100U/ml) and streptomycin
(100 μg/ml). Another ovarian cancer cell line, EFO27 were
grown in RPMI-1640 media supplemented with 20% FBS,
penicillin (100U/ml), streptomycin (100 μg/ml) and 1 mM
Pochechueva et al. Journal of Ovarian Research  (2017) 10:8 Page 2 of 6
40
sodium pyruvate (purchased from Sigma). The culture
condition for all cell lines were 37 °C in a 95% humidified
atmosphere containing 5% CO2.
Flow cytometry
Cells were seeded in T25cm2 flask cultivated to 70–80%
confluence, washed with PBS, harvested with 1x non-
enzymatic cell dissociation solution at 37 °C and counted
using trypan blue. Cells were than transferred to 96-
well- V-bottom micro test plate (105 cells/well) and pel-
letized at 400xg for 5 min. Analysis of cell membrane–
bound Globo H was performed with two-step staining
procedure. Anti-Globo H antibodies (Mbr1_IgM_1:500,
diluted in FACSWASH (1% BSA in PBS)) were added to
cells, resuspended and incubated on ice for 1 h. After
two washes with FACSWASH, cells were incubated with
R-PE (1:200) on ice for 30 min. Following two washing
steps, cells were incubated with 7-AAD (1:100) on ice
for 10 min. After the final wash, cells were resuspended in
200 μl of FACSWASH and analyzed with BD Accuri C6
flow cytometer (BD Pharmingen). Analysis of inhibition
experiments using microspheres and human cell lines
were analyzed with BD LSR Fortessa. Data analysis was
done using FlowJo v10.0.4 (Tree Star Inc., Ashland, USA).
Statistical analysis
The raw data (obtained as MFI) were log-transformed.
Statistical analysis was either performed by GraphPad
Prism 6 software or the statistical software R version
3.1.3 (www.R-project.org). Penalized logistic regression
and receiver operating characteristics (ROC) analysis was
performed using the R packages ‘glmnet’ and ‘ROCR’ [26],
respectively. Comparisons between subgroups were per-
formed using Mann Whitney U-test. A p value < 0.05 was
considered significant.
Results and discussion
Studies in the past suggested that levels of anti-Globo H
antibodies are predictive for breast cancer [20, 21].
Recent genomic and transcriptomic analyses by the
Cancer Genome Atlas (TCGA) revealed that basal-like
breast cancer displays significant molecular similarities
to undifferentiated (high-grade) SOC [27, 28]: both
diseases share molecular signatures (e.g. mutations in
TP53, BRCA1/2, and RB1). Thus, we investigated the
presence of AGA to Globo H in a cohort of 48 blood
plasma samples, consisting of high-grade SOC (n = 19)
and a control group (n = 29) comprising women with-
out or benign disease of the gynaecological tract (e.g.
leiomyoma, cystadenoma, or fibroadenoma).
The SGA utilized to measure AGA [22, 25] incorpo-
rated coupling of microspheres with an internal fluores-
cence to chemically synthesized glycans (Fig. 1a) via a
linker (Fig. 1b). Using monoplexed SGA levels of
antibodies to alpha-rhamnose (positive control) and
Globo H were generally high for both isotypes in all
samples (Fig. 1c-e). In contrast, aminoglucitol (negative
control) showed AGA levels below the threshold
(Fig. 1c). We observed significantly decreased anti-globo
H antibody levels of IgG isotype in SOC patients to the
control group (IgG 2642 MFI (338; 6067), p = 0.009,
Fig. 1d-e), hence clearly discriminating cancer patients
from healthy controls. The comparison for the IgM iso-
type showed a similar trend (1526 (492; 4154), p = 0.071,
Fig. 1d-e). We next performed ROC analysis including
the current clinical ovarian cancer biomarker CA125,
which was measured by ELISA during clinical exami-
nations at initial diagnosis. The combination of anti-
Globo H IgG and IgM revealed an area under the
curve (AUC) of 0.7441. The addition of CA125 in a
penalized logistic regression model increased the AUC
to 0.8711, which was even higher than CA125 alone
(AUC 0.8539). This indicates that anti-globo H anti-
body levels improve the diagnostic performance of
CA125 alone (Fig. 1f ).
Despite this intriguing finding it remained to be eluci-
dated whether anti-Globo H antibodies are capable to
bind the native Globo H antigen expressed on ovarian
cancer cells and whether plasma-derived AGA also
recognize other glycan structures (epitopes similar to
Globo H). Thus, we profiled a panel of ovarian (n = 15)
and breast (n = 2, used as positive control, [11]) cancer
cells (Fig. 2a) using the monoclonal antibody MBr1
(Fig. 2a). After the evaluation of the MBr1 in breast
cancer cell lines MCF7 and T47D, the working concen-
tration 2.5 μg/ml MBr1 was selected. We observed
Globo H expression in only three ovarian cancer cell
lines, OVCAR3, BG1, and IGROV1 (Fig. 2a). The
remaining ovarian cancer cell lines never showed any
positivity for Globo H. The normal ovarian surface
epithelial cell lines (HOSE17-1 and HOSE6-3), fallopian
tube secretory epithelial cells (FT237 and FT240), and
the mammary epithelial cell line MCF10A were also
negative for Globo H (Fig. 2a). In contrast to our
findings, the literature reported Globo H expression
also in TOV21G ovarian cancer cells [29]. This dis-
crepancy might be explained by the use of different
monoclonal antibodies to Globo H (MBr1 and VK9)
in these two studies.
In order to study the binding of naturally occurring
anti- Globo H antibodies from patient samples to
Globo H-positive ovarian cancer cell lines, we com-
pared SGA and standard flow cytometry. A total of
fourteen plasma samples reflecting the spectrum of
antibody levels were selected and profiled using both
methods. The comparison revealed a high correlation
(r = 0.992, p < 0.0001) concluding that flow cytometry is
suitable for AGA profiling (Fig. 2b).
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Fig. 1 Plasma-derived anti-glycan antibodies of IgG and IgM isotype bind to polymeric presented Globo H glyco-clusters differentiating healthy
controls from ovarian cancer comparable to CA125. a Schematic presentation of the coupling procedure of end-biotinylated glycoconjugates to
streptavidin containing beads. b Chemical structure of Globo H conjugated to biotin. c Human AGA (log median fluorescence intensity for IgG
and IgM separately) binding to positive (alpha-rhamnose) and negative (aminoglucitol) control. (d & e) Box-and-whisker plot showing distribution
of AGA levels directed to Globo H in the blood plasma of serous ovarian cancer (SOC) patients and control group. f ROC curve for both antibody
classes (IgG and IgM) together and with CA125 together. Individual CA125 levels are displayed
Fig. 2 Anti-Globo H antibodies bind ovarian cancer cell lines determined to express naturally synthesized Globo H on the cell surface membrane.
a Flow cytometry results showing expression of Globo H in selected breast and ovarian cancer cell lines. Representative histograms for cell lines
HOSE17.1, FT237, OVCAR3, BG1, MCF10A and MCF7. The percentages of positively stained cells were displayed and are a representative of five
independent experiments. Bar chart summarizing five independent experiments on all cell lines tested showing the mean and standard deviation for
each cell line. b SGA and FACS show high correlation for binding of plasma-derived anti-Globo H antibodies to Globo H-coupled microbeads (SGA)
and Globo-H positive cells (FACS, here MCF7 cells); plasma samples 1–14, dilutions 1/40 (SGA) and 1/200 (FACS). MFI values were log-transformed. c
Flow cytometry data represented as histogram for negative control (light grey) and positively stained sample (dark grey). The value provided in each
histogram refers to the percentage of positively stained cells
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To finally prove that plasma antibodies indeed bind to
Globo H on the cell surface, we co-incubated anti-Globo
H positive plasma (a pool of five individual samples)
with Globo H-coupled microbeads (105 beads). As a
negative control we used MCF10A. We found that
plasma antibody binding decreased to different extents
among all Globo H positive cancer cell lines (MCF7,
T47D, and OVCAR3) tested in flow cytometry (Fig. 2c).
We did not achieve pronounced decrease of binding
using plasma dilution 1/5–1/100 as well as with combin-
ation of less than 0.5 × 105 beads. The plasma binding in
case of MCF10A was high (86%) and did not decrease
after plasma pre-incubation with Globo H beads (Fig. 2c).
These data clearly demonstrate that ovarian cancer cells
express Globo H and that the antigen is recognized by
naturally occurring anti-Globo H antibodies from human
blood plasma.
Taken together, we demonstrate that women with
SOC and benign disease display different levels of
anti-Globo H antibodies. Moreover, these antibodies
are capable to bind Globo H expressing ovarian
cancer cell lines.
Conclusions
In this study we report on naturally occurring AGA to a
well-known tumour-associated carbohydrate antigen
(Globo H) in ovarian cancer. The current study is based
on Globo H identified by circulating AGA as well as the
monoclonal antibody MBr1. However, future studies
have to consider larger cohorts and the measurement of
combinations with other representative biomarkers in-
cluding AGA to evaluate the diagnostic performance of
Globo H. Further studies might also incorporate mass
spectrometry to confirm the presence of the antigen in
ovarian cancer cells. Verification in tissue samples might
also support a potential role of Globo H in this malignant
disease, e.g. by MALDI imaging mass spectrometry [30].
This knowledge might also contribute to our understanding
of the functional role of Globo H as it has been associated
with cancer stem (−like) cells previously [31].
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Altered (neo-) lacto series glycolipid 
biosynthesis impairs α2-6 
sialylation on N-glycoproteins in 
ovarian cancer cells
Shahidul Alam1,2,*, Merrina Anugraham1,*, Yen-Lin Huang1, Reto S. Kohler1, Timm Hettich3, 
Katharina Winkelbach1, Yasmin Grether1, Mónica Núñez López1, Nailia Khasbiullina4, 
Nicolai V. Bovin4, Götz Schlotterbeck3 & Francis Jacob1,2
The (neo-) lacto series glycosphingolipids (nsGSLs) comprise of glycan epitopes that are present 
as blood group antigens, act as primary receptors for human pathogens and are also increasingly 
associated with malignant diseases. Beta-1, 3-N-acetyl-glucosaminyl-transferase 5 (B3GNT5) is 
suggested as the key glycosyltransferase for the biosynthesis of nsGSLs. In this study, we investigated 
the impact of CRISPR-Cas9 -mediated gene disruption of B3GNT5 (∆B3GNT5) on the expression of 
glycosphingolipids and N-glycoproteins by utilizing immunostaining and glycomics-based PGC-UHPLC-
ESI-QTOF-MS/MS profiling. ∆B3GNT5 cells lost nsGSL expression coinciding with reduction of α2-6 
sialylation on N-glycoproteins. In contrast, disruption of B4GALNT1, a glycosyltransferase for ganglio 
series GSLs did not affect α2-6 sialylation on N-glycoproteins. We further profiled all known α2-6 
sialyltransferase-encoding genes and showed that the loss of α2-6 sialylation is due to silencing of 
ST6GAL1 expression in ∆B3GNT5 cells. These results demonstrate that nsGSLs are part of a complex 
network affecting N-glycosylation in ovarian cancer cells.
Glycosphingolipids (GSLs) have been shown to be essential in a wide variety of biological events - such as 
cell signalling, modification of insulin and EGF-receptor activities, and modulation of Notch ligand activity 
in Drosophila1. They also interact with well-known proteins such as EGFR2, TGFβ 1R3, and VEGFR4 in vari-
ous malignancies. GSLs are usually divided into two major families, known as galactosylated or glucosylated 
ceramides. The latter (glucosylceramide-related glycosphingolipids) is further divided into three major classes 
based on the action of specific glycosyltransferases; globo- (A4GALT), ganglio- (B4GALNT1 and ST3GAL5), and 
(neo-) lacto (B3GNT5) -series. Additional elongation of lipid-linked carbohydrate chains is determined by the 
intracellular localization, which is usually embedded in the endomembrane system and the regulation of specific 
glycosyltransferases within the GSL-glycan biosynthetic pathway5.
The B3GNT5 gene encodes the glycosyltransferase β -1,3-N-acetylglucosaminyl transferase 5, which 
attaches N-acetylglucosamine (GlcNAc) to lactosylceramide (Galβ 1-4Glcβ 1-1Ceramide) resulting in the pre-
cursor lactotriaosylceramide (Lc3, GlcNAcβ 1-3Galβ 1-4Glcβ 1-1Ceramide) for synthesis of lacto (Type 1) and 
neolacto-series (Type 2) GSLs6 (Fig. 1A). This enzyme, together with its associated glycosidic product (Lc3), 
plays a role in human malignant diseases, embryonic development and cell differentiation. Specifically, Lc3 
was shown to be elevated on the cell surface of human pro-myelocytic leukemia HL60 cells6,7. Moreover, it has 
also been suggested as a differentiation-associated GSL in the bone marrow of acute myeloid leukemia patients 
with corresponding elevated B3GNT5 expression8. In mice experiments, the current data on the potential func-
tion of B3GNT5 seems rather controversial, possibly due to the use of a multicellular organism and different 
mutation-generating techniques, thereby limiting biological interpretations regarding its role9–11. Other than 
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Lc3, it is also known that B3GNT5 is the key enzyme for several GSL structures associated with human diseases 
such as sialyl-Lewis x12 and human blood groups ABO and P [based on the Kyoto Encyclopedia of Genes and 
Genomes (KEGG, http://www.genome.jp/kegg/)]. Nevertheless, the biological function of B3GNT5-mediated 
GSLs is rather limited in the context of cancer and remains to be explained.
In this study, we successfully created a site-specific and heritable B3GNT5 knockout in human cancer cell 
lines. By utilizing the CRISPR Cas9 technology, we established an experimental tool for studying the function 
of B3GNT5-mediated GSLs, namely the entire (neo-) lacto series (nsGSL). In addition, we also performed a gly-
comics profiling using mass spectrometry to evaluate the effects of this GSL gene knockout on the entire glycome 
repertoire of membrane proteins and lipids. The specific glycan alterations described in this study are consistent 
in two ovarian cancer cell lines and seem to be specific for B3GNT5. It is envisioned that this gene-editing tech-
nology will serve as a useful platform to facilitate the downstream investigation of B3GNT5 and its regulation of 
both GSL and protein glycosylation in cancer development and progression.
Results
(Neo-) lacto- series glycosphingolipids are expressed on cancer cells. As part of our initiative to 
comprehensively characterize nsGSLs, we have recently reported the presence of paragloboside (nLc4, precursor 
of P1) and P1 pentasaccharide in tumor specimens and immortal ovarian cancer cells using two complementary 
methods; PGC-LC-ESI-MS/MS and flow cytometry13–15. In this study, we extended the profiling of nsGSLs into 
three distinct groups; Normal (HOSE17-1, FT33-Tag, FT190 and FT237 which were suggested as a potential 
origin of epithelial ovarian cancer16,17), Ovarian (IGROV1, SKOV3, BG1, and CAOV3), and Non-ovarian cancer 
cell lines (Ls174T, HeLa, HCT15, and HCT116). The flow cytometry data revealed a generally lower expression 
of nsGSLs in normal cells (nLc4 2–12% and P1 1–3%), while all four of the ovarian cancer cell lines displayed ele-
vated expression for nLc4 (25–98%). A distinct expression of nLc4 (5–43%) was observed in non–ovarian derived 
cancer cells (Fig. 1B). P1 expression was observed only in IGROV1 (27%) and Ls174T (23%) cell lines (Fig. 1B). 
Based on their nsGSL expression levels, IGROV1 was selected for genome editing to establish a heritable and 
site-specific B3GNT5 knockout cell line (∆ B3GNT5), which was then selected to study the influence of nsGSLs 
on the glycome repertoire.
Genome editing of B3GNT5 for depletion of nsGSLs and validation using flow cytome-
try. B3GNT5 is the key glycosyltransferase involved in synthesis of nsGSLs6,18. We utilized the genome edit-
ing technology, CRISPR-Cas9, to homozygously delete an 898 bp genomic region, including the translation 
start site of B3GNT5 (Fig. 2A). The plasmid pSpCas9(BB)-2A-GFP encoding two specific sgRNA sequences 
(Supplemental Table S1), was transiently transfected into IGROV1 and tested after 72 h incubation for Cas9 activ-
ity, in which an additional band at 309 bp (∆ B3GNT5) observed below 1208 bp (wildtype B3GNT5) indicates an 
active genome editing. Next, Cas9-active cell pools were subjected to single cell sorting (Supplemental Fig. S1) 
and incubated until further genotyping of single cell clones. The presence of homozygous ∆ B3GNT5 was verified 
by three independent PCRs, which showed the additional band at 309 bp in knockout (PCR_1) and no visi-
ble band at 617 bp and 329 bp, respectively for wildtype B3GNT5 (PCR_2 and PCR_3) (Fig. 2B). We identified 
two homozygous B3GNT5-deleted clones from a total of 320 clones profiled (0.625% efficiency). Despite equal 
mRNA expression of B3GNT5 transcripts (B3GNT5_1), a truncated transcript length was equally expressed in ∆ 
B3GNT5 cells as compared to wildtype (B3GNT5_2, Fig. 2C). The homozygous deletion was confirmed by Sanger 
DNA sequencing, showing knockout cells with alleles in varying lengths; (indel) 898 bp and 899 bp (Fig. 2D). 
In regards to potential off-target effects, both sgRNAs used for genome- editing did not show off-target effects 
(Supplemental Fig. S2).
Figure 1. The heterogeneous expression of (neo-) lacto series glycosphingolipids on normal and cancer 
cell lines. (A) Depiction of the three major glycosphingolipid series - globo, ganglio, and (neo-) lacto series 
glycosphingolipids. B3GNT5 attaches GlcNAc to the LacCer synthesizing Lc3, the precursor of all nsGSLs. 
Glycosidic linkages are displayed next to CFG notated monosaccharides. (B) Representative histograms of 
flow cytometry data on normal and cancer cell lines stained for paragloboside (nLc4, green) and P1 (red). 
Grey histogram depicts the negative control. Values within each plot show the mean out of three independent 
experiments for nLc4 (green) and P1 (red).
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The established ∆ B3GNT5 cell line was further investigated for GSL expression using flow cytometry, in which 
the human anti-P1 IgM P3NIL100 antibody, previously validated by printed glycan array, was utilized to detect 
the binding specificities to P1 epitope on these cells (Supplemental Fig. S3)14. The GSL pathways affected by the 
genetic disruption of B3GNT5 is hypothesized (according to the scheme presented in Fig. 1A) and the binding 
results were in full concordance with the expression levels for nLc4 and P1 (p < 0.001, Fig. 2E and F). In conclu-
sion, the absence of nLc4 and P1 epitopes confirmed our hypothesis that the nsGSLs were depleted in these cells, 
whereas ganglio- and globo- series GSLs were not affected by B3GNT5-editing (Fig. 2E and F). In addition, the 
absence of nLc4 and P1 in ∆ B3GNT5 cells was confirmed by confocal fluorescence microscopy (Fig. 2G and H).
Validation of altered GSL-glycans in ∆B3GNT5 cells by PGC-UHPLC-ESI-QTOF-MS/MS. We 
also utilized mass spectrometry (MS) to investigate the expression of cell surface glycans, which were subse-
quently altered due to the genome- editing of B3GNT5 in IGROV1 cells. This glycomics-based approach was 
performed to confirm the absence of nsGSLs due to genetic disruption of B3GNT5. Glycans were enzymati-
cally released from extracted GSLs of parental and ∆ B3GNT5 IGROV1 cells and analyzed using negative mode 
UHPLC-ESI-QTOF-MS/MS. The assignment of glycan structures was facilitated using diagnostic MS2 fragment 
ions previously described for the analysis of N-glycans released from glycoproteins as well as GSL-derived glycans 
using negative mode LC-ESI-MS/MS13,19.
The MS profiling revealed three neutral GSLs comprising of globo (Gb3)-, paragloboside (nLc4) as well as 
neolactopentaosylceramide (nLc-penta). All three neutral GSL species differed in chromatographic retention 
Figure 2. Deletion of B3GNT5 leads to depletion of nLc4 and P1. (A) B3GNT5-editing strategy using two 
different sgRNAs (red) contain PAM sequence (green) deleting a genomic region up- and downstream of the 
transcription start site (+ 1) including a part of the open reading frame (ORF). In silico analysis revealed a 
deletion of 898 bp. (B) Representative genotyping PCR for characterization of single cell clones. PCR numbers 
indicate the use of different primer pairs listed in experimental procedures. (C) Semi-quantitative PCR with two 
different primer pairs (B3GNT5_1 and B3GNT5_2) on wildtype (pIGROV1) and two representative knockout 
clones. SDHA was used as a reference gene. (D) DNA sequencing results for wildtype (WT), and selected 
biallelically deleted knockout clones (KO_1 and KO_2). (E) Representative counter plots for presence of Gb3, 
GM1, nLc4 and P1 before (wildtype B3GNT5) and after gene disruption of B3GNT5 in IGROV1 cells  
(∆ B3GNT5). Percentage of GSL-positive cells (FITC) is shown in each plot. Negative control (n.c.). (F) Box and 
Whisker plots representing CRISPR Cas9-mediated changes in expression of individual GSLs (percentage of 
FITC-positive cells, ordinate) for ∆ B3GNT5 and parental cells (abscissa). ***p < 0.001 was obtained by two-way 
ANOVA. Data are representative out of four independent experiments. (G,H) Confocal fluorescence images 
displaying presence and absence of nLc4 (green, G, 40x magnification) and P1 (green, H) in B3GNT5 wildtype 
(B3GNT5) and knockout (∆ B3GNT5) cells, respectively. Cells are counterstained with DAPI (blue). Data are 
represented as mean ± s.d.
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time, as well as MS2 fragmentation patterns facilitating the structural assignment of the GSL-glycans based on 
the fragment ions arising from various glycosidic and cross-ring cleavages. Table 1 shows the list of GSL-glycans 
and their relative intensities that were observed in both cell lines. The globo series glycosphingolipid, Gb3, 
was detected as [M-H]1− m/z 505.17291− in wildtype and ∆ B3GNT5 cells and was shown to elute at 12.16 min 
(Fig. 3A(i) and B(i)). The representative MS2 spectra of the precursor ion at m/z 505.17291− (Fig. 3C(i)) showed 
prominent glycosidic- type fragment ions (B1 at m/z 161.04381−, C1 at m/z 179.05411−) corresponding to the 
Gal-Gal-Glc trisaccharide sequence. The presence of the 4-linked terminal Gal to the inner (Gal-Glc) disaccha-
ride was further confirmed by the characteristic cross ring fragment ion corresponding to 2,4A2 at m/z 221.06441−. 
The second glycan structure, paragloboside (nLc4), detected as [M-H]1− m/z 708.25181− was found to be pres-
ent only in the wildtype IGROV1 cell line but not in the ∆ B3GNT5 cell line. This glycan was shown to elute at 
22.60 mins (Fig. 3A(ii)) and the MS2 spectra comprised of a mixture of B and Y ions (B1 at m/z 161.04401−, Y1 at 
m/z 181.06931−, Y2 at m/z 343.66531−) as well as C and Z ions (Z3 at m/z 528.19291−, C2/Z3 at m/z 202.06961−) 
that corresponded to the tetrasaccharide sequence, Hex-HexNAc-Gal-Glc (Fig. 3C(ii)). The absence of the 
Figure 3. LC-MS profiling of neutral GSLs and monosialylated N-glycans extracted from wildtype 
IGROV1 and genome-edited B3GNT5 cell lines. The extracted ion chromatograms (EIC) obtained 
from wildtype IGROV1 (A) and genome-edited B3GNT5 (B) cell lines are represented for Gb3 [m/z 
505.17291−Galα 1-4Galβ 1-4Glcβ 1] (i), nLc4 [m/z 708.25181−:Galβ 1-4GlcNAcβ 1-3Galβ 1-4Glcβ 1] (ii) and 
nLc-pentasaccharide [m/z 911.33091−:GlcNAcβ 1-3-Galβ 1-4GlcNAcβ 1-3Galβ 1-4Glcβ 1] (iii). (C) MS2 
spectrum of the precursor ion at m/z 505.17291−, m/z 708.25181− and m/z 911.33091− derived from Gb3 (i), 
nLc4 (ii) and nLc-penta (iii), respectively. PGC- LC allows for the separation of α 2-6 and α 2-3 sialylated 
N-glycans based on retention time. (D) The EICs obtained from the wildtype IGROV 1 depict three major 
monosialylated complex N-glycans at m/z 965.83852− [(Neu5Ac)1(Gal)2(GlcNAc)2+ (Man)3(GlcNAc)2] 
(i), m/z 1038.86792− [(Neu5Ac)1 (Gal)2(GlcNAc)2(Fuc)1+ (Man)3(GlcNAc)2] (ii) and m/z 1140.40812− 
[(Neu5Ac)1(Gal)2 (GlcNAc)3(Fuc)1 + (Man)3(GlcNAc)2] (iii) and two monosialylated hybrid N-glycans 
at m/z 937.32782− [(Neu5Ac)1(Gal)1(GlcNAc)1(Man)1 + (Man)3(GlcNAc)2] (iv) and m/z 945.32472− 
[(Neu5Ac)1(Gal)1(GlcNAc)1(Man)2 + (Man)3(GlcNAc)2] (v) which display α 2–3 and α 2–6 sialylated isomers 
at separate retention times. (E) The EICs of genome-edited B3GNT5 cells depicts the loss of the α 2–6 sialylated 
isomer for all five of the above mentioned monosialylated complex [m/z 965.83852− (i), m/z 1038.86792−(ii), 
m/z 1140.40812− (iii)] and hybrid [m/z 937.32782− (iv), m/z 945.32472− (v)] N-glycans. (F) SNA staining 
confirmed reduction of α 2–6 sialylation in ∆ B3GNT5 cells. Representative counter plot and barograph 
summarizing three independent experiments on parental IGROV1 cells (pIGROV1) and ∆ B3GNT5 cells 
(KO_1 and KO_2); **p-value < 0.01. Data are represented as mean ± s.d.
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cross ring cleavage ions characteristic of 4-linked GalNAc corresponding to 0,2A3 and 2,4A3 at m/z 484.16721− 
and m/z 424.14601−, respectively, further confirmed the presence of the 3-linked GlcNAc residue to the inner 
Gal-Glc of the tetrasaccharide. The late elution time observed for this glycan structure has been reported in 
our previous study demonstrating a similar retention time for nLc4 identified from IGROV1 cell lines using 
PGC-LC-ESI-IT-MS/MS (20). We also identified a third glycan structure at [M-H]1− m/z 911.33091− in wildtype 
IGROV1 which was shown to elute at 22.10 min (Fig. 3A(iii) and B(iii)). The MS2 spectra comprised of mainly B-, 
C- and Y-type fragment ions (B1 at m/z 202.06961−, C2/Y4 at m/z 179.05371−, B3/Y4 at m/z 364.78171− and Y3 at m/z 
546.20201−) that corresponded to the tentative pentasaccharide sequence, HexNAc-Gal-HexNAc-Gal-Glc corre-
sponding to a poly-LacNAc-type pentaosylceramide (Fig. 3C(iii)). The presence of the 1,3A2 at m/z 262.08741− 
further confirmed the terminal GlcNAc linked to the internal tetrasaccharide. However, this structure was not 
Type No
Glycan Mass 
[M-H]- Glycan Structures
PGC-ESI-QTOF-MS/MS PGC-ESI-IT-MS/MS
IGROV1
B3GNT5-edited 
IGROV1
P1-enriched IGROV1 
(Anugraham M, et al, 2015)
Neutral 
GSL
1 505.2 (Pk) 6.34 ± 0.31 4.72 ± 2.38 0.00
2 546.3 0.00 0.00 0.00
3a 708.3 (Globo) 0.00 0.00 0.00
3b 708.3 (Asialo-GM1) 0.00 0.00 0.00
3c 708.3 (Neo-lacto) 4.52 ± 1.58 0.00 7.64
4 870.3 (P1) 0.00 0.00 2.43
5 911.3 1.25 ± 0.48 0.00 Trace
Sialylated 
GSL
6 634.2 (GM3) 14.18 ± 0.61 23.40 ± 4.32 12.86
7 837.3 (GM2) 73.71 ± 2.40 71.88 ± 8.13 73.11
8a 999.3 (GM1) 0.00 0.00 0.68
8b 999.3 (α 2-3 sialyl Paragloboside) 0.00 0.00 2.15
8c 999.3 (LSTc) 0.00 0.00 1.14
Table 1.  Proposed GSL-glycan structures detected on the glycolipid membranes of ovarian cancer cells, 
IGROV1 (wildtype) and ∆B3GNT5 cells. Structures were assigned based on MS/MS fragmentation (where 
possible) and known biological GSL synthetic pathway constraints. All structures were depicted according to the 
CFG (Consortium of Functional Glycomics) notation with linkage placement. Specific linkages corresponding 
to Gal-GlcNAc (Type 1/Type 2) lactosamine linkages are also indicated (where possible). Values represent mean 
relative ion intensities ± s.d. of three replicates based on their extracted ion chromatograms (EIC). GSL-glycan 
structures derived from P1-enriched IGROV1 cell line previously analyzed with PGC-ESI-IT-MS (20) are also 
shown for comparative profiling using two different MS platforms. Gb3 (Pk).  Glucose  Galactose  N-
acetylglucosamine (GlcNAc)  N-acetylgalactosamine (GalNAc)  N-acetylneruaminic acid (NeuAc) 
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observed in the MS spectra of the ∆ B3GNT5 cell line. Whilst we were able to confirm the absence of nLc4 in the 
∆ B3GNT5 cell line, the presence of the P1 epitope was not readily detected in both the IGROV1 and ∆ B3GNT5 
cells analyzed in this study. This could be due to the low expression of the P1 epitope, coupled with the use of 
different MS instrumentation in this study (as compared to our previous study using PGC-LC-ESI-IT-MS/MS 
that was performed on P1 – enriched cell populations of IGROV113). Moreover, this study used a larger PGC 
column inner diameter on a conventional LC platform performed which resulted in less sensitivity as opposed to 
the microflow LC platform performed previously using PGC-ESI-IT-MS/MS. Apart from the neutral GSLs, two 
gangliosides were also detected in the MS spectra of both the wildtype and ∆ B3GNT5 cells. Both GM3 and GM2 
were detected as [M-H]1− m/z 634.21421− and [M-H]1− m/z 837.29261−, respectively, while the third ganglioside, 
GM1, at [M-H]1− m/z 999.35481−, did not appear to be present in both the cell lines (Table 1). These results indi-
cate that gangliosides remained unaffected by the genome-editing of B3GNT5.
Isomeric N-glycan profiling reveals concomitant loss of α 2-6 sialylation on membrane proteins 
in B3GNT5-mediated depletion of nsGSL. In addition to the profiling of the GSLs, we also compared 
the N-glycan profiles of the wildtype and ∆ B3GNT5 cell lines to gain an insight into the glycan structural changes, 
which could potentially be affected as a result of the GSL-related B3GNT5 genome- editing. We have previ-
ously reported an increased relative abundance of α 2-6 sialylation as compared to α 2-3 sialylation on membrane 
N-glycans of IGROV119. The presence of these isomeric structures in N-glycans can be differentiated based on 
their retention time on the porous graphitized carbon (PGC)-LC column, whereby glycans bearing the α 2-6 
sialic acid isomer are less strongly retained on the column and thus elute much earlier as compared to the α 
2-3 sialylated N-glycans. Likewise, in this study, a similar glycan elution pattern was observed in the wildtype 
IGROV1 cell lines confirming our previous results (which used another mass spectrometry setup), in which 
all five N-glycans comprising of the sialylated complex (m/z 965.83852−, m/z 1038.86792−, m/z 1140.40812−) 
(Fig. 3D(i–iii)) and hybrid (m/z 937.32782− and m/z 945.32472−) (Fig. 3D(iv–v)) glycans were found to con-
tain α 2-6 and α 2-3 isomeric structures which eluted at separate retention times. Surprisingly, we noted that 
in comparison to the wildtype IGROV1, the genome- edited ∆ B3GNT5 cells were shown to display only the 
α 2-3 sialylated glycans but not the α 2-6 sialylated N-glycan isomer for all five of the N-glycan masses described 
above (Fig. 3E(i–v)). We also profiled the membrane protein O-glycans of both cell lines to see if the difference 
in the sialylation pattern could be attributed to a global glycosylation change across all glycan types. However, we 
observed no change in the O-glycan sialylation profiles, further demonstrating that the preferential α 2-6 sialyl-
ation was specific to only the N-glycosylation pathway, as a result of the B3GNT5 genome- editing. The N- and 
O-glycans identified in both cell lines and their corresponding relative intensities are shown in Table 2.
In order to confirm the reduction of α 2-6 sialylation on membrane glycoproteins, we performed a staining 
using Sambucus nigra agglutinin lectin (SNA), which has been shown to bind preferentially to sialic acid attached 
to terminal galactose in via α 2-6 linkage20. The parental IGROV1 revealed positive staining (37% ± 6% FITC+) 
Figure 4. Loss of gangliosides by B4GALNT1-editing does not affect α2–6 sialylation in IGROV1 cells. (A) 
Depiction of CRISPR-Cas9-mediated B4GALNT1 editing in IGROV1 cells using two different sgRNAs [red; 
PAM sequence (green)]. In silico analysis revealed a deletion of 917 bp including translation start site located at 
exon 2. (B) Verification of ∆ B4GALNT1 cells by DNA sequencing. (C) Representative flow cytometry zebra blot 
for parental IGROV1 and ∆ B4GALNT1 cells. (D) Bar chart summarizing three independent flow cytometry 
experiments. (E) SNA-staining remains unaffected in ∆ B4GALNT1 cells compared to IGROV1 (B4GALNT1). 
Data are represented as mean ± s.d.
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for α 2-6Neu5Ac whereas for both ∆ B3GNT5 cells, the expression of α 2-6 –linked Neu5Ac was significantly 
reduced (KO_1 = 2% ± 1.7% and KO_2 = 6% ± 2.6% FITC+) (p < 0.01; Fig. 3F), thereby confirming the loss of 
membrane protein α 2-6 sialylation.
α2-6 sialylation is not affected in B4GALNT1 ganglioside-depleted IGROV1 cells. Our current 
data demonstrate that the deletion of B3GNT5 and consequently, the loss of nsGSLs, have unexpectedly led to 
the observation that α 2-6 sialylation is reduced on N-glycosylated proteins. To investigate whether this effect 
can be also observed when other GSL series are genome-edited, we utilized the CRISPR-Cas9 to homozygously 
delete the B4GALNT1 gene encoding for the beta-1,4-N-acetyl-galactosaminyltransferase-1 glycosyltransferase 
involved in the synthesis of gangliosides. IGROV1 cells were transfected with two sgRNA Cas9-encoding con-
structs to delete exon 2 of B4GALNT1, resulting in a 917 bp deletion (Fig. 4A). Clones identified as homozygously 
edited B4GALNT1 knockout cells (ΔB4GALNT1) were confirmed by DNA sequencing based on the deletion of 
916 bp (Fig. 4B). Following measurement of GSL expression, as expected, we observed a significant reduction for 
Figure 5. The reduction of α2-6 sialylation occurs in two ∆B3GNT5 ovarian cancer cell lines. (A) 
Representative genotyping PCR for ∆ B3GNT5 SKOV3 ovarian cancer cells. PCR_1, wildtype-specific PCR; 
PCR_2, deletion specific PCR. (B) Representative zebra plot for GSL expression in SKOV3 wildtype and  
∆ B3GNT5 cells. (C) Quantified data from three independent flow cytometry experiments. (D) The epitope 
for anti-nLc4 antibodies is present on glycoproteins and glycosphingolipids in SKOV3 and IGROV1 cells, 
respectively. Proteinase K treatment on SKOV3, SKOV3 ∆ B3GNT5 and IGROV1 cells following staining 
for CD44, nLc4 and α 2-6 neuraminic acid (with SNA). Representative histogram for unstained (white), 
proteinase K untreated (dark gray) and proteinase K treated cells (light gray). Bar chart summarizes three 
independent experiments. ***p < 0.001, **p < 0.01, *p-value < 0.05,p-value < 0.1. (E) Histogram for IGROV1 
cells treated with neuraminidase and stained for α 2-6 neuraminic acid (with SNA) and nLc4; unstained (white), 
neuraminidase treated (dark gray) and untreated cells (light gray). (F) Relative expression of genes encoding 
glycosyltransferase known to attach α 2-6 neuraminic acid to glycoproteins and glycosphingolipids. Bar chart 
shows the mean and standard deviation of three independent experiments of target genes (ST6GALNAC1-6, 
ST6GAL1, ST6GAL2, and B3GNT5) in wildtype (IGROV1 and SKOV3) and corresponding ∆ B3GNT5 cells. 
Data are represented as mean ± s.d.
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GM1 (p < 0.01) and no change in the expression of globoside Gb3 (Fig. 4C and D). In line with a previous report 
showing appearance of nLc4 after sialidase treatment in ganglioside-depleted mice21, we found that nLc4 and 
P1 are significantly elevated in Δ B4GALNT1 cells (p < 0.01, Fig. 4D). In regards to α 2-6 sialylation, we did not 
observe a difference in SNA staining to IGROV1 cells compared to Δ B4GALNT1 cells (p > 0.05, Fig. 4E). Taken 
together, CRISPR-Cas9 mediated disruption of B4GALNT1 leading to loss of gangliosides did not subsequently 
alter α 2-6 sialylation on glycosylated proteins in contrast to that observed for Δ B3GNT5 cells.
Loss of α2-6 sialylation is a result of silenced ST6GAL1 expression in ∆B3GNT5 cells. The 
reduction of α 2-6 sialylation in ∆ B3GNT5 IGROV1 cells, prompted us to investigate whether this observation 
is constrained to a specific cell line or reproducible in another ovarian cancer cell line. Thus, we applied the 
genome-editing strategy as reported for IGROV1 (Figs 2A and 5A) in SKOV3 cells, which were chosen based on 
their expression of nLc4 and α 2-6 sialic acid (Figs 1B and 5B). In contrast, Ls174T being positive for nLc4 and 
P1 did not show α 2-6 sialylation and was therefore not selected for genome- editing (Supplemental Fig. S4A). 
Analysis of the GSL expression in parental SKOV3 and corresponding ∆ B3GNT5 cells revealed only marginal 
changes for Gb3 and nLc4, whereas SNA staining was significantly reduced (p = 0.0232). This confirms what was 
previously observed in ∆ B3GNT5 IGROV1 cells, and further indicates that the disruption of B3GNT5 leads to a 
reduction in α 2-6 sialylation and may be a cell line-independent phenomenon (Fig. 5B and C).
It is interesting to note, however, that we did not observe any reduction of nLc4 in SKOV3 ∆ B3GNT5 cells 
(Fig. 5C). Thus, we hypothesized that besides GSLs, the antibody may also recognize the terminal nLc epitope 
(Galβ 1-4GlcNAc) on N- and O-glycoproteins carrying Type II LacNAc (Galβ 1-4GlcNAc) terminated anten-
nas and therefore, the binding levels in SKOV3 Δ B3GNT5 cells remained unchanged. To analyze whether the 
antibody-binding epitope is also carried on cell surface proteins, we treated SKOV3, SKOV3 Δ B3GNT5, and 
IGROV1 cells with Proteinase K and performed staining for nLc4, SNA, and CD44. The latter was used as a 
control antigen (sensitive to Proteinase K treatment). As shown in Fig. 5D, cells subjected to Proteinase K treat-
ment showed a complete loss of CD44 epitope, an ubiquitously expressed membrane protein, indicating that 
proteins on the cell surface are fully digested. In contrast, SKOV3 and SKOV3 Δ B3GNT5 cells showed reduction 
of nLc4 staining after Proteinase K treatment whereas IGROV1 cells remained positive after nLc4 staining. This 
suggests that the nLc4 epitope was potentially present on cell surface proteins on SKOV3 as well as Ls174T cells 
(Supplemental Fig. S4B). In regards to α 2-6 sialylation, Proteinase K treated cells showed only marginal reduction 
in SNA staining (Fig. 5D). Finally, IGROV1 cells (no reduction upon Proteinase K treatment for nLc4) were also 
treated with a broad-specificity neuraminidase to remove α 2-6/2-3-linked Neu5Ac, resulting in the reduction 
of SNA staining (Fig. 5E). This observation corroborated with a further increase in nLc4 staining, indicating 
that nLc4 on GSLs is terminated with Neu5Ac to form sialyl- 3 or 6- paragloboside GSLs in IGROV1 cells and is 
further exposed on the cell surface upon de-sialylation. Taken together, our results provide evidence that apart 
from nLc4 expression on GSLs, the anti-nLc4 antibody epitope is also preferentially expressed on glycoproteins 
in SKOV3 cells, as indicated by the sustained presence of nLc4 in SKOV3 Δ B3GNT5 cells and terminal nLc4 in 
GSLs may further be modified to form sialo-paraglobosides, as observed in IGROV1 cells.
Next, we investigated whether mRNA expression of genes encoding sialyltransferases involved in the synthesis 
of α 2-6-sialoglycans is altered upon deletion of B3GNT5. RT-qPCR was established in concordance with MIQE 
guidelines22 and glyco-gene expression was normalized to the geometric mean of three independent reference 
genes (Supplemental Table S2). We profiled ST6GALNAC1-6 and ST6GAL1-2 in parental IGROV1 and SKOV3 as 
Figure 6. A model summarizing the interaction of specific glycolipid synthases on glycosphingolipids and 
N-glycosylation of proteins. 
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Type No Glycan Mass [M-H]-
[M-
2H]2- Glycan Structures
PGC-ESI-QTOF-MS/MS PGC-ESI-IT-MS/MS
IGROV1 B3GNT5-edited IGROV1
IGROV1 (Anugraham 
M, et al, 2014)
N-glycans -High 
Mannose
1 1235.4 617.2 4.15 ± 0.11 5.54 ± 0.16 0.62 ± 0.06
2 1397.6 698.3 5.31 ± 0.24 4.88 ± 0.64 7.91 ± 0.15
3 1559.6 779.3 9.13 ± 0.27 9.48 ± 1.21 13.45 ± 1.35
4 1721.6 860.3 19.19 ± 1.15 20.85 ± 1.57 16.00 ± 3.73
5 1883.8 941.4 23.48 ± 2.02 22.29 ± 0.79 24.57 ± 6.02
6 2045.6 1022.3 1.88 ± 0.21 1.73 ± 0.52 1.43 ± 0.61
N-glycans 
-Hybrid
7 1567.6 783.3 0.00 0.00 0.19 ± 0.03
8 1584.6 791.8 0.00 0.00 0.34 ± 0.11
9 1600.6 799.8 0.63 ± 0.01 0.83 ± 0.12 1.04 ± 0.30
10 1713.6 856.3 0.00 0.00 1.76 ± 0.21
11 1729.6 864.3 0.00 0.00 0.68 ± 0.20
12 1746.6 872.8 0.00 0.00 0.20 ± 0.00
13a 1875.6
937.3 
(α 2-6) 0.65 ± 0.03 0.00 0.20 ± 0.25
13b 1875.6
937.3 
(α 2-3) 0.42 ± 0.05 0.74 ± 0.07 0.41 ± 0.20
14a 1891.6
945.3 
(α 2-6) 1.34 ± 0.09 0.00 0.47 ± 0.22
14b 1891.6
945.3 
(α 2-3) 0.67 ± 0.05 1.33 ± 0.17 0.43 ± 0.08
Continued
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Type No Glycan Mass [M-H]-
[M-
2H]2- Glycan Structures
PGC-ESI-QTOF-MS/MS PGC-ESI-IT-MS/MS
IGROV1 B3GNT5-edited IGROV1
IGROV1 (Anugraham 
M, et al, 2014)
N-glycans 
-Complex 
Neutral Hybrid
15 1463.6 731.2 1.25 ± 0.20 1.36 ± 0.35 0.74 ± 0.03
16 1625.6 812.3 0.00 0.14 ± 0.25 0.64 ± 0.14
17 1641.6 820.3 0.62 ± 0.01 1.16 ± 0.18 1.59 ± 0.62
18 1666.4 832.8 0.00 0.00 1.22 ± 0.40
19 1682.6 840.8 0.00 0.00 0.12 ± 0.05
20 1771.8 885.4 0.00 0.00 0.00
21 1787.6 893.3 1.99 ± 0.05 3.48 ± 0.47 3.50 ± 0.22
22 1812.8 905.9 0.00 0.00 0.24 ± 0.08
23 1828.8 913.9 0.00 1.30 ± 0.34 0.66 ± 0.12
24 1844.8 921.9 1.25 ± 0.06 2.01 ± 0.09 1.37 ± 0.19
25 1869.8 934.4 0.00 0.19 ± 0.33 0.51 ± 0.20
26 1933.6 966.3 1.23 ± 0.78 1.15 ± 0.13 0.00
27 1974.8 986.9 0.18 ± 0.31 0.00 0.79 ± 0.28
28 1990.8 994.9 6.29 ± 1.36 8.23 ± 0.73 2.62 ± 0.60
29 2006.8 1002.9 1.84 ± 0.39 1.75 ± 0.61 0.31 ± 0.15
30 2015.8 1007.4 0.00 0.00 0.14 ± 0.06
31 2079.8 1039.4 0.00 0.00 0.00
32 2120.8 1059.9 0.00 0.00 0.56 ± 0.19
33 2136.6 1067.8 2.32 ± 0.27 3.44 ± 0.35 0.31 ± 0.15
34 2152.8 1075.9 0.77 ± 0.40 1.47 ± 0.95 1.18 ± 0.16
35 2162 1080.5 1.22 ± 0.22 0.25 ± 0.15 0.39 ± 0.09
36 2356 1177.5 0.84 ± 0.07 1.13 ± 0.14 0.23 ± 0.02
37 2518 1258.5 1.88 ± 0.24 1.20 ± 0.22 0.37 ± 0.10
Continued
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Type No Glycan Mass [M-H]-
[M-
2H]2- Glycan Structures
PGC-ESI-QTOF-MS/MS PGC-ESI-IT-MS/MS
IGROV1 B3GNT5-edited IGROV1
IGROV1 (Anugraham 
M, et al, 2014)
N-glycans 
-Complex 
Sialylated 
Hybrid Complex 
Sialylated
38 1916.6 957.8 0.00 0.00 0.21 ± 0.06
39a 1932.8
965.9 
(α 2-6) 1.41 ± 0.11 0.00 1.38 ± 0.38
39b 1932.8
965.9 
(α 2-3) 0.86 ± 0.05 1.28 + 0.24 1.86 ± 0.49
40a 2078.8
1038.9 
(α 2-6) 4.96 ± 0.35 0.00 1.91 ± 0.23
40b 2078.8
1038.9 
(α 2-3) 1.68 ± 0.16 3.94 ± 0.27 3.23 ± 0.14
41 2119.8 1059.4 0.00 0.00 0.36 ± 0.15
42 2223.8 1111.4 0.00 0.00 0.41 ± 0.07
43 2265.8 1132.4 0.00 0.00 0.06 ± 0.02
44a 2282.0
1140.5 
(α 2-6) 1.35 ± 0.11 0.00 0.35 ± 0.14
44b 2282.0
1140.5 
(α 2-3) 1.20 ± 0.34 2.30 ± 0.06 0.30 ± 0.17
45 2297.8 1148.4 0.00 0.00 0.23 + 0.02
46 2370.0 1184.5 0.00 0.00 1.33 ± 0.36
47 2411.0 1205 0.00 0.00 0.06 ± 0.02
48 2444.0 1221.5 1.30 + 0.46 0.00 0.65 ± 0.07
49 2589.0 1294.0 0.00 0.00 0.03 ± 0.00
50 2735.0 1367.0 0.00 0.00 0.03 ± 0.00
51 3026.0 1512.5 0.00 0.00 0.19 ± 0.08
Continued
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well as their corresponding ∆ B3GNT5 cells. Apart from the expected change in B3GNT5 mRNA levels, ST6GAL1 
expression was found to be significantly decreased in both ∆ B3GNT5 cells of up to 166-fold for IGROV1 (Fig. 5F). 
The expression of the remaining sialyltransferases encoding genes examined was not significantly altered in the 
wildtype and ∆ B3GNT5 cells, except for ST6GAL2 in SKOV3 cells (Fig. 5F). In addition, ST6GAL1 expression 
in parental and IGROV1 ∆ B4GALNT1 cells revealed equal gene expression levels (Supplemental Fig. S5), cor-
roborating with no changes observed in SNA staining. In conclusion, these results indicate that the disruption of 
B3GNT5 and the corresponding loss of α 2-6 sialylation on N-glycans appear due to the preferential silencing of 
ST6GAL1 gene expression in both ovarian cancer cell lines, IGROV1 and SKOV3 (Fig. 6).
Discussion
The advent of novel nuclease-based precision genome- editing techniques is starting to revolutionize the field of 
glycobiology, enabling stable gene editing and potentially unravelling the roles of glyco-related genes and their 
corresponding glycosyltransferases in mammalian cell lines. This technology was first demonstrated by Henrik 
Clausen and his colleagues, through the introduction of the ‘Simple Cell’ strategy, to study the role of truncated 
O-glycans in malignant diseases23,24, specificity of anti-glycopeptide antibodies25, profile and map the human 
O-GlcNAc glycoproteome26,27, and produce novel antibodies to defined glycopeptides28. Whilst a majority of this 
work is based on O-glycans, there is very limited information on the use of genome- editing for glycosphingolip-
ids (GSLs) and in particular, the nsGSLs. Here, we utilized CRISPR-Cas9 nuclease genome- editing to explore the 
role of B3GNT5, the key glycosyltransferase responsible for the synthesis of precursor Lc3 that is extended to form 
the lacto (Type 1) and neo-lacto (Type II) series GSLs6. For the first time, using a combination of genomic-level 
editing and cell surface membrane protein and GSL-glycan profiling, we provide valuable insights into the com-
plex interplay regulating the expression of linkage-specific α 2-6 sialo-N-glycans on proteins as a consequence of 
GSL disruption. We demonstrate that by mutating B3GNT5, the depletion of nsGSLs consequently affects α 2-6 
sialylation on N-glycoproteins, not only at the cellular level, but also through the silencing of the corresponding 
ST6GAL1 gene.
As evidenced in this study, the genomic deletion of B3GNT5 resulted in the loss of the (neo-) lacto paraglo-
boside (nLc4, Galβ 1-4GlcNAcβ 1-3Galβ 1-4Glcβ 1-1Ceramide) as well as P1 (Galα 1-4Galβ 1-4GlcNAcβ 1-3Galβ 
1-4Glcβ 1-1Ceramide), a pentasaccharide moiety of which has not been annotated in the KEGG database so far. 
We recently reported the presence of the P1 glycan in tissue samples14 as well as on P1-enriched IGROV1 ovarian 
cancer cell lines13, serving as a cell-recognition molecule through its binding to naturally occurring anti-glycan 
antibodies14,29. The presence of nLc4 and P1 was detected on IGROV1 cells using flow cytometry, in which P1 was 
detected using P3NIL100 antibody, a well-validated monoclonal IgM antibody shown to specifically recognize 
the chemically synthesized P1 trisaccharide (Galα 1-4Galβ 1-4GlcNAcβ -), as indicated by glycan array profiling 
performed in this study. Both the flow cytometry and high-resolution ESI-QTOF-MS and MS/MS profiles con-
firmed that the levels of nLc4 were reduced, while the globo (Gb3) and ganglio (GM3, GM2 and GM1)- series 
Type No Glycan Mass [M-H]-
[M-
2H]2- Glycan Structures
PGC-ESI-QTOF-MS/MS PGC-ESI-IT-MS/MS
IGROV1 B3GNT5-edited IGROV1
IGROV1 (Anugraham 
M, et al, 2014)
O-glycans
1a 675.3 NA 9.10 ± 2.32 13.08 ± 2.43 NA
1b 675.3 NA 31.55 ± 4.19 27.59 ± 2.21 NA
2 966.3 NA 52.11 ± 2.60 52.25 ± 0.59 NA
3 749.3 NA 0.00 0.00 NA
4 1040.5 NA 7.24 ± 1.26 7.08 ± 0.44 NA
5 1331.5 NA 0.00 0.00 NA
Table 2.  Proposed N- and O-glycan structures detected on the membrane proteins of IGROV1 (wildtype) 
and ∆B3GNT5 cells. N- and O-glycan structures were separated by PGC-UHPLC-ESI-QTOF and their 
structures were assigned based on MS/MS fragmentation (where possible), retention time differences and 
biological pathway constraints. Structures were depicted according to the Consortium of Functional Glycomics 
(CFG) notation with linkages (α 2, 3 and α 2, 6) indicated for sialic acid (where known). Values represent 
mean relative ion intensities ± SD of three replicates based on their extracted ion chromatograms (EIC). 
N-glycan structures derived from IGROV1 cell line previously analyzed with PGC-ESI-IT-MS13,19 are also 
shown for comparative profiling using two different MS platforms.  Galactose  Mannose  Fucose  N-
acetylglucosamine (GlcNAc)  N-acetylgalactosamine(GalNAc) N-acetylneruaminic acid (NeuAc; sialic 
acid).
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GSL glycans remained unaffected in ∆ B3GNT5 cells. The presence of P1, however, was not detected on the paren-
tal IGROV1 cells by the mass spectrometry approach applied, possibly due to the low detection levels of P1 on 
non-P1 enriched IGROV1 cells used in this study, as well as the use of a different mass spectrometric platform. 
Nevertheless, we also observed that apart from IGROV1, the colon cancer cell line, Ls174T, showed detectable 
levels of P1 providing further evidence that P1 is not exclusively present on erythrocytes30–32. The results obtained 
herein support that the pentasaccharide P1 is indeed exclusively present as an nsGSL-glycan on membrane gly-
colipids and not on glycoproteins.
To date, it remains unclear if nLc4- and P1- GSL glycans are functionally relevant molecules in diseased states 
such as cancer and infection or if they are ubiquitously expressed. In regards to pathogenic infections, it has been 
previously shown that Helicobacter pylori induces B3GNT5 expression and that the ABO(H)/Lewis blood group 
antigens expressed in H. pylori- infected individuals act as receptors for BabA, thereby facilitating colonization 
of the gastric niche33. Likewise, the Shiga toxin from urinary tract infection-causing enterohemorrhagic E. coli 
was shown to recognize the terminal epitope of P1, Galα 1-4Galβ 1-4 following internalization of the toxin by 
receptor-mediated endocytosis34. Another study also showed that the Shiga-like toxin binds to P1 trisaccharide 
on core 2 O-glycoproteins in overexpressed CHO cells35. These findings indicate that this toxin may recognize P1 
pentasaccharide. It is evident that the successful B3GNT5 deletion performed in this study may be further applied 
to investigate the lectin binding specificities (e.g. Shiga toxin) in other human cancer cell lines expressing Gb3, 
nLc4 and P1.
Perhaps, the most intriguing finding from this study is the unexpected loss of α 2-6 sialylation observed 
using mass spectrometry in ∆ B3GNT5 cells which was further substantiated by SNA lectin staining on cultured 
cells and reduced ST6GAL1 mRNA expression. We have previously shown in two separate studies, respectively, 
that ovarian cancer cells, IGROV1 and SKOV3, have higher levels of glycoprotein α 2-6 sialylation as compared 
to non-cancer ovarian epithelial cells19 and nLc4 and P1 are both expressed on IGROV1 and ovarian cancer 
tissue-derived GSL-glycans13. Hence, the reduction of α 2-6 sialylation as a direct consequence of the B3GNT5 
deletion in ovarian cancer cells is indicative of their complex associations within the glycan-processing pathway. 
A recent publication reported a similar finding in the context of the rare autosomal recessive salt and pepper 
syndrome36. In this study, a homozygous transition mutation in the gene encoding sialyltransferase ST3GAL5 
(GM3 synthase) was described. More importantly, in addition to the reduced GSL complexity, the comprehensive 
glycomics analysis performed using mass spectrometry also revealed altered N- and O-glycans on proteins due 
to the point mutation in the ST3GAL536. In another study on respiratory chain disorders, the authors observed 
significant increases of Gb3 and Gb4 and a decrease of LacCer in fibroblasts36,37. Similarly, the appearance of 
unexpected gangliosides in homozygously deleted ST3GAL5 murine primary embryonic fibroblast cells was also 
reported38. Despite the limited number of publications, our current study provides another example on how a loss 
of a specific glycosyltransferase interferes with glycomic changes, as observed in the reduction of α 2-6 sialylation 
on N-glycoproteins, thereby recognizing the contribution of altered GSL expression in cell development and 
function. It is not known whether the loss of α 2-6 sialylation is thought to provide a compensation phenotype for 
the depleted nsGSLs in these cells or enables them to survive despite the glycan changes. It is also unclear as to 
how the ST6GAL1 is regulated in the context of their translocation within the Golgi membrane or their accessibil-
ity to the membrane proteins. It will be useful to further characterize membrane proteins bearing these sialylated 
N-glycans and observe corresponding changes in the proteome profiles of B3GNT5 –edited ovarian cancer cells.
Of note, despite similar observations in two independent ovarian cancer cell lines and due to our carefully 
designed sgRNAs in a way to minimize the probability of off-target activity; we cannot exclude unintended 
changes in the genome of our genome- edited ovarian cancer cell lines. Here, an unbiased approach would be 
necessary to exclude mutations anywhere in the genome39. Therefore, the most reliable method would be whole 
genome sequencing40. A direct in situ breaks labeling, enrichment on streptavidin, and next-generation sequenc-
ing also referring to BLESS41 as well as linear amplification-mediated high-throughput genome-wide transloca-
tion sequencing (HTGTS)42 can also be applied as less expensive alternatives to track genomic alterations caused 
by off target Cas9-activity.
In conclusion, the investigation of CRISPR-Cas9-mediated deletion of glycosyltransferase in ovarian cancer 
cells, coupled with the use of MS-based glycomics profiling, serve as a useful model for future studies to eluci-
date the biological roles of nsGSLs, an important group of GSLs which may be involved in specific cell physiol-
ogy functions. More importantly, the prominent changes in N-glycoprotein sialylation detected in the B3GNT5 
genome- edited cells are reflective of global alterations in one or more regulatory components essential for glycan 
biosynthesis, thereby warranting further research efforts into the complex and overlapping roles of glycosyltrans-
ferases involved in the downstream glycan biosynthesis pathways.
Methods
Cell culture. Cell lines (HOSE17.1, IGROV1, SKOV3, BG1, CAOV3, Ls174T, HeLa, HCT15, and HCT116) 
were grown in RPMI1640 media supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml) and 
streptomycin (100 μ g/ml) (Sigma-Aldrich, Buchs, Switzerland). Fallopian tube cell lines FT33 Tag, FT190, and 
FT237 (kind gifts by Dr. Drapkin) were cultured in DMEM F12/50 without HEPES supplemented with 2% (v/v) 
Ultroser (USG, Pall Corporation, USA) and penicillin/streptomycin. All cell lines were cultured at 37 °C in a 95% 
humidified atmosphere containing 5% CO2. Cell lines were short tandem repeat (STR) profiled and routinely 
tested for mycoplasma infection43.
Antibodies and reagents. Primary antibodies to detect the cell surface-associated GSLs were applied as 
described previously15. Briefly, the following primary antibodies were utilized; rat IgM anti-Pk (Gb3) antibody 
(ABDserotec, Germany); mouse IgM anti-nLc4 (paragloboside) antibody [clone 1B2 kindly provided by Prof. 
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Mandel and Prof. Clausen, Denmark]44; human IgM anti-P1 antibody (Millipore, Germany), and Cholera toxin 
B subunit (Sigma-Aldrich, Switzerland) to detect GM1. All secondary antibodies (mouse anti-rat IgM antibody 
conjugated to biotin, rat anti-mouse IgM conjugated to biotin and mouse anti-human IgM conjugated to biotin) 
were obtained from BD Pharmingen. Cell surface GSL expression was visualized with FITC conjugated to 
streptavidin (BD Pharmingen). Non-viable cells were positively stained with 7-amino-actinomycin D (BD 
Pharmingen). Isotype controls for each primary antibody used included the following: purified rat IgM (BD 
Pharmingen), purified mouse IgM and chrompure human IgM (Jackson ImmunoResearch, USA). Alpha 2-6 
sialylation on the cell surface was investigated using Sambucus nigra lectin (SNA) conjugated to biotin (Vector 
Laboratories, Reactolab, Servion, Switzerland). Lectin staining was visualized with streptavidin conjugated to 
FITC. Anti human CD44-PE antibody was purchased from Miltenyi Biotec (Bergisch Gladbach, Germany) for 
use as a positive control in Proteinase K treatment.
CRISPR-Cas9 sgRNA design and construction. The design of sgRNAs was carried out using the online 
program available from Zhang’s laboratory45. This program provides additional information about the quality 
of sgRNA by giving it a score value of up to 100 and additionally, the number and sites of potential off targets. 
Designed and processed sgRNAs to edit either B3GNT5 or B4GALNT1 (Supplemental Table S1) were cloned into 
pSpCas9(BB)-2A-GFP (addgene PX458) via BsbI restriction site using T4 DNA Ligase (Promega, Dübendorf, 
Switzerland).
IGROV1 and SKOV3 cells were transfected using ViaFect Transfection reagent (Promega, Dübendorf, 
Switzerland). A total of 4–5 × 105 cells were seeded into 6-well plates, cultured for 24 h and transfected with 2.5 μ g 
of pSpCas9(BB)-2A-GFP. Cells were harvested after 72 h and subjected to single cell sorting.
Flow cytometry-based single-cell sorting. IGROV1 transfected with pSpCas9(BB)-2A-GFP targeting 
either B3GNT5 or B4GALNT1 were grown for 72 h, washed twice in PBS and harvested using non-enzymatic 
cell dissociation buffer (Sigma-Aldrich, Buchs, Switzerland). Cells were then resuspended in RPMI containing 
10% FCS before single cell sorting was performed on a BD FACS Vantage SE DiVa Cell Sorter (BD Biosciences). 
Cells sorted for single DAPI− and GFP+ cells were seeded into 96-well flat-bottom plates with pre-warmed RPMI 
containing 10% FCS. Plates were incubated for 2 to 3 weeks following transfer to 48-well plates, prior to genomic 
DNA isolation for genotyping PCR to characterize single cell clones.
Genotyping PCR. Selected clones were characterized by three to four PCRs using appropriate primer 
pairs (Supplemental Table S1). PCR was performed using 1x GoTaq Green Master Mix (Promega, Dübendorf, 
Switzerland), 200 nM primer (Supplemental Table S1) and 30 ng gDNA and carried out on a Biometra Professional 
Trio cycler. PCR was performed under the following conditions: initial denaturation at 94 °C for 1 min followed 
by 33 cycles consisting of denaturation at 94 °C for 15 sec, annealing at 59 °C for 15 sec, and elongation at 72 °C for 
15–45 sec depending on the amplicon length. The PCR products were separated on a 1.7% agarose gel.
Sanger DNA Sequencing. PCR products were cloned into pGEM®-T Easy Vector System (Promega) 
according to the manufacturer’s protocol. DNA sequencing was performed by Source Bioscience Life Sciences 
(Berlin, Germany). Samples were shipped at a concentration of 100 ng/μ l with specific primer (if required) con-
centration of 3.2 pg/μ l.
Off target screening. Potential off target sites were amplified (Supplemental Table S1), cloned into 
pGEM®-T Easy Vector System (Promega) and sequenced. A total of three colonies per clone were selected for 
sequencing.
Reverse transcription semi-quantitative PCR (RT-qPCR) using total RNA. Total RNA was 
extracted from 80% confluent 6-well plates seeded initially with 1 × 105 cells. Cells were then washed twice with 
sterile PBS and total RNA was extracted using the ReliaPrep RNA Cell Miniprep System (Promega, Dübendorf, 
Switzerland). RNA was eluted in 60 μ l RNase free water and RNA concentration was measured using NanoDrop 
ND-1000 spectrophotometer (Thermo Fisher Scientific, Roskilde, Denmark).
Total RNA (500 ng) was reverse-transcribed using the iScript Reverse Transcription Supermix for RT-qPCR 
(Bio-Rad Laboratories, Zurich, Switzerland) in a total volume of 10 μ l according to the manufacturer’s instruc-
tions. RT-qPCR was performed on target and reference genes (HSPCB, SDHA, and YWHAZ) in 10 μ l reactions 
containing 10 ng cDNA (initial total RNA), 400 nM forward and reverse primer (Supplemental Table S2), nucle-
ase free water and 1x GoTaq® qPCR Master Mix with low ROX as the reference dye (Promega, Dübendorf, 
Switzerland) on a ViiA™ 7 Real-Time PCR System (Applied Biosystems, Thermo Fisher Scientific, Reinach, 
Switzerland). Quantitative PCR was performed on three independent experiments, in triplicates, and analyzed 
as recently described19,46. Each quantitative PCR was further established with a series of six 10-fold dilutions to 
calculate the efficacy of each reaction and to determine the optimal range of initial mRNA concentration for 
analysis (Supplemental Table S2).
Flow cytometry. Immuno staining and flow cytometry was performed as previously described14,15. 
Biotinylated SNA lectin (1:500) containing 10 mM CaCl2 was applied for detection of α 2-6 neuraminic acid using 
flow cytometry (BD Accuri™ C6, BD Bioscience).
Membrane protein extraction and N- and O-glycan release of parental and ∆B3GNT5 IGROV1 
cell lines. Membrane protein extraction and glycan release were carried out as previously described19. 
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Briefly, approximately 2 × 107 IGROV1 and ∆ B3GNT5 IGROV1 cells were washed with PBS and homoge-
nized in lysis buffer (50 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA and protease inhibitor, pH 7.4). Unlysed 
cells were pelleted through centrifugation and cellular membranes in the supernatant was subjected to ultra-
centrifugation at 120, 000 g prior to Triton X-114 phase partitioning of membrane proteins. Membrane proteins 
were acetone-precipitated, solubilized in 8 M urea and spotted onto polyvinylidene diflouride (PVDF) mem-
brane spots placed in a 96-well microtiter plate. Protein spots were treated with PNGase F enzyme and released 
N-glycans were treated with 100 mM ammonium acetate (pH 5.0) and reduced to alditols with 2 M NaBH4 in 
50 mM KOH. For O-glycans, the remaining PVDF spots in the 96- well microtiter plate were further subjected 
to reductive β -elimination by treatment with 0.5 M NaBH4 in 50 mM KOH to chemically release the O-glycans. 
Both the released N- and O-glycans were desalted by cation exchange chromatography as previously described 
and re-suspended in 15 μ l of MilliQ water prior to mass spectrometry analysis.
GSL extraction and enzymatic release of GSL-glycans from cell lines. Lipid extraction and release 
of GSL-glycans were performed as previously described13. Briefly, GSLs were extracted from approximately 
2 × 107 parental and ∆ B3GNT5 IGROV1 cells using a modified Folch extraction method. Cell pellets were treated 
with chloroform: methanol (2:1) and subjected to centrifugation. The supernatants were evaporated to dryness 
and crude GSL fractions were re-dissolved in 50 μ l of chloroform: methanol (2:1). Approximately 10 μ l of GSL 
standard (neutral glycosphingolipids: LacCer, Gb3 and Gb4) and 50 μ l of extracted GSLs were spotted onto the 
PVDF membrane and treated with 4 mU (2 μ l) of Endoglycoceramidase II. GSL-glycans released from the immo-
bilized GSL spots were reduced to alditols with 0.5 M NaBH4 in 50 mM KOH and desalted by cation exchange 
chromatography as previously described for N- and O- glycans.
PGC-UHPLC-ESI-QTOF-MS/MS profiling of released GSL- and N-and O-glycan alditols. The 
separation of glycan alditols was performed using an Agilent UHPLC modular system consisting of a degasser, 
binary pump, auto-sampler, thermostat and column oven (Agilent Series 1290, Agilent Technologies, Germany). 
The conventional flow LC system was connected to a mass spectrometer (MS) (Agilent Series 6540 Q-TOF, 
Agilent Technologies, USA) operating in negative mode and coupled to a jet stream electrospray ion source (ESI) 
as previously described for N- and O-linked glycans47. Briefly with some slight modifications for GSL-derived gly-
cans, an aliquot of 14 μ L of sample was injected onto the Hypercarb porous graphitized carbon (PGC) analytical 
column (ID2.1 × 150 mm column; 3 μ m particle size) (Thermo Fisher Scientific, United Kingdom). The column 
compartment was maintained at 40 °C. The mobile phase was made up of 10 mM ammonium bicarbonate (A) 
and 9:1 acetonitrile/water with 10 mM ammonium bicarbonate (B). The chromatographic separation was held 
with the initial mobile phase composition (1% B; 0–5 mins), followed by a segmented linear gradient to 25% B 
(5–40 mins), 50% B (40–42 mins) and a fast step at 42.5 mins to 80% B, with a hold for 1.5 mins. The ESI source 
was operated with the following parameter settings: nebulizer pressure (35 psig), nozzle voltage (0 V), sheath gas 
flow (11 L/min), sheath gas temperature (375 °C), drying gas flow (8 L/min), drying gas temperature (250 °C), 
capillary voltage (4000 V) and fragmentor voltage (175 V). High-resolution MS scan (m/z 100–1700 at 1.5 Hz) 
and MS/MS product scan (m/z 50–1700 at 3 Hz) were acquired with information-dependent acquisition (IDA) 
with static exclusion range m/z 100–300. An automated mass calibration performed by delivering constantly two 
reference masses (m/z 119.0363 and m/z 981.9956) on the end plate of the ESI source to obtain the highest mass 
accuracy during the measurement. Data analysis was performed with MassHunter B.06.00 (Agilent Technologies, 
USA). The monosaccharide compositions of monoisotopic masses were determined using GlycoMod tool (http://
web.expasy.org/glycomod/) with a mass error of ± 0.5 Da. The proposed glycan structures were manually assigned 
and interpreted based on MS/MS fragmentation patterns of known GSL-derived glycans13 and annotated using 
GlycoWorkBench 2.1 software48. In addition, UniCarb KB, a web-based LC-MS/MS database49, was also utilized 
to confirm fragmentation and retention time of sialylated N-glycans previously reported to contain sialylated iso-
mers19. Blank samples, fetuin glycoprotein with isomeric glycan compositions and reference glycolipid standards 
which served as quality control for sample preparation were randomly measured within each sequence run and 
checked for background contamination.
Confocal fluorescence microscopy. Cells were grown on polylysine glass slides attached to an 8-well 
chamber, fixed with 4% para-formaldehyde for 15 min and blocked with 5% (w/v) BSA fraction V (Sigma) dis-
solved in PBS for 1 h. Cells were then stained with either anti-P1 IgM15 (1:5 diluted with incubation buffer (1% 
BSA in PBS)) or anti-nLc4 (paragloboside) antibody (1:5) for overnight at 4 °C. Following extensive washing 
corresponding secondary antibodies (Biotin-anti-human IgM (1:100), Biotin- anti-mouse IgM (1:100)) were 
added to each chamber and incubated for 2 h at 4 °C. Afterwards, cells were washed with PBS and incubated 
with Streptavidin-FITC (1:200) for 1 h at 4 °C and counterstained with DAPI (Cell Signaling Technology). 
Fluorescence images were taken with a Zeiss LSM 710 confocal microscope (Zeiss, Feldbach, Switzerland).
Printed Glycan Array. The printed glycan array was performed as previously described with modifica-
tions29,50,51. Briefly, glycan arrays were prepared by covalent attachment of amino-spacered synthetic glycans to 
N-hydroxysuccinimide-activated Schott-Nexterion slides. Chemically synthesized carbohydrates with 95–98% 
purity were used for printing and obtained from Lectinity Holdings (Moscow, Russia) and the Consortium 
for Functional Glycomics (CFG). The slides were washed for 15 min with 0.1 М PBS (0.01 М Na2HPO4, 0.01 M 
NaH2PO4, 0.138 M NaCl, and 0.0027 M KCl, pH 7.4) containing 0.1% Tween-20. Anti-P1 antibodies were diluted 
1:50 in PBS containing 1% BSA. The slides with antibody solution were shaken for 1 h and incubated under rela-
tive humidity and temperature of 80% and 37 °C, respectively. The slides were washed with PBS and labeled with 
secondary antibodies consisting of goat anti-human IgM conjugated with Alexa647 (Invitrogen, USA), which 
was diluted with PBS (1:250). After incubation, the slides were washed with PBS containing 0.001% Tween 20 
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and subsequently with bi-distilled water and the fluorescence intensity was measured using a confocal ScanArray 
Gx scanner (PerkinElmer, USA) with 5 μ m resolution. The obtained data were processed using ProScanArray 
Express 4.0 software.
Proteinase K treatment. Proteinase K treatment was carried out as previously described52. Briefly, 
single-cell suspension of 2 × 106 IGROV1, Ls174T, SKOV3 and B3GNT5 - edited SKOV3 cells were treated with 
PBS containing 100 μ g/mL proteinase K enzyme (Promega) for 1 h at 37 °C with intermittent shaking. At the same 
cell density the control cells were also resuspended in PBS without proteinase K. The enzymatic reaction was 
stopped by adding phenyl methyl sulfonyl fluoride (PMSF) at a concentration of 1 mM/mL and incubated on ice 
for 10 min. Cells were then fixed with 1% PFA on ice for 15 min and washed twice with 5 mL PBS and pelleted at 
1200 rpm for 7 min at 4 °C. Finally, fixed cells were stained with SNA, nLc4 or anti-human CD44 antibody for flow 
cytometric analysis as previously described.
Neuraminidase treatment. To remove the cell surface neuraminic acids, neuraminidase treatment was 
performed with α 2,3-6, -8,- neuraminidase (New England BioLabs, UK) according to manufacturer’s instruc-
tions. In brief, IGROV1 cells (1 × 106) were fixed with 4% paraformaldehyde in PBS at room temperature for 
15 min, and then washed with PBS twice. Cells were resuspended in 200 μ l of glycobuffer (1x) containing 25 Units 
of the enzyme and incubated at 37 °C for 2 h. Cells were washed with PBS and followed by SNA staining and flow 
cytometry.
Statistical analysis. Experiments were performed in triplicates and comparisons were statistically eval-
uated with two-tailed Student’s t-test. P values of < 0.05 were considered statistically significant (***p < 0.001, 
**p < 0.01, *p-value < 0.05, p-value < 0.1.).
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Running title: Globosides are vital for mesenchymal-to-epithelial transition 
 
Highlight 
• EMT coincides with loss of globoside glycosphingolipids 
• Homophilic E-cadherin cell-cell adhesion depends on globosides 
• Loss of globosides results in epigenetic silencing of CDH1 
In brief 
Jacob et al. demonstrated that globoside glycosphingolipids are elevated in cancer cells with 
epithelial features and are pre-requisite for E-cadherin-mediated cell-cell adhesion. CRISPR-
Cas9-mediated depletion of globosides induces reversible epithelial-to-mesenchymal 
transition (EMT) coinciding with loss of E-cadherin expression due to DNA 
hypermethylation at the promoter region of CDH1. 
 
Summary 
The transitions of cancer cells between epithelial and mesenchymal states (EMT and 
respectively MET) comprise cellular and molecular processes essential for local tumor 
growth and respective dissemination. The transmembrane glycoprotein E-cadherin is known 
to induce cell-cell adhesion in epithelial cells and thus to pivotally regulate this process; 
however, the initiating events remain to be elucidated. Here, we report that globoside 
glycosphingolipid (GSL) glycosyltransferase-encoding genes are elevated in epithelial cells 
and correlate with characteristic EMT signatures predicting disease outcome. Importantly, 
depletion of globosides through deletion of the key enzyme A4GALT by CRISPR-Cas9 
induces EMT and consequently enhances chemo-resistance. In regards to cancer stem cells, 
increase of CD24low/CD44high cells was only observed in wildtype A4GALT expressing cancer 
cells upon cholera toxin treatment inducing MET. Molecularly, cells undergoing EMT lost E-
cadherin expression through epigenetic silencing at the promoter region of CDH1 (via DNA 
methylation), however, in ΔA4GALT cells de-methylation was only able to rescue E-cadherin 
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expression if wildtype A4GALT was provided. Our data suggest GSLs as another class of 
biomolecule vital for epithelial homeostasis and to maintaining cell integrity and function. 
 
3-7 key words: Glycosphingolipids, Epithelial Ovarian Cancer, CRISPR-Cas9, Zebrafish, E-
cadherin, Epigenetics, Glycosyltransferases  
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INTRODUCTION 
The requirement for epithelial- to- mesenchymal transition (EMT) is particularly well 
reported in ovarian carcinogenesis (Tan et al., 2014). Here, metastasis is established by the 
EMT driven delamination of tumor cells from the in situ tumor, followed by their penetration 
into the surrounding peritoneal cavity (Huang et al., 2013). The adaptation of spreading 
ovarian cancer cells requires EMT for dissemination while its reversed process, the 
mesenchymal-to-epithelial transition (MET), then fosters local tumor growth at the metastatic 
site. Thus, EMT and MET frequently alternate and are actively involved in different phases of 
tumor progression (Ahmed et al., 2010). 
Although the transition of cancer cells between epithelial and mesenchymal states is a central 
mechanism of tumorigenesis, its molecular regulation is not fully understood (Nieto et al., 
2016). Migrating cells are exposed to a different microenvironment, which might conversely 
again induce morphologic and molecular changes, in vitro as well as in vivo.  During EMT, 
epithelial cells lose their cell – cell junctions and apical - basal cell polarity and undergo 
morphological changes to convert into a state of low proliferation, resistance to anoikis, and 
increased migration and invasion (Diepenbruck and Christofori, 2016). The presence of a 
specific surface architecture of glycosphingolipids (GSL) in epithelial versus mesenchymal 
cellular states suggests that these surface structures might be important players mediating 
changes in cell behavior, however, the precise functional role of glycosphingolipids (GSLs) in 
this context is poorly understood.  
Multiple oncogenic events and signaling pathways, especially mediated by the transforming 
growth factor beta (TGFβ), have been implicated in the induction of EMT (Massague, 2008; 
Teicher, 2001). Beside TGFβ, the glucosylceramide synthase inhibitor EtDO-P4 was also 
capable of inducing partial EMT accompanied with decreased E-cadherin and increased 
Vimentin expression (Guan et al., 2009). Later, Guan et al. pointed out that the GSL 
repertoire alters during treatment with EtDO-P4 and TGFβ in NMuMG, HCV29, and MCF7 
cell lines (Guan et al., 2010). An association of the mesenchymal transcription factor Zeb1 
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with elevated St3Gal5 and gangliosides was furthermore reported in epithelial NMuMG cells 
(Mathow et al., 2015). Consistently, we have previously shown that individual glycans, 
usually linked to lipids, are prognostic markers in ovarian carcinoma (Jacob et al., 2012; 
Jacob et al., 2011; Pochechueva et al., 2011) and demonstrated that specific GSLs (Figure 
1A) of the (neo-) lacto and globo series are heterogeneously expressed in cancer cells derived 
from cell lines as well as primary patient samples (Alam et al., 2015; Anugraham et al., 
2015). However, the functional role of GSLs in EMT/ MET processes, and in particular, the 
role of globo, (neo-) lacto, and ganglio series GSLs, all determined by specific key 
glycosyltransferases (Figure 1A), are yet unexplored. Here, we address this question and 
dissect the role of globosides during EMT exemplified in ovarian carcinoma. We show that 
globosides are required for E-cadherin mediated cell-cell adhesion, and that loss of globosides 
triggers EMT through a mechanism involving DNA methylation at the CDH1 promoter.  Our 
results illustrate a paradigm in which globoside depletion is required to revolve EMT. 
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RESULTS 
Globoside-encoding genes are associated with EMT/MET 
In order to gain insight into the involvement of GSL glycosyltransferase-encoding genes 
(glyco-genes) in reversible transition of cancer cells between epithelial and mesenchymal 
phenotypes, we investigated the Tothill (Tothill et al., 2008), Bonome (Bonome et al., 2005), 
and TCGA (Cancer Genome Atlas Research, 2011) transcriptome data sets representing 
epithelial (E), intermediate epithelial (IE), intermediate mesenchymal (IM), and mesenchymal 
(M) states. We applied an EMT score, which was previously developed on transcriptomic 
data to universally predict EMT states across various cancer types (Tan et al., 2014). 
First, we tested whether the expression of glycosidase- and glycosyltransferase-encoding 
genes discriminates epithelial from mesenchymal cancer cells in those transcriptomic data 
sets. We selected all available Kyoto Encyclopedia of Genes and Genomes (KEGG) 
annotated glyco-genes involved in synthesis of globo-, neo-lacto, and ganglio-series GSLs 
and demonstrated that glyco-genes significantly discriminate E from M (Figure 1B). These 
results suggest that glyco-genes are coordinately altered during transition of cancer cells. 
EMT was previously shown to predict disease outcome in ovarian cancer (Blechschmidt et 
al., 2008; Davidson et al., 2000; Hosono et al., 2007), thus, we further tested the EMT score 
in regards to disease-specific and progression-free survival. Patients with mesenchymal 
features (IM and M) experienced a shorter overall survival (likelihood ratio test = 14.4, p = 
0.00239) and earlier disease recurrence (likelihood ratio test = 13.1, p = 0.00446) compared to 
IE and E subtype (Figure 1C). In regards to GSL-encoding genes, the Cox-proportional 
hazard model revealed A4GALT as predictor for longer overall survival and disease 
recurrence with a hazard ratio (HR) of 0.119. In contrast, the glyco-gene associated with 
ganglioside ST8SIA1 predicted disease recurrence with an HR 2.715 (p = 0.006) (Figure 1D).  
Next, we investigated the individual glyco-gene expression and found that all three data sets 
displayed a classical EMT marker spectrum including CDH1 and VIM revealing a decrease or 
increase of gene expression among the four different EMT states (E, IE, IM, and M), 
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respectively (Figure 1E). We observed significantly decreased A4GALT expression to 
particularly associate with a mesenchymal signature (Figure 1A and 1E). The A4GALT gene 
encodes the α1-4 galactosyltransferase, a key enzyme responsible for synthesis of globoside 
GSLs. In contrast, IM and M showed elevated expression of ST3GAL5 encoding α2-3 
sialyltransferase 5 (involved in ganglioside GSL synthesis (Figure 1E). A more detailed 
analysis of the Tothill data set in regards to all KEGG annotated glycosyltransferases 
involved in GSL synthesis revealed generally decreased globoside- and elevated ganglioside- 
gene expression profiles among the four EMT states (Supplementary Figure S1).  
These data demonstrate that globo series related genes, and in particular A4GALT are elevated 
in epithelial cancer cells and associated with improved patient’s outcome. In order to set up 
an experimental model for studies on the relevance of A4GALT and globosides during EMT/ 
MET, we next profiled six GSLs (lactosylceramide- LacCer; Gb3, SSEA3, paragloboside- 
nLc4, P1, and GM1, Figure 1A and 1F) in 34 cell lines. In general, all healthy and cancer cell 
lines displayed a heterogeneous expression of GSLs, with a peak of GM1 (82.0 ± 26.7 % 
FITC+, Figure 1F). In contrast, P1 displayed the lowest expression among all cell lines (4.6 ± 
15.9 % FITC+). The remaining tested GSLs, including globosides Gb3 and SSEA3, displayed 
a more heterogeneous expression ranging from 0 % to 97.7 % FITC+. Interestingly, the 
ovarian cancer cell line IGROV1 was positive for all GSLs. Moreover, IGROV1 displayed 
intermediated expression of epithelial and mesenchymal markers in the Cell Line 
Encyclopedia (Barretina et al., 2012) and has previously been considered as IE ((Huang et al., 
2013) and Supplementary Figure S2). We therefore selected IGROV1 as a model to study 
globoside depletion by genome- editing and the subsequent effects on EMT/ MET. 
 
Establishment of a globoside-depleted ovarian cancer cells using CRISPR-Cas9 
As IGROV1 cells express a comprehensive GSL repertoire including globo, (neo-) lacto, and 
ganglio series, we genome-edited A4GALT in this cell line to deplete the glycosidic products 
of this glycosyltransferase. Our paired-sgRNA-based strategy targets the entire open reading 
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frame (ORF) of A4GALT, a 1’335bp genomic region at chromosome 22q13 (Figure 2A). 
Transient transfection of PX458 containing two specific sgRNAs following GFP-based clonal 
selection revealed various genotypes (Supplementary Figure S3 and Figure 2B). We 
identified three homozygous knockout (ΔA4GALT) clones out of eighty-six clones profiled 
(3.5% efficiency). Insertions and deletions at the Cas9-active sites (indels) were detected by 
DNA sequencing. However, due to the use of paired sgRNAs targeting the entire ORF, the 
presence of indels did not influence the knockout of A4GALT (Figure 2C). The off-target 
analysis revealed no sequence variation (insertion/deletion) at predicted off-target sites 
(Figure 2D). We examined the expression of GSLs in wildtype (A4GALT) and ΔA4GALT 
cells by flow cytometry. All three ΔA4GALT cell clones were depleted for the expression of 
globosides (Gb3 1%, SSEA3 1%) and P1 (1%), while LacCer (3-20%), nLc4 (50-85%), and 
GM1 (70-100%) remained largely unchanged (Figure 2E).  
According to the transcriptomic data, the gene expression of specific ganglioside synthesizing 
glycosyltransferases (e.g. ST8SIA1) increases among the EMT spectrum. Thus, we performed 
quantitative analysis of the glycosylation of the GSLs expressed by these cells by 
enzymatically releasing the glycans from the isolated GSLs for analysis using LC-ESI-
MS/MS, in order to study the structure of the glycan component of the GSL product after 
deletion of A4GALT. In line with our flow cytometry data, the glycan mass of m/z 505.31- 
corresponding to the monosaccharide composition of globoside Gb3 [(Hex)3], which is the 
direct product of A4GALT, was not detectable in ΔA4GALT cells (Supplementary Table S1). 
Interestingly, the ganglioside GM1 (glycan mass m/z 999.5 ((Hex)3(HexNAc)1(NeuAc)1), 
Supplementary Figure S4) was increased significantly in ΔA4GALT cells (29.4%) compared 
to wildtype (13.4%) indicating that certain gangliosides increased as a consequence of 
globoside depletion. 
Globoside-depleted cells acquire mesenchymal properties in vitro and in vivo 
We next sought to ascertain the phenotypic changes of cells disrupted for A4GALT. When 
compared to wildtype cells, ΔA4GALT IGROV1 cells (IE) displayed a mesenchymal 
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morphology (Figure 3A). We also observed a loss of cell-clumps in cell cultures upon 
disruption of A4GALT with ΔA4GALT cells growing in monolayer instead of on top of each 
other (Figure 3A). With regards to cell proliferation, we observed no significant differences 
(p = 0.05 at 120 h) (Figure 3B). Next, we examined the influence of A4GALT on anchorage-
dependent (Figure 3C) and -independent growth in standard tissue culture plates and soft-
agar, respectively. Both assays revealed significantly reduced numbers of colonies in 
ΔA4GALT cells as compared to parental wild type (anchorage-dependent p = 0.0001 and -
independent p = 0.0002) (Figure 3D). 
The striking difference in anchorage-independent growth was further investigated in regards 
to cell-detachment-induced apoptosis (anoikis), which is a crucial step for tumor cells 
undergoing malignant transformation or adapting to a new microenvironment. Resistance to 
anoikis is typical for ovarian cancer cells that can survive in ascites fluids before forming 
metastatic foci at distant sites (He et al., 2013). We observed prolonged cell viability in 
ΔA4GALT cells after 7 and 10 days of cultivation (Figure 3E). This was in line with strongly 
increased percentage of dead (propidium iodide- positive stained) cells in wildtype compared 
to ΔA4GALT IGROV1 cells (Figure 3E). The significant decrease of apoptotic ΔA4GALT 
cells coincides with reduced cleaved PARP, another marker of cellular apoptosis (Figure 3F). 
We next examined the migratory and invasive phenotype of ΔA4GALT cells using in vitro 
directed cell motility assays (FCS as chemo-attractant). Cells harboring ΔA4GALT indeed 
displayed enhanced cell migration (Figure 3G, p = 0.0015) and invasion (Figure 3H, p = 
0.024). Intrigued by this result, we injected both cell types into zebrafish embryo to study cell 
motility and proliferation in vivo. Zebrafish embryos were examined after 3 days post 
injection (dpi) and in line with our above mentioned in vitro data, enhanced in vivo 
dissemination was observed between ΔA4GALT versus A4GALT cells (Figure 3I), while also 
in this in vivo model cell growth was altered, as revealed by flow cytometry quantification of 
CM-DiL positive cells in corresponding transplanted fish embryos (Figure 3I). 
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E-cadherin-mediated cell-cell adhesion requires A4GALT-dependent GSLs 
Because the gene disruption of A4GALT revealed well described phenotypic changes 
associated with EMT, both in vitro and in vivo, we characterized cells depleted for globosides 
in more detail. Specifically, we investigated the major player in EMT- E-cadherin, which has 
a pivotal role in cell-cell adhesion. 
To rule out whether the A4GALT deletion mediates its effect as functionally linked to E-
cadherin, we restored A4GALT levels in ΔA4GALT cells by ectopically expressing the ORF 
of A4GALT (Rescue DXD) in a doxycycline-inducible manner. The aspartate-any residue-
aspartate (DXD) motif, which is present in A4GALT, is important for enzymatic activity of 
several glycosyltransferases (Ihara et al., 2002; Li et al., 2001; Persson et al., 2007). Thus, a 
mutant (D194A) of A4GALT was generated as being enzymatically inactive (Rescue DXA) 
and tested for expression of various GSLs. The Rescue DXD revealed similar expression for 
LacCer, Gb3, nLc4, P1, and GM1. However, SSEA3 was not re-expressed in Rescue DXD 
cells. We also demonstrate for the first time that the DXD-motif in A4GALT is required for 
enzymatic activity, as none of the A4GALT-mediated GSLs were rescued in DXA cells 
(Figure 4A and 4B). 
Next, we determined the expression of E-cadherin in all four-cell lines- wild type, ΔA4GALT, 
rescue DXD, and DXA. In addition, we transduced ΔA4GALT cells with human full-length E-
cadherin as well as the cytoplasmic chimera IL2R/ E-cadherin (not capable of engaging 
hemophilic adhesive activity), and both ORFs generated previously (Gottardi et al., 2001) 
were cloned into pCW57.1. The wildtype and ΔA4GALT cells re-expressing E-cadherin and 
IL2R/E-cadherin revealed high expression of E-cadherin with an expected shift towards lower 
molecular weight for IL2R/E-cadherin (Figure 4C). We also observed a faint band for E-
cadherin in the rescue DXD cells, ΔA4GALT cells re-expressing A4GALT and globosides. In 
contrast, both, ΔA4GALT and rescue DXA cells were not capable expressing E-cadherin 
(Figure 4C). 
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Intact cell-cell adhesion via E-cadherin usually appears as membranous staining in epithelial 
cells and becomes intermittent and jagged during EMT, indicating a breakdown of cell-cell 
junctions (Maeda et al., 2005). This dispersed membrane-associated E-cadherin staining was 
reported in various epithelial cells undergoing EMT (Bassaganas et al., 2014; Busche et al., 
2010; Hoot et al., 2008). To determine whether A4GALT-mediated GSLs affect cell-cell 
junctions, we analyzed genetically engineered cells for the distribution of E-cadherin, the 
integral component of the adherens junctions. Despite the low E-cadherin expression in the 
rescue DXD (Figure 4C), only these cells revealed areas of typical membranous E-cadherin 
staining as observed in IGROV1 by confocal fluorescence microscopy (Figure 4D). Neither 
full length nor IL2R fused E-cadherin transduced ΔA4GALT cells displayed membranous 
staining as observed in IGROV1. Taken together, these results indicate that A4GALT-
mediated GSLs are required for E-cadherin mediated cell-cell adhesion and are important for 
MET. 
 
The presence of globosides is vital in intermediate EMT cells 
CDH1 and A4GALT expression are positively correlated in epithelial ovarian cancer tissue 
samples (Tothill, Pearson’s correlation 0.26, p = 6.25e-06). A4GALT and its enzymatic 
products seem to be preferentially expressed in cells with epithelial characteristics and are 
required for cell-cell adhesion via E-cadherin. To better understand the connection between 
A4GALT and E-cadherin in epithelial cells, we asked whether deletion of A4GALT affects 
globosides and function of E-cadherin in ovarian cancer cells representing the full spectrum 
of EMT. Thus, we tested the transition properties of ovarian cancer cells that have undergone 
genetic disruption of A4GALT in a broader panel of cell lines. A total of 10 ovarian cancer 
cell lines were selected showing broad variation of CDH1 and VIM expression. A4GALT 
expression coincides with CDH1 expression in those cell lines (Figure 5A). Next, we tested 
for expression of E-cadherin and Vimentin together with globosides in matching cell lines. 
Gb3 and SSEA3 was generally elevated in cell lines being primarily positive for E-cadherin 
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and almost negative for Vimentin indicating that globosides are preferentially expressed on 
epithelial cancer cells while losing expression during EMT (Figure 5B).  
In addition to IGROV1, cells representing an IE state, we selected BG1, SKOV3 and A2780 
cell lines displaying the remaining three different EMT states (E, IM, and M, respectively) 
and used them for depletion (via CRISPR-Cas9 mediated A4GALT editing; BG1, SKOV3,) 
and respectively over-expression of globosides via lentiviral transduction with 
pUltraA4GALT; A2780). As expected, genomic deletion (Supplementary Figure S5A and 
S5B) or overexpression of A4GALT resulted in the absence or presence of Gb3 and SSEA3, 
respectively (Figure 5B and Supplementary Figure S5C, S5F). However, E-cadherin 
expression levels were only reduced in SKOV3 ΔA4GALT cells whereas BG1 (E) and A2780 
(M) did not alter in E-cadherin expression (Figure 5C). Interestingly, BG1 ΔA4GALT cells 
showed partly intermittent and jagged staining at the cell-cell borders and significantly 
reduced colony formation (Supplementary Figure S5D and S5E) supporting previous findings 
in IGROV1. 
To further demonstrate the involvement of globosides in transition of cancer cells, we 
investigated SKOV3 in more detail, which usually exhibits an IM phenotype (Huang et al., 
2013). Studies on SKOV3ip, a derivative of SKOV3 obtained after passaging in mice, 
showed significantly increased growth rate, enhanced colony formation in soft agar and tumor 
formation in vivo compared with parental SKOV3 (Yu et al., 1993). Here, we observed 
elevated E-cadherin expression coinciding with increased globosides in SKOV3ip compared 
to SKOV3 cells (Figure 5C and 5D). There are characteristics of MET shifting parental IM 
SKOV3 into IE SKOV3ip cells, further supporting our data. Significantly increased 
anchorage-dependent growth and elevated cell membranous staining correlated with 
increased E-cadherin expression in SKOV3ip cells (Figure 5D and 5E). These results indicate 
that especially for IE/IM cancer cells, globosides are essential for epithelial properties 
involved in E-cadherin expression and cell-cell adhesion. 
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Cancer cells transitioning towards a mesenchymal state are associated with elevated 
resistance to a variety of conventional chemotherapeutics (Mani et al., 2008). Here, we tested 
how loss of A4GALT affects resistance to doxorubicin in ovarian cancer cells (Figure 5F). 
First, we observed increased resistance to doxorubicin in cancer cells reflecting the various 
EMT states represented by BG1 (E), IGROV1 (IE), and SKOV3 (IM). In contrast to BG1, 
IGROV1, and SKOV3 displayed 4.25- and 1.80-fold higher resistance to doxorubicin for 
ΔA4GALT cells, respectively. The SKOV3ip cell line was 2.12-fold more sensitive to 
doxorubicin compared to parental SKOV3 (Figure 5F), thus, confirming that intermediate 
EMT cell lines acquire doxorubicin resistance correlating with expression of globosides. 
Next, we studied the impact of A4GALT loss on the cancer stem cell (CSC) markers CD24 
and CD44 because EMT is usually accompanied by the lack of E-cadherin that enables cancer 
cells to acquire stem-like properties and enter into a more mesenchymal state (Kalluri and 
Weinberg, 2009). Thus, we examined whether ΔA4GALT cell populations undergoing EMT 
displayed an increase in the proportion of cells carrying the CD24low/CD44high marker profile 
associated with CSCs. We observed that the percentage of CD24low/CD44high cells was 
significantly higher in ΔA4GALT cells (Figure 5G). To prove that globosides are required for 
MET, we treated ΔA4GALT cells with cholera toxin (CTx), a MET inducing agent 
(Pattabiraman et al., 2016), and observed as expected no significant difference in 
CD24low/CD44high markers, while A2780 (M) and SKOV3 (IM) switched from 
CD24low/CD44high to CD24high/CD44low phenotypes after CTx treatment (Figure 5G). CSC 
marker alterations in SKOV3 were accompanied by an increase of the globoside Gb3 (4 to 
19% FITC+) and enhanced E-cadherin expression (Figure 5H and 5I). Neither globoside nor 
E-cadherin expression was observed in A2780 and ΔA4GALT cells (IGROV1, BG1 & 
SKOV3) treated with CTx (Figure 5G-I). Taken together, these data highlight not only the 
importance of globosides in MET but also their potential impact on the expression of CD24 
and CD44, thus further indicating that GSLs are directly involved in transition of cancer cells 
from an epithelial to a mesenchymal phenotype. 
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EMT upon A4GALT deletion is accompanied by DNA hypermethylation at the promoter 
region of CDH1 
Epigenetic programs, including DNA methylation and chromatin modifications play a key 
role in EMT (Nieto et al., 2016). Recent work by Pattabiraman et al. 2016 suggests that the 
protein kinase A pathway triggers epigenetic reprogramming by the histone demethylase 
PHF2. However, in our case CTx treatment only marginally affected expression of E-
cadherin, CD24 and CD44 markers, especially in ΔA4GALT cells (IGROV1, BG1 & 
SKOV3). Thus, we tested the impact of DNA methylation at the promoter region of CDH1. 
Independent of the program applied, the analysis of the promoter region of CDH1 predicted a 
CpG island surrounding the transcription start site (TSS) of CDH1 (Figure 6A). Since most 
changes in DNA methylation occur in a region of −250/+250 bp relative to the TSS (Kelly et 
al., 2012), we analyzed the DNA methylation status within the genomic region -116/+124 of 
the TSS CDH1 comprising 18 CpGs (Figure 6A). Cell lines in the E state (OVCAR3 and 
BG1) revealed DNA hypomethylation at the investigated locus in contrast to A2780, which 
showed 84 ± 2.65% DNA methylation (Figure 6B). Interestingly, we observed increased 
DNA methylation at the promoter region of CDH1 in both ΔA4GALT cell lines compared to 
parental IGROV1 and SKOV3 (Figure 6B). Next, we hypothesized that E-cadherin 
expression in ΔA4GALT cells can be re-expressed by the hypomethylating agent, 5-aza-2′-
deoxycytidine (5-Aza), treatment. Parental IGROV1, ΔA4GALT, and rescue DXD cells 
showed E-cadherin expression after 96 h of treatment with 5-Aza (Figure 6C). Finally, we 
investigated membranous staining of all three-cell lines and observed increased membranous 
staining in 5-Aza treated IGROV1 and rescue DXD cells whereas ΔA4GALT cells did not 
reveal such a pattern (Figure 6D). Here, we show that we substantially rescued E-cadherin-
mediated cell-cell adhesion only in cells with a functional α1-4 galactosyltransferase and its 
direct glycolipid products (globosides) indicating that DNA methylation coincides with the 
expression of E-cadherin upon loss of globosides. 
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DISCUSSION 
Glycosphingolipids (GSLs) have been studied for six decades and linked to embryonic 
development and cell differentiation in normal and diseased cells. They are compartments of 
the cell surface membrane acting as mediators for cell adhesion and signal transduction. 
However, we have identified novel roles for GSLs as mediators of cell-cell adhesion and 
EMT induction in ovarian cancer. We show that cancer cells undergoing EMT upon depletion 
of globoside GSLs through genomic deletion of the key glycosyltransferase A4GALT display 
silencing of E-cadherin expression resulting in loss of cell-cell adhesion properties. 
Remarkably, re-expression of globosides by A4GALT rescue partially restored homophilic 
cell-cell adhesion whereas ectopic E-cadherin was not able to. The pivotal role of globosides 
in this context was further demonstrated by global de-methylation on genomic DNA with co-
expression of A4GALT resulting in membranous E-cadherin staining. 
Epithelial and intermediate EMT cells were shown to generally express higher levels of globo 
and neolacto series GSLs. Beside cancer cells undergoing EMT upon A4GALT deletion, we 
also observed elevated levels of Gb3 and E-cadherin expression in SKOV3ip indicating that 
SKOV3ip cells underwent MET in mice. This is in line with work by Hakomori and 
colleagues describing a ganglioside enrichment and globoside (e.g. SSEA3) reduction in a 
hydroxytamoxifen inducible TWIST-EMT model system of human mammary epithelial cells 
(HMLE-TWIST-ER) that correlated with silencing of CDH1 expression (Liang et al., 2013; 
Liang et al., 2010). The authors performed knockdown of ST8SIA1 and B4GALNT1 (both 
enzymes involved in ganglioside synthesis) in MCF-7 cells indicating that specific 
gangliosides might be involved in mammosphere formation with alterations in random cell 
motility, however without showing E-cadherin expression upon the glyco-gene knockdown. 
Our transcriptomic data analyses support these findings since all significantly differentially 
expressed genes encoding for glycosyltransferases involved in the ganglio series GSL 
synthesis appear upregulated in mesenchymal phenotypes of these tissue samples. Moreover, 
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our quantitative analysis of glycans released from the expressed GSLs in the tissues 
demonstrated that gangliosides are increased upon depletion of globosides. 
Interestingly, 60.5% of ovarian cancer cell lines can be categorized into IE and IM states 
(Huang et al., 2013), which was also similarly reflected in ovarian cancer tissue samples and 
in the cell line encyclopaedia (Tan et al., 2014). Epithelial ovarian cancer seems to be 
therefore an optimal model for studying EMT/MET. During EMT, cells undergo a series of 
sequential events to disintegrate cell – cell contacts and the regulatory machinery that controls 
cell polarity (Nieto et al., 2016). Epithelial cells become progressively separated from 
mesenchymal-like cells by gradually loosening cell-cell contacts to transit from polarized 
epithelium to post EMT-mesenchymal state (Huang et al., 2012b). More recent studies point 
out that a greater flexibility exists in the EMT process, and cells are no longer thought to 
oscillate between the full epithelial and full mesenchymal state, but rather move through a 
spectrum of intermediate phases (Nieto et al., 2016). In this state of EMT, cells harbor the 
greatest plasticity because they are able to either reverse to an epithelial state or progress 
towards a mesenchymal phenotype (Huang et al., 2012a). Our observations upon GSL 
depletion support these hypotheses and further point out the importance of GSLs in this 
context, as here demonstrated in IGROV1 and SKOV3 (both intermediate EMT and E-
cadherin+/ Vimentin+) cell lines. In contrast, epithelial (BG1, E-cadherin+/ Vimentin-) and 
stable mesenchymal (A2780, E-cadherin-/ Vimentin+) cells did not fully undergo transition 
upon deletion or ectopic expression of A4GALT, respectively. However, we observed 
changes in cell morphology, E-cadherin cell-cell adhesion and differential expression of 
CD24 and CD44, all of which are well described to occur in various solid tumors 
distinguishing CSCs from bulk-tumor populations (Clevers, 2011) and have been related to 
GSLs (Liang et al., 2013; Pattabiraman et al., 2016).  
Interestingly ΔA4GALT IGROV1 cells also exhibited anoikis resistance as well as higher 
migratory and invasive phenotypes compared with wildtype, which are the typical 
characteristics of an EMT transition. In addition, after executing the EMT program, 
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ΔA4GALT cells acquired traits associated with metastatic characteristics, which leads to 
dissemination in vivo (Figure 3 and (Tam and Weinberg, 2013)). In light of our results, it 
becomes more evident that ovarian cancer cells in intermediate EMT/ MET states are 
characterized by a specific GSL composition which might functionally act upstream of E-
cadherin for affecting homophilic cell-cell adhesion. 
E-cadherin–mediated cell–cell adhesion usually provides a spatial cue for cells to distinguish 
an unbounded (apical) from a bounded (basolateral) cell surface and to accumulate acting 
membrane proteins on the correct surface (Wang et al., 1990), but the mechanisms linking E-
cadherin to protein sorting and redistribution to different plasma membrane domains are 
unknown. Although re-expression of A4GALT resulted only in partial rescue of E-cadherin 
and cell-cell adhesion, interestingly, no membranous staining was observed in either full-
length E-cadherin or IL2R/E-cadherin cytotail expression in ΔA4GALT IGROV1 cells. 
Treatment of cells with an agent inducing global DNA de-methylation (5-Aza) increased E-
cadherin expression in ΔA4GALT IGROV1 cells; however, only co-expression of A4GALT 
in these cells re-stored the wildtype E-cadherin-mediated cell-cell adhesion, indicating that 
globosides are vital for cancer cells with epithelial features. Thus, we propose that the 
composition of globosides, herein referred to as a ‘lipid glyco-fingerprint’, intrinsically 
defines cell-cell adhesion between cells. It remains to be elucidated how the recognition 
between two cells, before forming adhesion via E-cadherin, occurs, either by carbohydrate-
carbohydrate (Bucior et al., 2004; Hakomori, 2004) or carbohydrate-protein recognition. 
Interestingly, examples in the literature show differentially expressed glyco-genes involved in 
glycosylation of ceramides during EMT/ MET. One study on HMLE-TWIST-ER cell system 
found 44 genes involved in mesenchymal (CD24low and CD44high) metabolic pathways 
including genes encoding for enzymes involved in GSL synthesis UGCG and ST6GAL1 
(Shaul et al., 2014). Our hypothesis is supported by recent work demonstrating that the CTx 
induces MET in several cell lines via the PKA pathway inducing epigenetic changes that can 
modulate MET together with loss of mesenchymal characteristics (Pattabiraman et al., 2016). 
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The cholera toxin is known to bind the ganglioside GM1 (Galβ1-3GalNacβ1-4(Neu5Ac(α2-
3)Galβ1-4Glc-ceramide) and associated structures (Merritt et al., 1994). Considering the fact 
that gangliosides seem to be preferentially expressed in mesenchymal cells, CTx might 
indeed induce MET by selectively binding to ganglioside-expressing cancer cells with 
mesenchymal features. Reduced expression of gangliosides on epithelial cells might therefore 
be an explanation of non-inducible MET in epithelial-like cells. In sum, our current findings 
identify globoside GSLs as a new major player triggering the transition of ovarian carcinoma 
cells between epithelial and mesenchymal states.  
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MATERIAL AND METHODS 
Cell culture 
A total number of thirty-four different cell lines were acquired via different sources and 
maintained in house in appropriate growth media (Supplementary table S2). All cell lines 
were cultured at 37°C in a 95 % humidified atmosphere containing 5 % CO2. All cell lines 
were authenticated using short tandem repeat (STR) profiling and regularly tested for the 
absence of mycoplasma (Uphoff and Drexler, 2005). 
Reagents, antibodies and enzymes	
Antibodies for detection of cell surface-associated GSLs were applied as described previously 
(Alam et al., 2015). Additional antibodies were applied; primary antibodies E-Cadherin 
(#3195) and Tubulin (#2148), secondary antibodies HRP-anti-rabbit IgG  (#7074) and HRP-
anti-mouse IgG (#7076) all obtained from Cell Signaling Technology (BioConcept Ltd, 
Allschwil, Switzerland). Vimentin (#MS-129-P1) antibody was purchased from Thermo 
Fisher Scientific (Life technologies, Reinach, Switzerland). Anti-human CD44-PE (#130-
098-108) and CD24-PE-Cy7 (#561646) antibodies were obtained from MACS Miltenyi 
Biotec (Bergisch Gladbach, Germany) and BD Pharmingen (Allschwil, Switzerland), 
respectively. 
Endoglycoceramidase II (EGCase II, recombinant clone derived from Rhodococcus sp and 
expressed in Escherichia coli) was purchased from Sigma-Aldrich (MO, USA). 
Glycosphingolipid standards from Matreya LLC (Neutral Glycosphingolipid Qualmix 1505, 
globotriosylceramide (CTH), Monosialoganglioside Mixture 1508, Gangliotetraosylceramide 
1064) were obtained from Adelab Scientific (SA, Australia). Immobilin-P Polyvinylidene 
Difluoride (PVDF, 0.2 μm) was obtained from Millipore (MA, USA). Microtiter plates 
(Corning 96-well clear flat bottom, COR3364) were purchased from Invitro (Vic, Australia). 
Cation exchange resin beads (AG50W-X8) was obtained from BioRad (Hercules, CA, USA) 
and PerfectPure C18 Zip Tips were obtained from Eppendorf (Hamburg, Germany). 
Potassium hydroxide and sodium borohydride were obtained from Sigma-Aldrich (MO, 
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USA). Other reagents and solvents such as methanol, ethanol, chloroform and acetonitrile 
were of HPLC or LC/MS grade. 
 
Single-guided RNA design and vector construction 
Single guided RNAs (sgRNA) targeting exon 3 of A4GALT were designed using the web tool 
of the Zhang laboratory (http://crispr.mit.edu) (Ran et al., 2013). sgRNA1 and sgRNA2 
(Supplementary table S3, Figure 2) with scores of 91 and 85, respectively, were selected for 
gene editing of the entire open reading frame (ORF) of A4GALT. Intended oligo pairs 
encoding 20nt targeted sequences (Supplementary table S3) with overhangs (both 5’ and 3’) 
from BsbI restriction site were ordered, annealed and finally cloned into either pSpCas9(BB)-
2A-GFP (addgene, #PX458) or pSpCas9(BB)-2A-puro (addgene, #PX459) via BsbI 
restriction site using T4-DNA ligase (Promega, Dübendorf, Switzerland). Constructs were 
transformed into DH5alpha E. coli strains and sequenced for confirmation of the sgRNA 
inserted into PX458 by Sanger DNA sequencing using Primer human U6. 
Transfection and single cell sorting 
IGROV1, BG1 and SKOV3 cell lines were grown in 6-well plate (3x105 - 5x105 cells/well) 
for 24 h and transiently transfected using Viafect® transfection reagent (Promega) with 2.5 μg 
of sgRNA containing either PX458 (Addgene # 48138) or PX459 (Addgene # 62988) donor 
plasmid to generate homozygous ΔA4GALT. Cells were washed with PBS, harvested using 
cell dissociation buffer (non-enzymatic, Sigma-Aldrich, Buchs, Switzerland) and finally re-
suspended in RPMI containing 10% FCS 72 h after transfection. Following single cell sorting 
was performed on a BD FACS Aria Cell Sorter (BD Bioscience) sorting for single DAPI- and 
GFP+ cells into 96-well flat-bottom plates with pre-warmed RPMI containing 10% FCS. 
Plates were incubated for up to 3 weeks following transfer to 48-well plates and genomic 
DNA isolated for genotyping PCR to characterize single cell clones. 
Genotyping PCR 
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Selected clones were characterized to identify homozygous knockout by using three 
independent PCR primer pairs (Supplementary table S3). PCR was performed using 2.5x 
GoTaq Green Master Mix (Promega), 300nM primer, 30ng genomic DNA (gDNA). PCR 
conditions were 95°C for 2 min, then 32 cycles of 94°C for 15 sec, 58.9°C for 15 sec, 72°C 
for 30-45 sec (depending on the amplicon length), finished with 1 cycle at 72°C for 5 min. 
Amplicons were visualized on a 1.5 % agarose gel. 
DNA sequencing 
PCR products corresponding to genomic modifications were purified and cloned into the 
pGEM®-T Easy Vector System (Promega) according to the manufacturer’s protocol and 
sequenced using T7-F (Supplementary table S3) primer by Sanger DNA sequencing service 
from Source Bioscience Life Sciences (Berlin, Germany). Samples were shipped at a 
concentration of 100 ng/μl with specific primer (if required) of 3.2 pg/μl. 
Flow cytometry 
Immunostaining and flow cytometry was performed as previously described (Alam et al., 
2015; Jacob et al., 2014). 
Analysis of glycans released from GSLs using PGC LC-ESI-MS/MS 
The extraction of GSLs from cell lines was carried out with some modifications based on our 
previously described method (Anugraham et al., 2015). Briefly, cells (1 x 107) were 
harvested, washed thrice in 10 ml of phosphate buffered saline and pelleted through 
centrifugation at 1800 g for 20 min. A total of 5 ml of chloroform: methanol (2:1) was added 
to the cell pellet and incubated overnight in a 40C incubator shaker. The supernatant was 
collected after centrifugation at 1800xg for 20 min and the pellet was re-extracted again as 
described above. The combined supernatants were evaporated to dryness under vacuum and 
the dried glycosphingolipid mixture was re-dissolved in 50 μl of chloroform: methanol (2:1). 
Subsequently, GSLs were spotted onto a polyvinylidene diflouride (PVDF) membrane to 
immobilize the GSLs. PVDF spots were cut and placed in a chloroform-compatible 96-well 
microplate, to which 50 μl of re-dissolved glycosphingolipid mixtures from cell line samples 
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were spotted. 10 μl of neutral and acidic glycosphingolipid standards were also on individual 
PVDF spots and the 96-well microplate was air-dried at room temperature to ensure proper 
binding of the GSLs . To release the glycans from membrane-bound glycosphingolipids, 2 μl 
(4mU) of Endoglycoceramidase II in 50 μl of 0.05 M sodium acetate buffer, pH 5.0 was 
added to each sample well and incubated for 16 h at 37oC. Approximately 50 μl of released 
glycans was recovered from the individual sample wells and transferred to Eppendorf tubes 
containing 1ml of chloroform: methanol: water (8:4:3). The sample well was then washed 
with 50 μl of water and residual glycans were added to the Eppendorf tube. The upper 
methanol: water layer containing the released oligosaccharides (~400 μl) was dried and kept 
for subsequent analysis.  
The released glycans were reduced to alditols with 20 μl of 200 mM sodium borohydride in 
50 mM potassium hydroxide at 50oC for 2 h. The reaction mixture was quenched using 2 μl 
of 100% glacial acetic acid. The glycan alditols (~20 μl) were applied to individually 
prepared cation exchange columns which consist of 45 μl of cation exchange resin beads 
(AG50W-X8) deposited onto reversed phase μC18 ZipTips (Perfect Pure, Millipore) and 
placed in microfuge tubes. The columns were conditioned by a series of pre-washing steps 
with a) 50 μl of 1 M HCl, b) 50 μl of methanol and c) 50 μl of water as previously described 
(Jensen et al., 2012). Glycan alditols were eluted with Milli Q water (50 μl, twice) and dried. 
Subsequent drying steps with methanol (100 μl, thrice) were performed to remove residual 
borate. Purified glycan alditols were re-suspended in 15 μl of water prior to MS analysis. 
The reduced GSL glycans were analyzed by a capillary LC (Dionex) connected to a linear 
ion-trap mass spectrometer (LTQ Velos Pro, Thermo Scientific). 3 μl of the sample was 
injected onto a Hypercarb porous graphitized carbon (PGC) capillary column (5 μm 
Hypercarb KAPPA, 180 μm x 100 mm, Thermo Hypersil, Runcorn, UK). The separation of 
glycans was carried out over a linear HPLC gradient of 0-70 % (v/v) acetonitrile /10 mM 
ammonium bicarbonate for 45 mins followed by a 10 min wash-step using 90 % (v/v) 
acetonitrile /10 mM ammonium bicarbonate at a flow rate of 4 μl/min. The MS spectra were 
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obtained within the mass range of m/z 400 - m/z 1500. The temperature of the transfer 
capillary was maintained at 325 oC and the capillary voltage was set at 3.2 kV. Neutral and 
acidic glycans were detected in the negative ion mode as [M-H]1- and [M-2H]2- ions and their 
signal intensities and fragmentation were analyzed using the Thermo Xcalibur Qualitative 
Analysis (Versions 2.2) software. 
MTT assay 
To identify the proliferation rate cells were seeded at a density of 20’000 cells/ well in 96-
well plates and incubated for 24 h to 120 h. At each time point MTT dye (Sigma-Aldrich) was 
added at a final concentration of 500 µg/mL and incubated for 3 h. After removal of 
supernatant 200 µl of DMSO was added to dissolve the crystals. The optical density (OD, 
absorbance at 540 nm) was measured with a Synergy H1 Hybrid Reader (Biotek, Basel, 
Switzerland). The measurement was performed in quadruplets and experiments were repeated 
thrice. 
Colony formation assay 
Cells were harvested and adjusted in cell number for seeding of 500 cells per well of a 12-
well plate. The standard culture medium was replaced every 3 days. On the 10th day after 
seeding, colonies were counted only if they contained more than 50 cells. Finally, the cells 
were stained using crystal violet and images were taken. 
Soft agar assay 
Cells were grown in medium containing 1 % base agar and 0.3 % top agar. Additional culture 
media were overlaid every 3-4 days. After 10-14 days of culture, colonies were enumerated 
and pictures were taken. The experiments were independently repeated at least three times. 
Aggregation or anoikis assay 
To evaluate anchorage-independent growth, cells were grown in ultra-low attachment T25cm2 
flasks. Cells were than harvested at day 4, 7 and 10, washed with PBS and stained with 
propidium iodide (PI) following the manufactures instructions. The percentage of PI positive 
cells was analyzed by flow cytometry using BD AccuriTM C6.  
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Cell motility (migration and invasion) 
Directed cell motility assay was performed as described previously (Jacob et al., 2014). In 
brief, sub-confluent cells were grown in serum-free media for 24 h and 7.5 x 105 cells were 
seeded into the upper chamber of each insert following incubation at 37°C for 18 h allowing 
cells to migrate to the chemo-attractant (medium containing 10 % FBS). After incubation, 
media in the interior part of the insert was removed and the insert was immersed in 0.2% 
crystal violet/ 10% ethanol for 20 min. The insert was intensively washed and non-migrated 
cell in the interior of the insert were removed using a cotton-tip swab. Five random areas of 
the inserts were photographed for migrated cells, and cell counts were performed. 
In regards to invasion assay, trans-well inserts were covered with a final volume of 100 μl 
Matrigel (diluted with media, 1:80) for 1 h at room temperature to settle down and 
polymerized. The plate was then placed in the incubator at 37°C for overnight. Cells were 
then processed according to the previously described cell migration protocol mentioned above 
and after incubation at 37°C for 24 h, media was removed and the insert was immersed in 
crystal violet for 20 min and followed the same protocol as described before. 
A4GALT rescue, mutagenesis and cloning of E-cadherin constructs 
To rescue the A4GALT in ΔA4GALT cells, we utilized IGROV1 genomic DNA as template 
and designed primer to amplify the A4GALT open reading frame. The PCR was performed 
using 2 U Pfu DNA polymerase (Promega), 1 x Pfu DNA polymerase buffer, 300nM forward 
and reverse primer, 30 ng genomic DNA (gDNA), 200 μM dNTPs and nuclease free water 
under following conditions: 95°C for 2 min followed by 32 cycles of 94°C for 15 sec, 58°C 
for 15 sec, 72°C for 3min, and finished with 1 cycle at 72°C for 5 min. Amplicons were 
visualized on 1 % agarose gel and purified by Wizard SV gel and PCR Clean-Up System 
(Promega) and finally cloned into plasmid pcDNA3.1 (Addgene #V790-20) which was used 
as mutagenesis template. After DNA Sanger sequencing the mutagenesis PCR was performed 
as previously described (Zheng et al., 2004). The PCR amplifications were carried out with 
ExpandTm High Fidelity PCR system (Roche, Switzerland) in a 50 μl reaction volume, which 
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was carried out with 100 ng pcDNA3.1A4GALT open reading frame as template, 1 μM primer 
pair, 200 μM dNTPs and 2 U of DNA polymerase. The PCR was performed under following 
conditions: 94°C for 5 min; 16 cycles of 94°C for 1 min, 52°C for 1 min and 72°C for 16 min; 
followed by 72°C for 1 h. The Amplicons were then evaluated by agarose gel electrophoresis 
and purified by Wizard SV gel and PCR Clean-Up System (Promega) and further treated with 
restriction enzyme DpnI (NEB). An aliquot of 1 μl PCR product was transformed into DH5α 
and plated on LB plate containing 100μg/ml ampicillin. Positive mutants were selected by 
BsmI restriction digestion. The desired A4GALT open reading frame was then introduced into 
pUltra (Addgene #24129, (Lou et al., 2012)) and pCW57.1 (Addgene #41393) via NheI and 
XhoI/SalI cloning procedure for further lentiviral transduction. In parallel, full length E-
cadherin (addgene #45769) and IL2R/E-cadherin cytotail (addgene #45773) were amplified 
via Quick Fusion Cloning Kit (bimake.com, Munich, Germany) for cloning into desired 
lentiviral vector. All primers are listed in supplementary table S3. 
Lentivirus production and transduction 
HEK293T cells were cultured as described above. One day prior to transfection, cells were 
seeded at ~40% confluence in a T75cm2 flask. Cells were transfected when they reached 70–
80% confluence. For each flask, 4 µg of plasmid pUltra (Addgene #24129, (Lou et al., 2012)) 
and pCW57.1 (Addgene #41393) encoding the genes of interest (A4GALT (DXD), A4GALT
(DXA)), full length E-cadherin, or IL2/E-cadherin cytotail) and 2 µg of pMD2.G (Addgene 
#12259) and 2 µg of pCMVR8.74 (Addgene #22036) were transfected using 24 µl of jetPEI 
reagent and 1 ml of 150 mM NaCl solution (Polyplus-transfection, Chemie Brunschwig AG, 
Basel, Switzerland). Media was changed 24 h after transfection. Virus supernatant was 
collected 48 h later and filtered with a 0.45 µm polyvinylidene fluoride filter (Millipore), and 
stored at -80°C. IGROV1 ΔA4GALT cells were transduced with pUltra and pCW57.1 
lentiviral supernatant in 4 ml of media supplemented with 8 µg/ml polybrene (Sigma) in 
T25cm2 flask and selected after 3 passages by GFP enrichment and 5 µg/ml puromycin 
treatment. 
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Reverse-transcription quantitative polymerase chain reaction (RT-qPCR) 
In order to extract RNA, 105 cells were seeded in 6-well plates, grown them to 70-80% 
confluence, then washed twice with sterile PBS prior to total RNA extraction using the 
ReliaPrep® RNA Cell Miniprep System (Promega). RNA was eluted in 60 µl RNase- free 
water and RNA concentration measured using a NanoDrop ND-1000 spectrophotometer 
(Thermo Fisher Scientific, Roskilde, Denmark). An amount of 1 μg of RNA in a total volume 
of 20 µl was reverse transcribed using the iScript® Reverse Transcription Supermix for RT-
qPCR (Bio-Rad Laboratories, Zurich, Switzerland) according to the manufacturer’s 
instructions. RT-qPCR was performed on CDH1, VIM, A4GALT and reference genes HSPCB, 
SDHA, and YWHAZ in 10 μl reactions containing 10 ng cDNA (initial total RNA), 400nM 
forward and reverse primer (Supplementary table S3), nuclease free water and 1× GoTaq® 
qPCR Master mix with low ROX as reference dye (Promega) on a ViiA™ 7 Real-Time PCR 
System (Applied Biosystems, Thermo Fisher Scientific, Reinach, Switzerland). Quantitative 
PCR was performed in triplicates and analyzed as recently described (Kohler et al., 2016).  
Western blot 
Whole cell lysates were obtained from sub-confluent cultures. Cells were lysed for Western 
blot analysis according to standard laboratory protocols. The protein concentration of cell 
lysates was determined by BCA Protein Assay Kit (Pierce, Perbio Science, Lausanne, 
Switzerland). Equal amounts of protein (20 μg) were loaded and separated using SDS-PAGE, 
followed by blotting onto a polyvinylidene difluoride membrane (Amersham Biosciences, 
Otelfingen, Switzerland). Later, the membrane was blocked with 5 % (w/v) BSA (Sigma) in 
TBST and incubated with primary monoclonal antibodies E-cadherin (1:1000), Vimentin 
(1:1000) and tubulin (1:1000) diluted in 5 % (w/v) BSA in TBST at 4°C overnight. 
Afterwards, membranes were washed in TBST and incubated with corresponding HRP-
conjugated secondary antibodies (anti-rabbit and -mouse) in 3 % BSA in TBST for 3 h at 
room temperature. Finally after washing in TBST, detection was carried out with the Super 
Signal West Dura Extended Duration Substrate (Life technologies). 
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Confocal fluorescence microscopy 
Cells were grown on polylysine glass slides attached to a 8-well chamber, fixed with 4 % 
para-formaldehyde (Polysciences, Hirschberg an der Bergstraße, Germany) for 15 min, 
permeabilized with 0.3 % Triton X-100 (Sigma) and incubated with blocking buffer  (5 % 
(w/v) BSA fraction V (Sigma) in PBS) for 1 h. Cells were then stained with E-cadherin 
antibody and mounted in ProLong® Gold Antifade Reagent with DAPI (Cell Signaling 
Technology #8961). Fluorescence images were taken on a LSM 780 confocal microscope 
(Zeiss, Feldbach, Switzerland). 
Zebrafish xenograft model 
The ‘Kantonales Veterinaeramt Basel- Stadt’ approved animal experiments and zebrafish 
husbandry. A4GALT and corresponding control cells were labeled with the fluorescent 
CellTracker CM-DiI (Life Technologies) as previously described (Konantz et al., 2012; 
Schaefer et al., 2015). In brief, nacre/transparent zebrafish were maintained, collected, grown 
and staged in E3 medium at 28.5°C according to standard protocols (Krauss et al., 2013). For 
xenotransplantation experiments, zebrafish embryos were anesthetized in 0.4% tricaine 
(Sigma-Aldrich) at 48 h post fertilization and 75-100 control or knockdown cells were 
microinjected into the vessel free area of the yolk. Embryos were incubated for 1 h at 28.5–29 
°C for recovery and then screened for the presence of fluorescent human cancer cells in the 
yolk. Fish harboring red cells were incubated at 35°C as described before (Haldi et al., 2006). 
Five days after transplantation, embryos were screened microscopically for tumor formation 
using a Zeiss LSM 710 confocal microscope. Fish were furthermore dissociated into single 
cells as described (Svoboda et al., 2016) and cells analyzed on a BD AccuriTM C6 for CM-
DiI-positive cells. For each experiment 75–100 cells per fish were transplanted and at least 5 
fish for each condition were analyzed.  
Bisulfite-sequencing 
Four different web-based bioinformatic engines were applied as recently described (Kohler et 
al., 2016) to predict the genomic location of the CpG island in the CDH1 gene (UCSC 
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Genome Browser, CpGPLOT, Methprimer and CpG island searcher). For analysis of the 
methylation status genomic DNA was isolated from exponentially growing cells as described 
previously (Kohler et al., 2016). An amount of 1 μg DNA was bisulfite converted using the 
EZ Methylation-Gold Kit (Zymo Research Inc., Lucerna-Chem AG, Luzern, Switzerland) and 
was further subjected to PCR reaction using MyTaq™ HS DNA polymerase (Bioline, abc 
biopply, Solothurn, Switzerland). PCR reactions contained: 1× MyTaq reaction buffer, 
MyTaq HS polymerase, 300 nM CDH1_Bis_1F and CDH1_Bis_1R (DNA sequence is listed 
in Supplementary table S2) and nuclease free water to a final volume of 10 μl performed 
under following conditions; 95°C for 10 min, 35 cycles of 95°C for 15 sec, 50°C for 15 sec, 
and 72°C for 20 sec, and finished by elongation at 72°C for 3 min. PCR products were 
subjected to a second PCR using CDH1_Bis_2F and CDH1_Bis_2R following same 
conditions as described before (Supplementary table S2). The PCR product were visualized 
on a 2% agarose gel and purified from the gel using the Wizard SV Gel and PCR clean up 
system (Promega) and cloned into pGEM®-T Easy (Promega). Plasmid minipreps 
(PureYield™ Plasmid MiniPrep System, Promega) from individually grown colonies were 
sequenced using SP6 primer. Bisulfite sequencing data were analyzed and visualized using 
the Quantification tool for methylation analysis (QUMA) web-based application 
(http://quma.cdb.riken.jp/top/index.html). 
Cholera toxin and 5-Aza treatments 
Cells were treated with 100 ng/ml of CTx (Sigma), which was replenished every 3-4 days 
over a period of 14 to 16 days. Cells were split to a ratio of 1:6 every 3-4 days during the 
treatments. In regards to global DNA de-methylation, cells were treated with 2.5 μM 5-aza-2′-
deoxycytidine (5-Aza) for up to 96 h with replenishing media every 24 h. 
Data acquisition and statistical analysis 
Publicly available transcriptomic data sets (GSE26712, GSE68661, and GSE9899) were 
downloaded from Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/). Statistical 
analysis and figures were obtained through the use of the software R version 3.1.3 (www.R-
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project.org). Gene expression data for the “Cancer Cell Line Encyclopedia were accessed 
through the cbioportal using R (www.cbioportal.org, (Gao et al., 2013)) using cgdsr, a R-
based application programming interface (API) that provides a basic set of R functions for 
querying the Cancer Genomics Data Server (CDGS) hosted by the Memorial-Sloan-Kettering 
Cancer Center (MSKCC). 
Overall survival and relapse-free survival was investigated using Kaplan-Meier curves. Gene 
expression was dichotomized using tree based model partitioning (“ctree” in R package 
“party”). Computations of the predicted survivor curves were used for Cox proportional 
hazards regression model (R package “survival”). Results were presented as hazard ratios 
(HR) with 95% confidence interval (CI) and corresponding p-values.  
All experiments were performed in triplicates and statistical evaluation was done using 
unpaired Student’s t-tests. P values of < 0.05 were considered statistically significant (*** p < 
0.001, ** p < 0.01, * p-value < 0.05, p-value < 0.1.)  
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Figure legends: 
Figure 1 
Expression of globoside-encoding genes is elevated in epithelial cancer cells.  
A) Glycosphingolipid biosynthesis pathway- glucose is attached to ceramides and further 
elongated into three major series with the precursor lactosylceramide (LacCer). GSL-series 
are boxed in colors. Carbohydrate structures provided along with the name were investigated 
in this study. B) Linear discriminant analysis in three transcriptomic ovarian cancer data sets 
separating epithelial (E, dark green) from mesenchymal (M, red) tissue samples. Wilks 
lambda and corresponding p-value is provided along with each dot plot. C) Kaplan-Meier 
curves for overall survival and relapse-free survival in four EMT states (E, IE, IM, and M) in 
the Tothill data set. D) Table summarizing globo and ganglio-series synthesizing 
glycosyltransferase-encoding genes predicting overall and relapse-free survival determined 
for by Cox proportional hazard model. E) Boxplots showing gene expression of CDH1, 
A4GALT, VIM, and ST3GAL5 among four different EMT states in three independent ovarian 
cancer data sets (Tothill, Bonome, and TCGA). Color indicates typical expression of genes up 
in epithelial (green) or mesenchymal (red), Epithelial (E), intermediate epithelial (IE), 
intermediate mesenchymal (IM), and mesenchymal (M). F) Heatmap of GSL marker 
expression across normal and cancer cell lines. The heatmap illustrates the unclustered 
distribution of cell lines from the mean GSL expression out of three independent experiments. 
GSLs markers arranged by average linkage clustering. Cell line origin is provided along with 
the heatmap. 
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Figure 2 
Generation of a heritable and site-specific A4GALT mutant ovarian cancer cell line 
using CRISPR-Cas9 technology: A) Strategy to delete the A4GALT gene (ΔA4GALT) - two 
different sgRNAs targeting the entire ORF (light blue). Cas9 active sites are shown in yellow 
color. ΔA4GALT cells were identified using three different primers (CRISPR_F, CRISPR_R 
and ORF_R; blue) resulting 1335bp deletion. B) Identification of homozygous ΔA4GALT 
cells: Single cell clones were assayed by three genotyping PCRs (1:Deletion PCR; 1863bp 
and 500bp, 2:wild type specific PCR; 1378bp and 3:inversion PCR; 937bp) showing various 
genotypes (wild type-wt, deletion-del, inversion-inv; wt/del, inv/del, inv/inv and del/del). C) 
DNA sequence variation (indels) at the CRISPR-Cas9 active sites: homozygous ΔA4GALT 
(1335bp) was detected in ΔA4GALT _1 and ΔA4GALT _2 while ΔA4GALT _3 was 
heterozygously deleted (1335bp and 1208bp). Protospacer adjacent motif (PAM) (red), red 
arrows indicate predicted deletion sites. D) Off target data displayed no sequence variation 
compare to wild type. Predicted Cas9-active off target sites are displayed in red arrows shown 
in a representative ΔA4GALT clone. E) Depletion of globosides and P1 in ΔA4GALT clones: 
Counter plot represents the data for wild type and ΔA4GALT showing negative control 
(unstained cells, red) and GSL positive cells (green). The value provided in each counterplot 
refers to the percentage of GSL positive cells. Corresponding barchart displays the mean ± 
standard deviation (S.D.) of three independent experiments for wildtype (light grey) and three 
ΔA4GALT clones (dark grey), student t-test, **p-value < 0.01, ***p-value < 0.001. 
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Figure 3 
Appearance of mesenchymal features upon deletion of globosides A) Cell morphology of 
A4GALT and ΔA4GALT (40x magnification): the arrows indicate (a) goblet like epithelial 
structure (b) formation of clamp and (c) cell protrusions. B) Cell growth curve for 120h. The 
value provided in each time point refers to the number of cells counted every 24h. C) MTT 
cell viability and proliferation assay for wild type (A4GALT, grey line) and ΔA4GALT (black 
line) cells. D) Representative wells with cell colonies and bar chart for quantification of 
anchorage-dependent growth E) Anchorage-independent growth in show reduced colonies in 
ΔA4GALT cells compared with wild type cells. F) Representative histograms for cell-
detachment-induced apoptosis (anoikis) in wildtype and ΔA4GALT cells showing unstained 
or negative control (green) and percentage of propidium iodide (PI, stained for dead cells)-
stained cells (red). The percentage in each histogram refers to the PI-positively stained cells. 
Corresponding line chart showing viable cells (y-axis) measured by MTT absorbance ratio 
(normalized to 100% at day 0) between day 0 and day 10 in both wildtype (A4GALT) and 
ΔA4GALT cells. G) Western-blot data represents more cleaved PARP during day 7 and day 
10 in wild type cells compare with ΔA4GALT cells. H) Cell migration assay, I) Cell invasion 
(Matrigel) assay, J) Wound healing assay, K) phagokinetic track motility. Representative 
images are shown along with data quantification. A number of 10 images were analyzed for 
each experiment. Data are presented as bar charts showing mean ± standard deviation (S.D.) 
of three independent experiments, student t-test, *p-value < 0.05, **p-value < 0.01. Loss of 
A4GALT results in enhanced cancer cell dissemination in tumor xenograft model. L) 
Confocal imaging (z-stack images at 40x magnification) shows that metastatic ΔA4GALT 
IGROV1 cells are dispersing throughout the fish body (arrows) whereas non-invasive wild 
type IGROV1 cells remain in the yolk sac. Corresponding counterplot and bar chart to the 
right displayed the percentage of CM-Dil positive caner cells. 
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Figure 4 
E-cadherin mediated cell-cell adhesion depends on the upstream glycosphingolipids A) 
Bar chart represents the GSLs expression of different IGROV1 (A4GALT, ΔA4GALT, Rescue 
(DXD) and Rescue mutant (DXD)) cell lines. B) Western blot data display the loss of E-
cadherin in ΔA4GALT cells and re-expression of E-cadherin (full length and cytosolic). 
Second Western blot shows partial rescue of E-cadherin expression in ΔA4GALT re-
expressing A4GALT (DXD) in contrast to mutant A4GALT (DXA). C) Confocal 
fluorescence images (40x magnification) show loss of membranous E-cadherin staining in 
ΔA4GALT compare with wild type A4GALT and in DXD rescued cells displaying partial 
membranous E-cadherin staining, whereas overexpression of E-cadherin (full length and 
cytosolic) in ΔA4GALT cells were diminished E-cadherin membranous staining. 
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Figure 5 
The presence of globosides is vital in intermediate EMT cells A) CDH1, VIM and 
A4GALT expression among ovarian cancer cell lines representing the full EMT spectrum. B) 
Corresponding Western blot showing expression of E-cadherin, Vimentin and tubulin. 
Matching heatmap shows the means of Gb3 and SSEA3 expression of three independent flow 
cytometry experiments for each cell line. C) Deletion or overexpression of A4GALT leads to 
absence or presence of globosides, respectively. Wildtype and ΔA4GALT cells are shown 
BG1 and SKOV3. Overexpression of A4GALT (OE A4GALT) is shown next to parental 
A2780. E-cadherin expression is lost in SKOV3 ΔA4GALT cells. SKOV3ip cells show 
elevated E-cadherin expression. D) Representative immunofluorescence images for E-
cadherin (green) and DAPI (blue) in SKOV3, SKOV3 ΔA4GALT, and SKOV3ip cells. E) 
Corresponding anchorage-dependent growth (colony formation assay) and Barchart 
summarizing three independent experiments. F) Increasing resistance to doxorubicin in 
intermediate EMT cells deleted for A4GALT. Line charts showing three independent MTT 
assays. IC50’s for parental (wildtype, black), ΔA4GALT  (red), and SKOV3ip (green) are 
provided below each line chart. G) Representative dot plot for un- and CTx-treated cancer 
cell lines unstained (red) and double-stained for CD24 and CD44 (light blue). H) Alteration 
of GSLs (LacCer, Gb3, and SSEA3) upon CTx treatment in corresponding cancer cell lines. 
I) Expression of E-cadherin, Vimentin, and tubulin in parental and genetically modified 
(A4GALT) cell lines treated with CTx.  
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Figure 6 
Degree of DNA methylation at the promoter region of CDH1 correlates with presence of 
A4GALT and its glycosidic products.  
A) CpG island analysis predicts a CpG island at the transcription start site of human CDH1. 
Exon 1 and 2 are shown in black and predicted (depending on the algorithm used) CpG 
islands are shown as green vertical bars. Genomic region analyzed by bisulfite sequencing in 
more detail (red bar) and further magnified for CpGs analyzed throughput this study. B) 
Lollipop plots showing degree of DNA methylation at the promoter region of CDH1 for 
representing the EMT spectrum based on E-cadherin expression. Total of methylated CpGs 
are provided along with the standard error between sequences (n=6). C) Western blot 
showing re-expression of E-cadherin in mock (DMSO) and 5-Aza-treated cancer cells 
IGROV1, IGROV1 ΔA4GALT, and IGROV1 ΔA4GALT Rescue DXD cells. D) Membranous 
staining of E-cadherin is only present in cells being positive for A4GALT and globosides. 5-
Aza treatment in IGROV1 ΔA4GALT Rescue DXD cells reveals cell-cell adhesion via E-
cadherin whereas IGROV1 ΔA4GALT remain negative for membranous E-cadherin staining. 
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5. Further discussion and conclusion 
Results obtained throughout this PhD thesis are discussed in greater detail in chapter 
4. Here, I will include a general conclusion and discuss how achieved publications are 
related to each other. 
In the present study (Publication I), we demonstrated for the first time that GSLs are 
expressed in ovarian cancer, in particularly, Gb3, P and P1 are found to be present in 
patient-derived ovarian cancer tissues as well as in immortal ovarian cancer cell lines 
[182]. We further show that ascites derived from late-stage ovarian cancer patients 
contain detectable levels of circulating anti-glycan antibodies compared with matched 
blood plasma independent of the volume of ascites accumulated [182]. Moreover, 
affinity purified anti-P1 antibodies isolated from patient’s ascites recognize P1 
expressing ovarian cancer cells [182]. We further demonstrated that fluorescence-
activated cell sorted (FACS) IGROV1 cells expressing different levels of P1 show 
different capability of in vitro directed cell motility [182]. Based on these findings 
together with previous work published by the Ovarian Cancer Research group, parts 
of the current PhD thesis aimed to establish an experimental model to elucidate the 
biological role of certain GSLs in the context of ovarian cancer.  
As an initial approach (Publication II) we utilized two widely used glucosylceramide 
synthase (GCS) inhibitors, PPMP and PDMP, aiming to inhibit the expression of all 
glucosylceramide-related GSLs. However, our results clearly demonstrated that both, 
PPMP and PDMP inhibit the GSL synthesis selectively and in a cell line-dependent 
manner. In contrast to Gb3 which revealed reduced expression on the cell surface of 
four different cancer cell lines upon GCS inhibitor treatment, the downstream 
glycosidic product of Gb3 and SSEA3 was only in reduced in one out of four cell 
lines. Moreover, no change was observed for GM1, nLc4, and P1 indicating that GCS 
inhibitors selectively inhibit GSL synthesis. Thus, we concluded that our initial 
strategy was not sufficient for future applications to elucidate the function of GSLs. A 
plausible approach might apply genome editing (e.g. by utilizing CRISPR-Cas9) to 
generate a GCS synthase deletion (∆UGCG), which will be an effective method to 
identify the specific function of glucosylceramide-related related GSLs. However, 
considering that individual GSLs or series of GSLs have various functions described 
in the literature, a deletion of the GCS synthase might not be the optimal experimental 
model to study individual GSLs. We therefore decided to deplete the different GSL 
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series by knocking out the gene encoding for the key glycosyltransferase (annotated 
in the KEGG database) (Figure 3). Initially, we tested the use of zinc finger nucleases 
in combination with single-strand oligonucleotides [183] but found out that CRISPR-
Cas9 system was more efficient and straightforward in our hands. 
 
5.1 Altered α2-6 sialylation in ovarian cancer cells upon depletion of 
GSL series  
Our previous studies demonstrated using printed glycan array that anti-glycan 
antibodies can discriminate healthy controls from ovarian cancer patients [181]. The 
glycan structure with the most significant discriminatory was P1, which has been 
shown to present in tissue samples [182] as well as on ovarian cancer cell lines [184]. 
P1 glycan structure belongs to (neo)-lacto series GSLs and the biological function of 
this series GSLs is rather limited in context of cancer and remains to be elucidated. In 
this study, we utilized the CRISPR-Cas9 system to deplete (neo-) lacto series GSLs 
by knocking out the open reading frame encoding for the key glycosyltransferase 
B3GNT5 (publication III) and revealed an unexpected loss of α 2-6 sialylation on N–
glycoproteins due to the silencing of ST6GAL1 expression. The exact mechanism by 
which the reduction of α2-6 sialylation on N–glycoproteins is still unclear. One of the 
possibilities might be a direct consequence of the B3GNT5 deletion, which regulates 
complex associations within the glycan-processing pathway. A recent study reported 
similar finding in the context of salt and pepper syndrome [185], in which a 
homozygous transition mutation in ST3GAL5 (GM3 synthase) was described. More 
importantly, in addition to the reduced GSL complexity, altered N- and O-glycans on 
proteins was observed due to the point mutation in the ST3GAL5 [185]. It is still 
unclear whether the loss of α 2-6 sialylation on N–glycoproteins is thought to provide 
a compensation phenotype for the depletion of (neo-) lacto series GSLs. Another 
possibility is epigenetic regulation of ST6GAL1, which might include histone 
modification, remodeling of microRNA (miR), and DNA methylation (hyper). 
Histone modifications, such as methylation and acetylation, can either repress or 
activate gene transcription through alterations in the chromatin structure. For 
example, expression of gangliosides synthesis enzymes GalNAc transferase and 
Sialyl transferase II are regulated by histone acetylation during brain development 
[186]. miRs control the production of the gene product through binding to the mRNA 
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3’ UTR regions, thereby inhibiting protein translation or enhancing mRNA 
degradation. In metastatic melanoma cells, specific microRNAs (miR-30b and miR-
30d) were highly expressed, which has been shown to suppress GALNT7 expression 
[187]. DNA methylation primarily occurs on CpG rich regions (CpG islands), where a 
methyl group is covalently attached to a cytosine with the aid of DNA 
methyltransferases (DNMTs). In cancer cells, some glycosyltransferase genes (EXT1, 
B4GALNT2, ST3GAL6, MGAT3, MGAT4A) are suppressed by hypermethylation of 
gene promoters [188-190]. The use of DNA methylation or histone deacetylation 
inhibitors and development of the chromatin immunoprecipitation (ChIP) technique 
with antibodies for these modifications allow analysis of the ST6GAL1 regulatory 
mechanisms that link to the deletion of B3GNT5. 
It has been demonstrated that cell surface sialylated glycans are upregulated in cancer 
and contribute to increased aggressiveness, metastasis and invasion of a tumor by 
increasing cancer cell motility, extravasation from the circulation into tissues and 
resistance to cell death [191-195]. Moreover, hypersialylation of cancer cells 
enhances the resistance to chemotherapy. Particularly, ST6GAL1 has been shown to 
be upregulated in various cancers as a consequence of oncogenic Ras activation [196-
198]. For example, the metastatic growth of colon cancer is accompanied by a 
significant increase of α2-6 sialylation synthesized by ST6GAL1 [199] and siRNA 
knockdown of ST6GAL1 significantly inhibited cell invasion in various carcinoma 
cell lines [200-202]. On the other hand, forced expression of ST6GAL1 in breast 
(MDA-MB-435) and ovarian (OV4) cancer cells leads to reduced cell–cell adhesion 
and enhanced capacity for invasion [201, 203]. In addition, the expression of stem cell 
markers has been also correlated with ST6GAL1 expression in colon, pancreatic and 
ovarian cancers, which has been directly shown to promote cell motility and 
survival/resistance to drug treatment [204-206]. Enzymatic removal of neuraminic 
acid through neuraminidase treatment of metastatic murine cell lines dramatically 
decreases the amount of liver metastasis after splenic injection [207]. Recent data 
suggest that ST6GAL1 promotes activation of PI3K/Akt signaling pathway [208, 209] 
for cell migration [208, 209]. However, in vitro studies show that the migratory 
responses are mediated at least in part, by the α2, 6 sialylation on the glycoprotein β1 
integrin [210]. Cells that do not express integrin β1, do not exhibit differential 
invasion upon forced expression of ST6Gal I [203, 210, 211].  
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This is in full concordance with our most recent observations (unpublished data). We 
found that the loss of α2-6 sialylation was mostly on the proteins integrin β1, α2, α3, 
and α5. Integrins are heterodimeric transmembrane receptors capable of bidirectional 
signaling (‘‘outside-in signaling’’ and ‘‘inside-out signaling’’) [212]. 
Hypersialylation of β1-integrin has been shown to impact on cell adhesion (cell to 
extracellular matrix (ECM)) and cell motility as well as resistance to cell death [213]. 
The oncogenic Ras expression promotes the upregulation of ST6GAL1 and as a result 
the hypersialylation of the N-glycans on β1-integrin, which is part of the integrin 
receptor for collagen (α1β1 and α2β1), fibronectin (α5β1) and laminin (α3β1) [210, 
214-217]. It has been demonstrated that hypersialylation of β1-integrins in ovarian 
adenocarcinoma cells results in increased cell motility by enhancing collagen binding 
and migration toward collagen [203, 218]. In addition to that, cell surface α2-6 
sialylation has the ability to block apoptosis and anoikis (cell death related to 
detachment from other cells or the ECM) [219-223]. For example, the sialylation of 
α5β1 fibronectin receptor blocks galectin-1 binding and the induction of anoikis [220, 
222]. Along with these studies, ST6GAL1 overexpression displayed resistance to 
chemotherapy agents such as cisplatin, irinotecan and gemcitabine [204-206]. Taken 
together, all of these studies demonstrated that sialylation plays essential roles in 
mediating cell-ECM adhesion and migration. Hyper sialylation on integrin has been 
reported to increase the mobility of cancer cells, thus contributing to tumor 
progression. Our study displayed depletion of B3GNT5 leads loss of α2-6 sialylation 
on integrin, which plays important role in migration and adhesion. Thus depletion of 
B3GNT5 might reduce the metastatic growth of ovarian cancer. The investigation of 
CRISPR-Cas9 mediated B3GNT5 deleted IGROV1 and SKOV3 cells can also be 
used as a model to role out the possibility of integrin subunits (β1, α2, α3 and α5) in 
context of ovarian cancer in a greater detail. 
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Figure 4: Integrin-ECM interaction. Integrins are heterodimeric cell-surface 
receptors for ECM proteins and composed of an α and a β subunit. A simplified 
version of the α-β-subunit pairing displayed the major extracellular ligands for each 
heterodimer is represented. The same integrin receptor can bind to several different 
ECM ligands. Intriguingly, engagement of different integrins by the same matrix 
molecule can elicit very different cellular responses.  
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5.2 Involvement of GSLs in epithelial to mesenchymal transition 
(EMT) 
Epithelial cells are capable of changing their phenotypes including morphology, 
growth behaviors, adhesion characteristics and motility, while they encounter a 
different microenvironment or external stimuli and the well studied process in known 
as EMT (epithelial mesenchymal transition) [224-227]. Hay and colleagues first 
observed this phenotype, which was identified as an essential cellular mechanism at 
several specific stages in ontogenetic development [228-234]. In addition to cell 
morphology, adhesion and motility, the EMT process has been characterized by a 
decrease in epithelial markers (E-cadherin, desmoplakin and cytokeratins) while an 
increase in mesenchymal cell markers (N- cadherin, vimentin, fibronectin) [234, 235].  
GSLs have been shown to play important role in embryogenesis [236], tumorigenesis 
and cancer progression [237]. Specific types of glycosyl residues are involved in 
specific signaling pathways and regulate cell phenotypes. For example, GM3 inhibits 
epithelial growth factor receptor (EGFR) activation [238, 239], GM2 associated with 
tetraspanine CD82 inhibits the activation of hepatocyte growth factor receptor cMet 
[240], and O-fucose glycan modulate Notch signaling, which control the fate of many 
cell types [241, 242]. Because changes in cell adhesion, motility, and growth are an 
essential phenotypic change in EMT, we considered the possible involvement of 
GSLs in control of EMT. Our recent study revealed that CRISPR-Cas9 mediated 
deletion of A4GALT leads loss of globoside GSLs as well as depletion of E-cadherin 
(an epithelial molecule) expression in intermediate EMT ovarian cancer cell lines 
(Manuscript V). Therefore the results displayed a possible correlation of GSLs with 
EMT process, and in particular, that specific series of GSLs might contribute more to 
EMT than others. 
Several studies have indicated that transcription factors (SNAI1 [243], SNAI2 [244], 
ZEB1 [245], ZEB2 [246], TCF3 [247], TWIST1[248], etc.), signal transducers 
(RBFOX2 [249], CK1 [250], MDM2 [251], etc.), and microRNAs (miR-200 family 
[252], miR-205 [253], miR-34 [254], miR-9[255], miR-101[256]) are involved as 
inducers or regulators of the EMT process. The interesting possibility is that GSLs 
may affect the EMT regulatory networks to initiate the expression of mesenchymal 
molecules or inhibit the expression of epithelial molecules. The ability of GSLs to 
interact with various signal transducers, as well as with receptors for growth factors or 
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integrin’s seems to be established. For example, i) ganglioside (GM3) was shown 
previously to interact with tetraspanine CD9 and integrin α3 to inhibit cell motility 
and growth [257-259], and ii) GM2-CD82 complex inhibits cMet and its crosstalk 
with integrin α3β1 provide a basis to control cell motility [240]. 
Recent reports also demonstrated that the GSL expression dynamically alters during 
EMT progression [227, 260-262]. For example, i) treatment with TGFβ (an EMT 
inducer) caused Gg4, GM2 reduction in normal murine mammary gland cells 
(NMuMG) and GM2 depletion in human normal bladder cells (HCV29) [227]. ii) 
When seeded at low density, MDCK cells undergo progressive epithelialization, 
which reveal a shift from sphingomyelin expression towards GSLs (GM3, 
galactosylceramide-sulfate (Sulf), and the globoside derivative Forssman (For)) and 
the reverse pattern during EMT progression by TGFβ treatment [263]. All of these 
studies mostly focused on the ganglio series GSLs, while the expression of neutral 
GSLs were not considered. Our studies demonstrated for the first time loss of neutral 
GSLs (globosides) induced mesenchymal phenotypes in intermediate EMT cells and 
no significant difference was observed in Gg4 and GM2 expression, while there was 
two fold increased in GM1 expression pattern. This might be compensation 
phenotype to survive due to the loss of globosides. In another study on cancer stem 
cells, the author observed significant increase of ganglio series GSLs (GM2, GD2, 
GD3, and GD1a) while there was a reduction of globo series GSLs (Gb3) [264]. In 
line with this study our results displayed that not only increase of ganglio series GSLs 
but also the reduction of globosides depletion are required for the EMT process.  
The EMT markers examined in our study were E-cadherin and Vimentin based on the 
transcriptomic data and defining the intermediate EMT ovarian cells. However, there 
are several other epithelial (cytokeratin, desmoplakin, MUC1) and mesenchymal 
markers (fibronectin, N-cadherin, Snail, Slug, Zeb, TWIST, etc.), which may also be 
applicable for the future studies. It should be noted that most of the EMT markers 
follow the classical EMT expression spectrum among our ovarian cancer cell lines 
tested (n=10) and the gene expression data from the cell line encyclopedia 
(unpublished data and Mansucript V). The variation of EMT marker expression 
pattern has been reported previously, and appears to depend on type, origin, and 
history of the cell lines [230, 232, 233, 265] indicating that the principal EMT 
markers (E-cadherin, Vimentin, etc.) are necessary to define the intermediate EMT 
cells. Results of our study clearly indicated that the EMT process is closely correlated 
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with the expression of neutral GSLs particularly globosides. Based on these results, 
we hypothesized that a high level of globosides are required for the maintenance of E-
cadherin mediated cell-cell adhesion, possibly at junction points. Studies on 
organizational assembly of globosides with epithelial and mesenchymal molecules 
and the basis of genetic and epigenetic regulation of specific GSLs involved in EMT 
or MET process are expected to clarify the detail mechanism. To address this issue, 
we could introduce (knock-in) a controllable endogenous epithelial molecule (E-
cadherin) and look for the possible interaction with globosides. 
5.3 GSLs in cancer stem cells and its association to EMT 
A specific glycosyl epitope (e.g. stem cell markers SSEA3 and SSEA4) in tumor cells 
whose expression is affected during the EMT process may be associated with the 
capability of inducing cancer stem cells (CSC) in breast cancer, which is known to 
provide self-renewing, invasive property of tumor cells [266-268]. Here, we 
demonstrated that the most commonly applied CSC marker CD24 and CD44 alter 
upon A4GALT deletion in IGROV1 and SKOV3 cell lines. In addition, Pattabiraman 
et al. induced MET (mesenchymal to epithelial transition) by treatment of cells with 
cholera toxin and forskolin. Interestingly, cholera toxin binds gangliosides, which are 
supposed to be elevated in cancer cells with mesenchymal characteristics. The study 
revealed that these agents elevated intracellular cAMP and subsequently activates 
PKA (protein kinase A). The PKA-C subunit then enters into the nucleus, which in 
turn regulates PHF2, a histone H3 with acetylated lysine 9 (H3K9) demethylase to 
induce MET [269]. In order to gain an insight into the function of GSLs in this 
context, defined number of cells (ΔA4GALT) might be injected into nude mice 
studying the tumor initiating capability. More importantly, other classical CSC 
markers should also be considered here. Another possibility to study the tumorigenic 
ability, cells might be stained with SSEA3, SSEA4, CD24 and CD44 antibodies for 
the sorting and isolated populations (SSEA3+CD44+CD24-, SSEA4+CD44+CD24-, 
SSEA3-CD44+CD24-, SSEA4-CD44+CD24-, and CD44+CD24-) will then injected into 
the nude mice. It showed also noted whether they are forming local tumors 
(remaining epithelial state) or metastatic growth (displaying mesenchymal 
phenotypes). Moreover, mesenchymal breast cancer cells became epithelial upon 
cholera toxin or forskolin treatment shown by increased E-cadherin expression 
together with an increase of CD24 and decrease of CD44. However, not all cancer 
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cell lines investigated in this study were inducible by neither cholera toxin nor 
forskolin. This is because those cell lines displayed DNA promoter hypermethylation 
for several key epithelial genomic loci [269]. Another possibility might be due to the 
different stages of EMT/MET, as intermediated EMT cell lines seem to response to 
various inducing agents (manuscript V). In line, CTx-induced MET was only 
observed in intermediate mesenchymal cells among all ovarian cancer cell lines 
(characterized by the expression of E-cadherin and Vimentin) tested in Jacob et al. 
(Manuscript V). Of note, we also demonstrated that inducible MET depends on the 
expression of globosides in ovarian cancer cells. To further investigate the role of 
globosides in cholera toxin inducible MET system, ectopic expression of mutant PKA 
(a constitutive expression of PKA) might be the next step to study whether the PKA 
pathway alters the presence of A4GALT and downstream globosides in intermediate 
EMT ovarian cancer cells.  
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7. Abbreviations 
GCS - Glucosylceramide synthase 
EMT - Epithelial mesenchymal transition  
MET – Mesenchymal epithelial transition 
AGA - Anti glycan antibodies 
GSLs - Glycosphingolipids 
HGSC – High grade serous carcinoma 
LGSC – Low-grade serous carcinoma 
FIGO - International federation of gynecology and obstetrics 
OSE - Ovarian surface epithelium 
STIC - Serous tubal intraepithelial carcinomas 
FTSEC - Fallopian tube secretory epithelial cells 
ECM - Extra cellular matrix 
GPI – Glycosylphosphatidylinositol 
Asn – Asparagine 
Ser - Serine  
Thr - Threonine  
O-GlcNAc  - O-linked N-acetylglucosamine 
O-Man - O-mannose 
O-Fuc - O-fucose 
O-Gal - O-galactose  
GlcCer – Glucosylceramide 
GalCer  - Galactosylceramide 
EGFR - Epidermal growth factor receptor 
MMP9 - Matrix metalloproteinase-9 
HGF - Hepatocyte growth factor 
ER - endoplasmic reticulum 
FACS - fluorescence-activated cell sorted 
miR – microRNA 
PKA - Protein kinase A 
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SUPPLEMENTARY INFORMATION 
 
Material and Methods 
Cell cultures 
Normal human ovarian surface epithelial cell line originated from the ovary (HOSE6-3) and 
ovarian cancer cell lines OVCAR3, SKOV3, A2780, IGROV1 were cultured in RPMI 1640 
medium containing penicillin/streptomycin and 10% fetal calf serum (FCS). Ovarian cancer 
cells TOV112D and TOV21G (clear cell) were cultivated in DMEM containing 10% FCS and 
penicillin/streptomycin. Cell cultures were maintained at 37°C in 5% CO2 and tested routinely 
for mycoplasma infection (VenorGeM® Mycoplasma Detection Kit (Biocene Pty Ltd, 
Rozelle, Australia) and (Uphoff & Drexler, 2005)). 
 
Extraction of GSLs from cancer tissue samples 
Fresh primary tumor samples from patients with serous ovarian cancer and endometrioid 
peritoneal cancer were washed twice with PBS. GSLs were extracted as previously described 
(Korekane et al, 2007). Briefly, tissues (~100mg) were homogenized in 5ml of chloroform: 
methanol (2:1) and stored for 2h at room temperature (RT), with intermittent sonication for 
30sec every 30min. Prior to centrifugation at 1800xg for 15min, 2.5 ml of methanol was 
added to the homogenate. Supernatant was collected and residual tissue was homogenized 
again in 5ml of chloroform:methanol:water (1:2:0.8). The tissue homogenate was stored for 
2h at RT and subjected to centrifugation at 1800xg for 15min. Supernatant was collected and 
combined with the previous supernatant and evaporated under vacuum. The dried residue 
containing the glycosphingolipid mixture was then re-dissolved in 100µl of 
chloroform:methanol (2:1). 
 
Extraction of GSLs from IGROV1 cells 
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Ovarian cancer cell line IGROV1 was grown in large quantities (1 x 108), harvested and 
stored in -80oC until use. GSLs were extracted as previously described with some 
modifications (Durrant et al, 2006). Cells were harvested and washed thrice in 10ml of PBS 
and centrifuged at 1800xg for 15min. A volume of 5ml of chloroform: methanol (2:1) was 
added to the cell pellet and the tube was kept overnight in a 4°C incubator shaker prior to 
centrifugation at 1800xg for 15min. Supernatant was collected and pellet was re-extracted 
again as described above. The combined supernatants were subjected to centrifugation at 
1800xg for 15min to remove residual protein pellet. The supernatant was evaporated to 
dryness under vacuum and the dried residue containing the glycosphingolipid mixtures was 
re-dissolved in 50µl of chloroform: methanol (2:1). 
 
PVDF blotting of extracted GSLs, enzymatic release of glycans and purification of 
glycan alditols 
GSLs were blotted onto a polyvinylidene diflouride (PVDF) membrane, an adaptation from a 
previous method developed for the release of N- and O-glycans (Jensen et al, 2012). Re-
dissolved glycosphingolipid mixtures (50µl) were blotted (10µl x 5 times) onto cut pre-
activated PVDF spots which were placed in a chloroform-compatible 96-well microtitre plate. 
Neutral and acidic glycosphingolipid standards (10µl) were blotted (2.5µl x 4 times) on 
individual PVDF spots. The spots were air-dried at RT to ensure proper binding of GSLs to 
the membrane. Once the spots were dried, the glycosphingolipid mixture (acidic and neutral) 
was digested with 5mU of Endoglycoceramidase II (EGCase II, recombinant clone derived 
from Rhodococcus sp. and expressed in Escherichia coli, Sigma-Aldrich, St. Louis, USA) in 
50µl of 0.05M Sodium acetate buffer pH 5.0 for 16h at 37oC. The 96-well microtiter plate 
was sealed with parafilm to avoid sample evaporation. After incubation, approximately 50µl 
was recovered from the individual PVDF spots and transferred to 1.5ml Eppendorf tubes. The 
sample wells were washed with 50µl of water and combined with the enzyme mixture of 
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released glycans for each sample. The reaction was stopped by adding 1ml of 
chloroform:methanol:water (8:4:3) (Karlsson et al, 2010). The upper layer (methanol:water) 
containing the released oligosaccharides (~400µl) was dried and used for subsequent 
reduction and desalting steps. 
Released glycans were reduced to alditols with 20µl of 200mM sodium borohydride in 
50mM potassium hydroxide at 50oC for 2h. The reduction mixture was quenched using 3µl of 
100% glacial acetic acid. 
Glycan alditols were desalted using cation exchange columns that were prepared 
individually. Approximately 45µl of cation exchange resin beads (BioRad, Hercules, USA; 
AG50W-X8) were deposited onto reversed phase µ-C18 ZipTips (Perfect Pure, Millipore, 
Billerica, USA) that were placed in individual microfuge tubes. The tubes were then subjected 
to a brief spin and followed by a series of individual pre-washing steps with a) 50µl of 1M 
HCl, b) 50µl of methanol and c) 50µl of water. Each washing step was repeated three times, in 
which the columns were subjected to a brief spin after the addition of each solution. 
Approximately 20µl of glycan alditols were applied to the previously prepared cation 
exchange columns and they were eluted with water (50µl, twice) and dried. Residual borate 
was removed by drying the samples under vacuum after the addition of methanol (100µl, 
thrice). The purified glycan alditols were re-suspended in 15µl of water prior to mass 
spectrometry analysis. 
Negative-mode LC-ESI-MS of released glycan alditols mixtures 
Samples (4µl) were injected onto a Hypercarb porous graphitized carbon (PGC) capillary 
column (5 µm Hypercarb KAPPA, 180µm x 100mm, Thermo Hypersil, Runcorn, UK) using a 
Surveyor auto-sampler. The separation of glycans was carried out over a linear HPLC 
gradient of 0-45 % (v/v) acetonitrile/ 10mM ammonium bicarbonate for 35min followed by a 
10min wash-step using 90 % (v/v) acetonitrile/ 10mM ammonium bicarbonate at a flow rate 
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of 3µl/ min. Glycans were analyzed by nanoLC-MS/MS using a LTQ linear ion-trap mass 
spectrometer (LC/MSD Trap XCT Plus Series 1100, Agilent Technologies, USA) which was 
connected to an ESI source (Agilent 6330, Agilent Technologies, USA). The MS spectra were 
obtained within the mass range of m/z 200 - m/z 1500. The temperature of the transfer 
capillary was maintained at 300oC and the capillary voltage was set at 3kV. Neutral and acidic 
glycans were detected in the negative ion reflector mode as [M-H]- ions and their signal 
intensities analyzed using Compass Data Analysis Version 1.1 software (Bruker Daltonics, 
Billerica, USA). The proposed oligosaccharide structures of experimental samples were 
verified through annotation using a fragmentation mass matching approach based on the 
MS/MS data and further validated based on the retention times of specific glycan masses of 
released glycans from glycosphingolipid standards. 
 
Statistical analysis 
All evaluations were performed using the R statistical programming language, version 2.15.1 
(http://www.r-project.org/). Suspension array data are presented as logarithmized median 
fluorescence intensity (log(MFI)) which is defined as relative fluorescence unit (RFU). Two-
group comparison was performed by Welch Two Sample t-test. Logistic regression was 
performed to predict low anti-P1 trisaccharide antibody levels in the tumor group, with  linear 
predictors being “cancer histotype”, “FIGO stage”, “grade”, “CA125”, “tumor origin”, “ABO 
blood group”, “past history of infections”, “BRCA1/2 status” and “smoking”. Cox regression 
was performed on relapse- and disease-free survival to investigate the prediction of anti-P1 
trisaccharide antibodies. Results are presented as differences of mean values with 
corresponding 95% confidence intervals (CI) and p-values. A p-value <0.05 was considered 
significant. Pearson’s correlation was applied to investigate the relationship between age and 
AGA levels. 
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In regards to printed glycan array experiments, the concordance correlation coefficient 
(CCC) was applied on total signal intensities as a median out of eight replicates (relative 
fluorescence unit, RFU) in order to calculate the correlation of AGA comparing ascites and 
blood plasma. The CCC was calculated on both printed glycan concentrations (10 and 50µM) 
for IgA+IgG+IgM together, as well as individually for IgA, IgG and IgM. The results were 
summarized in scatter plots. 
In regards to xCELLigence experiment, to compare the effects of "P1-high versus P1-
low" expressing IGROV1 cells with and without inhibitor araC, a linear mixed effects-model 
was applied across time points. Factors "high-low", "with/without inhibitor" and "time" were 
modified parameters. Measured cell indices were treated as a random effect. "P1high-low" 
was nested in "Inhibitor", "Inhibitor" was nested in "time". 
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Table	1S	Clinicopathological	characteristics	of	ovarian	cancer	cohort	(n=155)	
Disease	status	 	 n	 %	 Total	in	%	
Control	group	(81)	 Healthy	and	benign	 81	 100	 52.3	
Tumors	(74)	 Borderline	tumor	 8	 10.8	 47.7	
	 Ovarian	cancer	 38	 51.3	 	
	 Peritoneal	Cancer	 19	 25.7	 	
	 Tubal	Cancer	 9	 12.2	 	
FIGO	Stage	(74)	 I	 17	 23.0	 	
	 II	 3	 4.0	 	
	 III	 40	 54.0	 	
	 IV	 9	 12.2	 	
	 unknown	 5	 6.8	 	
Grade	(74)	 Borderline	 8	 10.8	 	
	 1	 7	 9.5	 	
	 2	 4	 5.4	 	
	 3	 55	 74.3	 	
Histotype	(74)	 Serous	 53	 71.6	 	
	 Mucinous	 10	 13.6	 	
	 Endometrioid	 3	 4.0	 	
	 Mixed	 3	 4.0	 	
	 Clear	cell	 2	 2.7	 	
	 Transitional	cell	 2	 2.7	 	
	 Undifferentiated	 1	 1.4	 	
	
148
	
	
2	
	
	
Table	 2S	 Summary	 of	 profiled	 printed	 glycans	 showed	 binding	 with	 ascites-derived	 anti-P1	
antibodies	
Glycans	 are	 ranked	 from	 highest	 to	 lowest	 median	 RFU	 referring	 to	 AGA	 levels.	 The	 presence	 of	
particular	 disaccharide	 motifs	 is	 indicated	 by	 “X”.	 P1	 trisaccharide	 is	 highlighted	 in	 bold.	
Abbreviations:	Lewis	x	 (Lex);	Lewis	y	(Ley);	Lewis	b	(Leb);	H	antigen	(H);	Tn	antigen	(TnSer);	Lacto-N-
fucopentaose	I	(LNFP-1).	
	
	 Median	
RFU	
Spacered	form	of	saccharide	 Common	
name	
G
al
β1
-4
G
lc
(N
A
c)
	
G
al
α
1-
4G
al
β 
1.	 19443	 Galα1-4Galβ1-4Glcβ-sp3 Pk,	Gb3	 X	 X	
2.	 11807.5	 GalNAcβ1-3Galα1-4Galβ1-4Glcβ-sp3 Gb4,	P	 X	 X	
3.	 11209.5	 Galα1-4Galβ1-4Glcβ-sp2 Pk,	Gb3	 X	 X	
4.	 8251	 Galα1-3GlcNAcβ-sp3 	 	 	
5.	 7772	 Fucα1-4(Fucα1-2Galβ1-3)GlcNAcβ1-3Galβ1-4Glcβ-sp4 Leb-Lac	 X	 	
6.	 7501	 Fucα1-4(Fucα1-2Galβ1-3)GlcNAcβ-sp3 Leb	 	 	
7.	 7218	 Galβ1-4GlcNAcα1-6Galβ1-4GlcNAcβ-sp2 	 X	 	
8.	 6224	 Galα1-4Galβ1-4GlcNAcβ-sp2 P1	 X	 X	
9.	 4380	 Galα1-4(Galα1-3)Galβ1-4GlcNAcβ-sp3 	 X	 X	
10.	 3855.5	 Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ-sp3 Ley	 X	 	
11.	 3557	 GalNAcβ-sp3 β-GalNAc	 	 	
12.	 3492	 Galα1-4(Fucα1-2)Galβ1-4GlcNAc 	 X	 X	
13.	 3142.5	 4-O-Su-Galβ1-4GlcNAcβ-sp3 4'-O-Su-
LacNAc	
X	 	
14.	 2863.5	 Manα1-6(Manα1-3)Manα1-6(Manα1-3)Manβ-sp4 Man5	 	 	
15.	 1655	 ManNAcβ-sp4 β-ManNAc	 	 	
16.	 1647	 Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-sp4 LeY-Lac	 X	 	
17.	 1471	 GalNAcα-sp0 TnSer	 	 	
18.	 1435	 Galα1-4GlcNAcβ-sp3 α-LacNAc	 	 	
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19.	 1335.5	 (Glcα1-6)6β-sp4 maltohexaose	 	 	
20.	 1302	 Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAcβ-sp2 H(type	1)	
penta	
X	 	
21.	 1289	 Galβ1-3GlcNAcα1-3Galβ1-4GlcNAcβ-sp3 	 X	 	
22.	 1250.5	 Fucα1-2Galβ1-4GlcNAcβ-sp3 H	(type	2)	 X	 	
23.	 1132	 Galα1-3Galβ1-4GlcNAcβ-sp3 αGalLex	 X	 	
24.	 1095.5	 6-O-Su-GalNAcβ1-4GlcNAcβ-sp3 6'-O-Su-
LacdiNAc	
	 	
25.	 1057.5	 GlcNAcβ1-4Mur-L-Ala-D-i-Gln-Lys GMDP-Lys	 	 	
26.	 1020.5	 Galα1-4GlcNAcβ1-3Galβ1-4GlcNAcβ-sp3 	 X	 	
27.	 985.5	 Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ-sp4 LNFP-I	 X	 	
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Figure 1S Relationship of age and anti-P1 antibody levels. Scatter plot showing anti-P1 
antibody levels (y-axis) and age (x-axis) in patient plasma for the control (grey) and tumor 
(black) group for IgM and IgG.	
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Figure	2S	Identification	of	P1	in	ovarian	cancer	cell	line	(IGROV	1)	using	negative	ion	mode	LC-ESI-
MS/MS	Base	 peak	 chromatogram	 is	 shown	 for	 glycans	 extracted	 from	GSLs	 of	 ovarian	 cancer	 cell	
line,	 IGROV	 1	 (A).	 Representative	 extracted	 ion	 chromatogram	 (EIC)	 of	 the	 P1	 pentasaccharide	
(Hex4HexNAc1)	at	m/z	870.31-	as	indicated	by	the	selected	mass	peak	(red	arrow)	(B).	MS2	spectrum	
of	 the	m/z	 870.31-	 ion	which	 corresponds	 to	P1	pentasaccharide	 (Galα1-4Galβ1-4GlcNAcβ1-3Galβ1-
4Glcβ1)(C).	
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Figure	3S	Representative	fluorescence	scan	of	randomly	selected	patient	profiled	for	AGA	in	ascites	
(right	panel)	and	blood	plasma	(left	panel)	on	50µM	and	10µM	prints	
	
	
Ascites: IgA + IgG + IgM  Plasma: IgA + IgG + IgM  
Ascites: IgA Plasma: IgA 
Ascites: IgG Plasma: IgG 
Ascites: IgM Plasma: IgM 
50 µM  10 µM 50 µM   10 µM 
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Figure 4S. Cell viability measured by MTT assay showed no statistical difference comparing 
P1-low and –high expressing IGROV1 cells exposed to increasing concentrations of araC. 
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Supplemental Fig. S1 
Single- cell selection after transient transfection of CRISPR- Cas9 encoding plasmids. Representative 
gating of fluorescence activated single cell sorting into 96-well plates after transient delivery of 
pSpCas9(BB)-2A-GFP (PX458) encoding sgRNA. 
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Supplemental Fig. S2 
Determination and verification of potential off targets. In silico analysis revealed 50 and 17 potential off-
targets for sgRNA_1 and sgRNA_2, respectively. The sgRNA_1 had only one predicted off-target in gene 
NM_001242377 chr5:+112339780 whereas sgRNA_2 was not predicted for an off-target site in a gene. 
Genomic sequences of predicted off-targets with highest score for each sgRNA were further amplified and 
sequenced, in which no mutations were observed. Off target DNA sequencing results for B3GNT5 wildtype 
(IGROV1) and knockout (clone KO_1 and KO_2) cells performed in triplicates. Genomic DNA sequence 
according to February 2009 human reference sequence (http://genome.ucsc.edu/index.html, GRCh37). 
Standard SP6 DNA Sequencing primer was used. 
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Supplemental Fig. S3 
Determination of anti- P1 IgM binding epitopes using printed glycan array. Barchart demonstrating the 
binding specificity for human anti-P1 IgM P3NIL100 antibodies. We performed a broad screening of glycan 
binding specificity of the monoclonal antibody P3NIL100 across 381 glycans by utilizing glycan array 
technology. The results clearly demonstrated that antibody bound specifically to glycans with Galα1-4Galβ1-
4GlcNAcβ as well as glycans terminating with Galα1-3(Galα1-4)Galβ1-4 and GalNAcα1-4Galβ1-4, with 
some of these structures bearing α1-2-linked fucose. As expected, there was no binding of the antibody to 
Gb3 glycan (Galα1-4Galβ1-4Glcβ-sp). 
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Supplemental Fig. S4 
The epitope for anti- nLc4 IgM is present on glycoproteins in colon cancer cell line Ls174T. A) 
Histogram showing the absence of α2-6 sialylation in Ls174T cells. B) Proteinase K treatment on Ls174T 
cells following staining for CD44 and nLc4. Representative histogram for unstained (white), Proteinase K -
untreated (dark gray) and -treated cells (light gray). Data are represented as mean ± s.d, *** p < 0.001, ** p < 
0.01. 
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Supplemental Fig. S5 
Quantitative gene expression of ST6GAL1, B4GALNT1, and B3GNT5 in IGROV1, ∆B3GNT5-, and 
∆B4GALNT1- cells. Barchart represents three independent experiments. Data are represented as mean ± s.d. 
RT-qPCR was performed in triplicates on three independent experiments. 
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Supplemental Table S1 
Oligonucleotides used in the study. 
single guided RNAs
oligonulceotide 5 '- 3' Gene Method
sgRNA 1 CAC CGA TAC ACG ATT ATA GCC GTT T AAA CAA ACG GCT ATA ATC GTG TAT C B3GNT5 Gene-editing
sgRNA 2 CAC CGA TCG ACG TTC CGG AAT TAG A AAA CTC TAA TTC CGG AAC GTC GAT C B3GNT5 Gene-editing
sgRNA 1 CAC CGT GGA TGC CGC GGT TTC GAC G AAA CCG TCG AAA CCG CGG CAT CCA C B4GALNT1 Gene-editing
sgRNA 2 CAA CGC CTT CAA ATA GTC CTC GGG A AAA CTC CCG AGG ACT ATT TGA AGG C B4GALNT1 Gene-editing
genotyping PCR primer
oligonulceotide 5 '- 3' (Forward) oligonulceotide 5 '- 3' (Reverse) Gene Method
PCR_1 GTA TCT GCT TTC ATC CTG ACC AT TGC CCA ACT GAA CTG CAT AAG B3GNT5 Genotyping
PCR_2 GTA TCT GCT TTC ATC CTG ACC AT TCG AGA CCA TAG AAC TTC GTG T B3GNT5 Genotyping
PCR_3 GGC CTC GCT ACC AAT ACT T TGC CCA ACT GAA CTG CAT AAG B3GNT5 Genotyping
PCR_4 GAT GAG GAT AAA GCA GTG CAG AT GCC TCA GCC CTG CTT CAA ATC chr5:113003768+113004235 off target
PCR_1 AGA GCG TTA GAC AGG TCA GT TGG AGG AAG GAG AGG ACA GA B4GALNT1 Genotyping
PCR_2 CTG TGC GCT CTG GTC CTT TGG AGG AAG GAG AGG ACA GA B4GALNT1 Genotyping
PCR_3 CCA CTA CTT GCT CCT TGA TCC TGG AGG AAG GAG AGG ACA GA B4GALNT1 Genotyping
PCR_4 CCA CTA CTT GCT CCT TGA TCC CTG TGC GCT CTG GTC CTT B4GALNT1 Genotyping
PCR_5 GCA CAT ACT GAA GCG TTC ACA ATC CCA GCT CCT CAG CTA CA chr22:30296425-30296628 off target
PCR_6 TTG GCC AGA GGT TCA TGC TA ACC GTC ACC CTA CTC AAG TG chr12:52518025-52518321 off target
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Supplemental Table S2 
Details of target and reference genes, primers and amplicons investigated in this study by RT-qPCR. QPCR 
parameters are provided including efficiency (E in %; calculated based on the standard curve according to the 
equation E=10(-1/slope)-1) x 100 and expressed as percentage) and correlation coefficient (R2). 
Symbol Gene name Accession number 
Chr. 
location 
Forward Primer 
5‘-3‘ 
Reverse Primer 
5‘-3 
Amplicon 
size in bp 
E in 
% R
2 
B3GNT5 
UDP-GlcNAc β -1,3-N-
acetylglucosaminyl- 
transferase 5 
NM_032047.4 3q28 GGCTTGAACTTCGTGAGTTTCGC 
TCGAGACCATAGAA
CTTCGTGT 305 92.2 0.994 
ST6GALNAC1 GalNAc α -2,6-Sialyltransferase I NM_018414.3 17q25.1 
CGAAATAGGAGGCC
TTCAGACGAC 
TTTCTGGAGCCACA
GCGACTTG 76 74.1 0.999 
ST6GALNAC2 GalNAc α -2,6-Sialyltransferase II NM_006456.2 1q31.1 
ATCGAATTCTTGGA
CAGGAAAGGG 
GATTGAACAGGCCA
CGGAAGTG 92 83.9 0.899 
ST6GALNAC3 GalNAc α -2,6-Sialyltransferase III NM_001160011.1 1q31.1 
AGCGCATGAGTTAC
TGTGATGG 
TGCATGGTCACTCT
GTACTGTCC 69 103.9 0.999 
ST6GALNAC4 GalNAc α -2,6-Sialyltransferase IV NM_175039.3 9q34.11 
ACCAGATCTTCCAG
GACGAGAC 
TCTTCTCCCTGCAGT
AGCTGTC 150 86.7 0.998 
ST6GALNAC5 GalNAc α -2,6-Sialyltransferase V NM_030965.1 1q31.1 
TGACAATTGCACTG
GAGCTCTG 
GTGATTGGGATCCC
TGCAGAAG 80 131.6 0.955 
ST6GALNAC6 GalNAc α -2,6-Sialyltransferase VI NM_013443.3 9q34.11 
CATGCGGCAATTTG
ACGACCTC 
CACGAATGAGACTT
CTCCCTGTCC 66 106.1 0.999 
ST6GAL1 β -galactosamide α-2,6- sialyltransferase 1 NM_173217.2 
3q27-
q28b 
CCATCCTCTGGGAT
GCTTGGTATC 
ACGTCAGTCTTGCG
CTTGGATG 95 98.1 0.997 
ST6GAL2 β -galactosamide α-2,6- sialyltransferase 2 NM_001142351.1 2q12.3 
TTCCTTGGGCGAGG
AAATAGATTC 
TCATAACCACGTGT
AGGAGCAGAG 72 99.2 0.991 
B4GALNT1 
β -1,4-N-Acetyl-
Galactosaminyl 
Transferase 1 
NM_001276468 12q13.3 TGTGCGCTCTGGTCCTTCTG 
TTGATCCTGACCGG
GATGTGT 181 74.1 0.999 
HSPCB Heat shock protein 90kDa alpha (cytosolic) NM_007355 6p12 
TCTGGGTATCGGAA
AGCAAGCC 
GTGCACTTCCTCAG
GCATCTTG 80 87.2 0.999 
YWHAZ 
Tyrosine 3-
monooxygenase/ 
tryptophan 5-
monooxygenase 
activation protein 
NM_003406 8q23.1 ACTTTTGGTACATTGTGGCTTCAA 
CCGCCAGGACAAAC
CAGTAT 94 94.1 0.999 
SDHA Succinate dehydrogenase complex, subunit A NM_004168 5p15 
TGGGAACAAGAGGG
CATCTG 
CCACCACTGCATCA
AATTCATG 86 100.9 0.999 
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Supplementary Figure S1 
Globoside GSL synthesizing glycosyltransferases show elevated gene expression in 
epithelial tissue samples. Tothill transcriptomic data set was divided into four EMT states: 
epithelial (E), intermediated epithelial (IE), intermediate mesenchymal (IM), and 
mesenchymal based on previously developed EMT score (1). A) Upregulated EMT markers
in epithelial (green) and mesenchymal (red) cells among four EMT states, respectively. B) 
KEGG annotated glycosyltransferases involved in glucosylceramide-related 
glycosphingolipids divided into three major series- globo, (neo-) lacto, and ganglio series 
glycosphingolipids. Boxplot showing expression of glycosyltransferase-encoding genes 
significantly up-regulated in epithelial (green), in mesenchymal (red), or without changes 
(black). Black solid arrows indicate elongation of glycan structures.  
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Supplementary Figure S2 
EMT marker gene expression in 47 ovarian cancer cell lines. Normalized transcriptomic 
data were accessed via the http://www.cbioportal.org. The cell line CCLE Broad Cancer cell 
line encyclopedia (Novartis/ Broad, (2)) containing mRNA expression Z-scores (microarray) 
were sorted in descending order for CDH1 expression in all available ovarian cancer cell lines 
(n=47) including IGROV1. Five corresponding epithelial markers (KRT19, SPP1, CAV2, and 
FGFBP1) and mesenchymal markers (CDH2, VIM, FN1, TWIST1, and SERPINE1) were 
plotted in bar charts accordingly. In addition, findings on EMT states in ovarian cancer cells 
published in Huang et al. 2013 (3) were highlighted for cell lines matching in both data sets 
(color code and legend below the figure). 
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Supplementary Figure S3 
Single cell sorting strategy after transient transfection of sgRNA CRISPR-Cas9 
constructs. Cancer cell lines were transfected with equal amount of PX458 incorporating two 
different A4GALT-specifci sgRNA in addition to Cas9 and GFP. Single cell sorting was 
performed as exemplified for IGROV1 ovarian cancer cells.  
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Supplementary Figure S4 
Quantification of glycans released from glycosphingolipids in wildtype and ΔA4GALT 
ovarian cancer cells using LC-ESI-MS/MS. Proposed GSL-glycan structures and their
relative abundance as detected on the glycolipid membranes of ovarian epithelial cancer cells 
IGROV1 wild type and the knockout. GSL-glycan structures were enzymatically released 
from glycolipids and separated by PGC-LC-ESI MS/MS analysis. Structures were assigned 
based on MS/MS fragmentation (where possible) and biological GSL pathway constraints. 
Structures are depicted according to the CFG (Consortium of Functional Glycomics). 
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Supplementary Figure S5 
Genetic depletion of A4GALT correlates with the absence of globosides in ovarian 
cancer cells representing the four different states of EMT.  
A) PCR for initial verification of selected ΔA4GALT clones obtained from BG1 and SKOV3.
B) Sanger DNA sequencing results for selected clones at the Cas9-targeted region showing
deletion and inversion in two additional genome edited cell lines. C) Corresponding flow 
cytometry results shown as representative counter plots for validation of GSL expression in 
selected ΔA4GALT. D) Anchorage-dependent growth investigated by colony formation assay 
in SKOV3 and BG1 cells and their corresponding ΔA4GALT cell clones. E) Overexpression 
of A4GALT in A2780 cells negative for GSL expression. Counter plots display expression of 
GSL expression in A2780 cells stably expressing A4GALT cloned into pUltra (co-expression 
with EGFP). G) Barchart summarizing three independent experiments for overexpression of 
A4GALt in A28780 cells. 
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Supplementary Table S1 
Quantification of glycans released from glycosphingolipids in wildtype and ΔA4GALT 
ovarian cancer cells using LC-ESI-MS/MS. Proposed GSL-glycan structures and their
relative abundance as detected on the glycolipid membranes of ovarian epithelial cancer cells 
IGROV1 wild type and the knockout. GSL-glycan structures were enzymatically released 
from glycolipids and separated by PGC-LC-ESI MS/MS analysis. Structures were assigned 
based on MS/MS fragmentation (where possible) and biological GSL pathway constraints. 
Structures are depicted according to the CFG (Consortium of Functional Glycomics). 
[M-H]1- ([M-2H]2-) Proposed structure Wildtype  
Relative 
abundance % 
(SE) 
ΔA4GALT
Relative 
abundance % 
(SE) 
1 505.3 3.8 (0.32) 
2a 708.3 3.3 (0.24) 2.6 (0.12) 
2b 708.2 1.3 (0.08) 2.1 (0.03) 
3 626.2 6.9 (0.37) 0.8 (0.03) 
4 837.4 0.3 (0.01) 0.4 (0.02) 
5 911.4 2.6 (0.43) 0.4 (0.03) 
6a 1202.5 (600.8) 2.2 (0.33) 1.7 (0.09) 
6b 1202.5 (600.8) 4.6 (0.17) 2.4 (0.21) 
7 634.2 13.9 (1.32) 17.0 (1.45) 
8 1405.6 (702.3) 3.6 (0.43) 1.6 (0.23) 
9a 999.5 1.6 (0.16) 0.1 (0.01) 
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9b 999.5 0.0 0.6 (0.03) 
9c 999.5 13.4 (1.05) 29.4 (2.65) 
10a 1290.6  (644.8) 40.4 (1.89) 38.5 (1.65) 
11 1655.8  (827.4) 2.3 (0.24) 2.4 (0.17) 
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Supplementary Table S2 
Cell lines used in this study. Table provides details of all cell lines including type of cells, 
name of the cell lines, culture media conditions, and supplements. 
Cell types Cell Lines Culture media Supplements
FT190
FT133tag
FT237
FT240
HOSE6.3
HOSE17.1
IGROV1
A2780
SKOV3
OVCAR3
OVCAR4
OVCAR5
OVCAR8
BG1
OAW42
CAOV3
TOV21G
OVSAHO
KURAMOCHI
Tyk-Nu
EFO27 1mM Sodium pyruvate (Sigma- Aldrich)
MCF7
T47D
MDA-MB-231
HCT16
HCT116
HT29
LS174T
THP-1
K562
HeLa
ME-180
Kidney HEK293T
Neuroblastoma U521
Cervical cancer
Normal
DMEM-Ham’s F12 
without HEPES Buffer, 
penicillin (100U/ml) 
and streptomycin 
(Sigma-Aldrich)
2% UltroserTm (PALL, Life Science)
RPMI-1640 
supplemented with 
10% FBS, penicillin 
(100U/ml) and 
streptomycin 
(100μg/ml) (Sigma-
Aldrich, Buchs, 
Switzerland)
Ovarian Cancer
Breast Cancer
Colon Cancer
Leukemia
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Supplementary Table S3 
Table providing details of oligonucleotides used in this study. Name of oligonucleotides, 
DNA sequence, and method applying particular oligonucleotides are provided. RT-qPCR 
primer were established as recently described (4). 
Oligonucoleotide name Sequences (5’—3’) Method
sgRNA1_Forward Caccg TGG CTG CTC ACC TAC GAA ATG GG CRISPR-Cas9
sgRNA1_Reverse aaac ATT TCG TAG GTG AGC AGC CAC CRISPR-Cas9
sgRNA2_Forward caccgCAATCTTGCCTCCCCGGGAA CRISPR-Cas9
sgRNA2_Reverse aaacTTCCCGGGGAGGCAAGATTGC CRISPR-Cas9
Human U6_Forward GAGGGCCTATTTCCCATGATTCC Cloning
PCR_1,2_Forward ACCAGGAAAGAGAGGTCTAATG Genotyping A4GALT
PCR_1,3_Reverse CTGTTGAGGAGCTGTGGGAG Genotyping A4GALT
PCR_2,3_Reverse CTCAACGGCGCGTTCCTGG Genotyping A4GALT
T7_F TAATACGACTCACTATAGGG Cloning
Sequencing_A4_Forward GGACCACTACAACGGCTGGAT DNA Sequencing
Sequencing_A4_Reverse ACGAAGTCCCGCATGCACA DNA Sequencing
A4_qPCR_Forward GTCTGCACCCTGTTCATCA RT-qPCR
A4_qPCR_Reverse AGAGCTGCCCTTTCTCCTTG RT-qPCR
CDH1_Forward GCCTCCTGAAAAGAGAGTGGAAG RT-qPCR
CDH1_Reverse TGGCAGTGTCTCTCCAAATCCG RT-qPCR
Vimentin_Forward TGCAGGAGGAGATGCTTCAGAG RT-qPCR
Vimentin_Reverse CAGAGACGCATTGTCAACATCCTG RT-qPCR
HSPCB_Forward TCTGGGTATCGGAAAGCAAGCC RT-qPCR
HSPCB_Reverse GTGCACTTCCTCAGGCATCTTG RT-qPCR
YWHAZ Forward ACTTTTGGTACATTGTGGCTTCAA RT-qPCR
YWHAZ Reverse CCGCCAGGACAAACCAGTAT RT-qPCR
SDHA_Forward TGGGAACAAGAGGGCATCTG RT-qPCR
SDHA_Reverse CCACCACTGCATCAAATTCATG RT-qPCR
A4GALT_Exon3_NheI_F CATGCTAGCGGATACCATGTCCAAGCC Cloning
A4GALT_Exon3_XhoI_R1 CATCTCGAGTCACAAGTACATTTTCATGGC Cloning
CMV_F CAAATGGGCGGTAGGCGTG Cloning
BGH_R TAGAAGGCACAGTCGAGG Cloning
A4GALT_DXA_forward GTTCGGCGGCATCTAACTGGACACGGCATTCATTG Mutagenesis PCR
A4GALT_DXA_reverse CCGCAGGTTCTTGAGAACAATGAAGTCCGTGTCCAGGTAG Mutagenesis PCR
InFusion_CDH1_F CGCCTGGAGAATTGGATGGGCCCTTGGAGCCGC Cloning
InFusion_CDH1_R ATCCAGTCACTATGGCTAGTCGTCCTCGCCGCC Cloning
InFusionIL2RCDH1_F CGCCTGGAGAATTGGATGGATTCATACCTGCTGAT Cloning
InFusionIL2RCDH1_R ATCCAGTCACTATGGCTAGTGGTCCTCGCCGCC Cloning
CDH1_Bis_1F ATTTTAGTAATTTTAGGTTAGAGGG Bisulfite Sequencing
CDH1_Bis_1R TCCAAAAACCCATAACTAACC Bisulfite Sequencing
CDH1_Bis_2F AGTAATTTTAGGTTAGAGGGTT Bisulfite Sequencing
CDH1_Bis_2R CTAAAATCTAAACTAACTTC Bisulfite Sequencing
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